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Stellingen behorende bij het proefschrift ;�.:r-1? 1- "Develooment of Influenza Vaccines in the Face of Pandemic Threat" Felix Geeraedts, 25 april 2012 1. Gebruik van een gemactiveerd heel-virus vaccinformulering ten tijde van een influenzapandemie is een efficiente strategie om de beschikbaarheid van vaccins te vergroten (dit proefschrift). 2. Bij de beoordeling van influenzavaccins moet, naast de hoeveelheid opgewekte antistoffen, ook de kwaliteit van de immuunrespons in de afweging betrokken warden (dit proefschrift). 3. Aangezien adjuvantia onvoorziene bijwerkingen kunnen hebben, die juist bij vaccinatie van grate massa' s zichtbaar warden, en sommige adjuvantia zelfs de beschermende werking van een vaccin kunnen verminderen, is het raadzaam het gebruik van ( deze) adjuvantia voor pandemische griep te minimaliseren. 4. Activatie van het aangeboren immuunsysteem via specifieke receptoren speelt een belangrijke rol bij vaccin-gemduceerde adaptieve afweer (dit proefschrift). 5. De partikelstructuur van het influenza virus, inclusief het virale RNA, dient behouden te blijven voor een optimale immuunrespons (dit proefschrift). 6. Vriesdrogen van gemactiveerd heel-virus influenzavaccin met stabiliserende suikers vergroot de mogelijkheden voor opslag en snelle verspreiding van vaccins om een beginnende pandemie in de kiem te smoren ( dit proefschrift). 
7. De relatie tussen pathogene micro-organismen en ons immuunsysteem zou je kunnen samenvatten met de bekende uitdrukking 'als je er niet dood aan gaat wordt je er alleen maar sterker van'. 8. Wat betreft de vraag of het mogelijk is om in de tijd te reizen blijkt de kink in de kabel toch niet alleen in ons voorstellingsvermogen te zitten. (Error Undoes Faster-Than-Light Neutrino Results, http://news.sciencemag.org /scienceinsider/2012/02/breaking-news-error-undoes-faster.html) 9. Concurrentie in de gezondheidszorg door de invoering van winstuitkering kan tot innovatie leiden, maar maakt ook dat nieuwe inzichten niet meer snel gedeeld zullen worden, waardoor dit beleid in zekere zin een dooddoener is. 10. Van de dosis-sparende influenza vaccins is ge'inactiveerd heel-virus vaccin het beste adjuvans-sparende vaccin. 11. Je hebt een microscoop nodig om de relatie tussen arts-microbioloog en patient goed zichtbaar te maken. 12. 'Nature is very predictable when properly understood' (Big wave surfer Laird Hamilton, in SURF magazine 5, juli 2007). 
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The research described in this thesis was performed at the Department of Medical Microbiology, Molecular Virology Section, of the University Medical Center Groningen within the Groningen University Institute for Drug Exploration (Guide). Part of the work was performed in collaboration with the Department of Pharmaceutical Technology and Biopharmacy of the University of Groningen, and the Department of Medicine, Division of Infectious Diseases and Immunology of the University of Massachusetts Medical School, Worcester, Massachusetts, United States of America. The conducted studies were part of the activities of the Netherlands Influenza Vaccine Research Centre (NIV AREC). The objectives of NIV AREC were stated as follows: The primary objective of the NIV AREC program is to establish a virtual research centre in which academic groups active in the area of influenza virus biology and vaccine development join forces with a leading influenza vaccine manufacturer in synergistic fashion in order to contribute to an optimal preparedness in The Netherlands for a situation in which a new influenza pandemic would strike. The NIV AREC partners are the Department of Medical Microbiology, Molecular Virology Section, University Medical Center, Groningen (UMCG), the Department of Virology, Erasmus MC, Rotterdam (EMCR) and Solvay Biologicals, Weesp (recently acquired by Abbott). The NIVAREC consortium will specifically focus on the following key areas: (i) generation of novel recombinant influenza virus strains covering a broad spectrum of currently known influenza viruses with pandemic potential, (ii) developing technology for the rapid production of vaccine viruses on an industrial scale (iii) developing innovative technology for the generation of safe and efficacious influenza virus vaccines that can be manufactured rapidly and on a large scale when required. Emphasis in the research activities of NIVAREC will be on the H5Nl ("bird flu") virus, since this virus at the start of the NIV AREC program posed, and continues to pose, a serious influenza pandemic threat. The work described in this PhD thesis was performed under the auspices of the NIVAREC, with financial support from the Netherlands Organization for Health Research and Development (ZonMw). Funding for a part of the study was obtained from the Jan Kornelis de Cock Foundation. 
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GENERAL INTRODUCTION AND AIM OF THE THESIS 
Chapter 1 Influenza pandemics 
An influenza pandemic is a sudden global outbreak of the disease which occurs at 
an unpredictable time and causes excess morbidity and deaths [l]. In the past 300 
years, about 11 influenza pandemics have occurred at intervals ranging from 
approximately 10 to 50 years [2,3]. The pandemics of modem history are the 1918 
'Spanish flu', 1957 'Asian flu', 1968 'Hong Kong flu', and 2009 'Mexican flu'. The 
causative agent is an influenza A virus strain, other than the seasonal strains 
circulating among humans just before the outbreak [4]. Influenza virus is a highly 
transmissible pathogen which primarily infects the epithelial cells of the 
respiratory tract. The clinical presentation may vary from asymptomatic to flu-like 
symptoms (fever, myalgia, dry cough, headache, chills, diarrhea), to life­
threatening viral pneumonitis, and secondary bacterial pneumonia [5]. Influenza 
epidemics are responsible for an estimated 250,000 to 500,000 deaths worldwide 
each year [6a]. There may be a large variation between flu seasons with death rates 
ranging from 3,000 to 49,000 in the US alone [6b]. Excess deaths due to pandemics 
also varies considerably from 18,000 in 2009, which is likely an underestimation, 
up to 50-100 million in 1918 [7-9]. Where most casualties of epidemic influenza 
concern the very young and the elderly, pandemic influenza may show high 
lethality in young healthy adults, as was the case in 1918. The rapid death of these 
young adults has been explained in part by a 'cytokine storm' resulting from a 
severe immune response to an unusually virulent virus [10]. BIOLOGY OF INFLUENZA VIRUS 
Influenza virus is an enveloped single stranded (ss)RNA virus which belongs to 
the family of Orthomyxoviridae [11,12]. It is further classified in type A,B and C, of 
which only influenza A is known to cause pandemics. The viral genome of 
influenza A consists of 8 RNA segments containing 11 genes, encoding for 11 
proteins: hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), RNA 
polymerase acidic protein (PA), and basic protein 1 (PBl), 1-F2 (PB1-F2) and 2 
(PB2), non-structural protein 1 (NSl), and 2 or nuclear export protein (NS2 or 
NEP), and matrix protein 1 (Ml), and 2 (M2). The RNA segments together with 
NP and the polymerase subunits form the ribonucleoproteins, which together with 
the Ml protein constitute the viral core [11, 13]. The core is surrounded by a lipid 
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Introduction envelop membrane, derived from the host cell, to which it is linked via Ml [11]. The HA and NA spike proteins are located in the membrane and project from the lipid envelop into the external environment. Small amounts of M2 are present in the membrane. NS2 is also associated with the viral particle (Figure 1). NSl is not represented in the viral particle but produced in the host cell upon infection. Figure 1. Schematic model of influenza A virus. Lipid bilayer HA (Hemagglutinin} NA (Neuraminidase) M2 (Ion channel) RNP (R.lbonucleoprotein; RNA segment, PB 1 . PB2. PA, NP) M1 (Matrix protein) NS2 Influenza virus enters the host cell by binding of the HA to sialic-acid receptors on the cell surface, followed by endocytosis [14]. The virus is further trafficked to late endosomes, where the acidic pH of the endosomal lumen initiates a conformational change in the HA molecules, which triggers fusion of the viral membrane with the endosomal membrane[14]. Additionally, the low pH initiates the process of uncoating, by proton influx through the M2 ion channels in the viral membrane, resulting in dissociation of the RNP from Ml and release of the viral RNA into the cytoplasm, after viral membrane fusion has occurred [13]. The RNA is transported to the nucleus, where it is transcribed and replicated. Synthesis of viral proteins occurs in the cytosol. New viral particles are assembled at the plasma membrane and subsequently released from the cell by budding. The viral NA plays an important role in the release of off-spring virus from the cell surface. 11 
Chapter 1 The function of NSl is to counteract antiviral type I interferon production by the host cell. HA and NA are important antigens and antibody responses to HA confer protection against infection [11]. Currently, 16 antigenically distinct HA and 9 NA subtypes are known, and an influenza virus subtype is denoted by a number combination referring to its HA and NA subtype. The virus subtypes that caused the pandemics of 1918, 1957, 1968, and 2009 were HlNl, H2N2, H3N2, and HlNl respectively [15,16]. Birds are the main reservoir for all influenza A virus subtypes [17, 18], and numerous different combinations of the 16 HA and 9 NA subtypes can be found in wild fowl and poultry [19]. Other natural hosts to influenza virus include pigs, and horses [17]. Influenza A virus exhibits a high frequency of antigenic variation. Firstly, new influenza viruses with a different HA may be introduced in the human population, which causes an 'antigenic shift'. Lack of pre-existing immunity to this new HA promotes the rapid spread of the virus, which results in a pandemic. The pandemic virus replaces the previously circulating epidemic virus. Secondly, point mutations in the viral RNA easily occur during replication, due to the absence of a proofreading system. In circulating influenza strains, these point mutations accumulate and gradually alter the antigenicity so that a previously immune person becomes susceptible again, every 3-5 years [29]. This process is called 'antigenic drift'. ORIGIN OF PANDEMIC VIRUSES Pandemic viruses in general originate from an animal source, notably birds or swine. This is confirmed by molecular analysis of strains from pandemics in the era of modern virology [20-22]. Isolation of influenza virus first became possible in 1933 [23]. The genomic RNA sequences of the notorious 1918 virus, which seemed to be lost to time, have recently been recovered from archived materials, and from frozen samples of victims buried in the permafrost [24,25]. The 1918 RNA sequences point to an avian and/ or swine origin of the Spanish flu virus [26,27]. Animal viruses may be introduced in the human population through gene­reassortment with human influenza viruses, or directly from an animal progenitor virus, as has also been argued for the 1918 virus [26, reviewed in 28]. Gene­reassortment is the process of gene exchange between two different viruses, for instance an avian virus and human virus, which may occur when they 
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Introduction simultaneously infect the same host cell [11]. This process is facilitated by the segmented nature of the RNA genome, and can lead to the generation of a new virus. The 1957 and 1968 viruses were reassortants between circulating human viruses and avian viruses. The 1957 virus obtained its H2, N2, and PBl, and the 1968 virus its H3, and PBl from avian viruses [28]. The 2009 virus was a triple re­assortant virus, containing genes of swine, avian and human influenza viruses that were already circulating in swine [28, 22]. Obviously, the 2009 virus entered the human population without the direct involvement of a human influenza virus [28]. World-wide outbreaks caused by human influenza viruses have been either disqualified by definition or disputed for other reasons as being a true pandemic. These events include the outbreak in 1947 / 48 of what turned out to be a major drift variant of the circulating human HlNl virus, while the pandemic definition excluded drift variants as causative agent, and the reintroduction in 1977 of an HlNl strain which was identical to the strain which had been circulating among humans in the 1950s [ 4,5]. Where this virus came from is unknown, perhaps some institutional freezer [4]. The HlNl also did not replace the pre-existent epidemic virus. It started to co-circulate with the H3N2 that was already circulating since 1968 [4,15]. Although the outbreak fulfilled the criteria of the pandemic definition at that time, which included the requirement of a new subtype introduction [4], it was still disputed if it was a true pandemic (Textbox 1). UNPREDICTABILITY OF PANDEMICS It is not known when a next pandemic will occur, or what virus subtype will be the cause of it. In the past decade human H2N2 as well as a number of different avian influenza subtypes, including HS, H6, H7 and H9 were thought to be likely candidates [10]. The 2009 swine HlNl pandemic therefore came as a surprise [16]. With an HlNl already circulating in humans, the introduction of a similar subtype seemed rather unlikely, but obviously, the human HlNl had not generated sufficient cross-protective immunity to avoid a pandemic [30]. Still, pandemic preparedness in 2009 was better than ever before, due to the pandemic threat created by the cross-species transmission of a particular avian influenza virus, which had generated a surge in pandemic vaccine technology and knowledge in the preceding years [31, 32]. 
13 
Chapter 1 Textbox 1: Until 2009, indisputable pandemics have been caused by newly introduced viruses from an animal source [15]. In 2009 a swine­
origin HlNl virus was introduced, followed by a rapid worldwide spread, 
while at that moment an HlNl was already circulating in the human 
population since 1977. One might question the requirement for a new 
subtype virus in the pandemic definition, as it would disqualify this event 
as a true pandemic. Recently, a new broader definition has been proposed 
which circumvents this issue [4]. One of the criteria is that 'the new and 
spreading influenza A virus has an HA which does not cross-react in HI 
tests with the HA of the immediately preceding and circulating influenza 
virus strain(s)'. This also allows for drift variants like the 1947 virus to be 
included, but might diminish the distinctive character of pandemic 
influenza as opposed to its epidemic form. Perhaps, a pandemic should be 
defined just by the behaviour of the virus in the population and the term 
true pandemic virus be reserved to pandemic viruses with an animal 
origin. Obviously there are more pandemics than true pandemic viruses. The H5Nl pandemic threat The first time that highly pathogenic avian influenza (HPAI) H5Nl virus was encountered in humans was in 1997 during an outbreak in Hong-Kong. Eighteen persons became infected of whom six died [33,34]. The human cases occurred amidst large outbreaks of HPAI H5Nl among poultry on live animal markets and farms in Hong-Kong, where it was 70 to 100 percent lethal in chicken [33]. It soon became evident that the human cases had contracted the virus from birds [33]. The second occasion in which H5Nl appeared in humans occurred early in 2003, when three persons from Hong-Kong, who recently travelled to the Fujian province of China, became ill with H5Nl. Two of them died [35]. So far, these two events concerned isolated incidents. However, at the end of 2003 through early 2004 Korea, Thailand and Vietnam started to report of continuous outbreaks of HPAI H5Nl among poultry, and reports of human H5Nl cases with high fatality rates followed in January 2004 in Vietnam and Thailand [35]. These outbreaks could not be contained, and since then H5Nl has spread to at least 15 countries causing an ever increasing number of laboratory confirmed H5Nl human infections, 562 up 
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to this time of writing, with a case-fatality rate approaching 60% [39] (Textbox 2, 3 
and 4). Textbox 2. In 2006, a fatal case from Bejing back in november 2003, which had first been diagnosed as severe acute respiratory syndrome (SARS), was re-examined. SARS is a potentially lethal complication of a coronavirus (SARS-Co V) infection. The true causative agent, however, turned out to be HPAI HSNl virus. In retrospect, this casualty marks the beginning of the currently ongoing episode of (sporadic) bird to human transmissions with HPAI HSNl [1,3]. Textbox 3. In 1997, containment measures included the culling of all poultry (1.5 million chicken) in Hong-Kong which effectively eliminated the virus from sight [36], although occasionally new HSNl genotypes kept reappearing in poultry in Hong-Kong, despite of stringent control­measures [34,36,37]. Similar efforts to eliminate the virus by massive culling of poultry in Vietnam and Thailand in March 2004 led to a decline in cases [38]. But this time this drastic measure proved insufficient to contain the situation, and soon hereafter the number of HSNl cases started to increase again and the virus started to spread to other countries in Asia [38,39]. Textbox 4. Spread of HPAI HSNl likely occurs through trade of infected poultry and transport of infected materials. Other factors that played essential roles in the occurrence and dissemination of HSNl are domestic waterfowl, specific farming practices, and agro-ecological environments [19]. HPAI HSNl has been found in many wild migratory birds, also in several European countries. Its lethality in these birds is variable and it is argued that HSNl might be spreading by migration. Yet, whether these infected birds represent an important vector remains to be proven [19]. 
15 
Chapter 1 HUMAN-TO-HUMAN TRANSMISSION As the H5Nl outbreak turned beyond control, the chance that human-to-human transmission would evolve also increased. It was feared that the virus might adapt to its new host or reassort with a human influenza virus to become highly transmissible. Indeed, there is evidence that limited human-to-human transmission may have occurred in household clusters [40,41]. Yet, none of these transmissions became sustained. Human-to-human transmission may be inefficient because avian influenza viruses, unlike human virus, generally do not bind to alpha-2,6Gal sialic acid receptors located in the human upper respiratory tract, but instead preferentially attach to the alpha-2,3Gal receptor type, which is restricted to the lower respiratory tract in humans [42,43] (Textbox 5.). 16 Textbox 5. Which mutation would turn H5Nl into a human influenza virus remains unknown, but a mutation that changes its receptor specificity is highly suspected [44]. The avian derived H2 and H3 of the pandemic viruses of 1957 and 1968 have mutations that changed their receptor specificity to the human-type alpha-2,6Gal receptor. Similar mutations experimentally applied to HSNl have been shown to shift the virus preference to the alpha-2,6Gal receptor [44]. If such a mutation would occur, HSNl might find foot-hold in humans [44]. It has however been argued by others that mutations in the HA gene on itself may not be enough to allow for efficient spreading among humans, and that an additional mutation in the PB2 gene of HSNl, which increases viral replication in human cells, may be needed [45a]. It has been recently announced on the fourth ESWI Influenza Conference in Malta that an airborne HSNl virus has been deliberately created in a laboratory by infecting ferrets with a mammalian adapted version of HSNl bearing 3 mutations, and then passing this virus 10 times from ferret to ferret. Only a total of 5 mutations in two genes were required to induce transmissibility by aerosols in ferrets. Even more troublesome, the virulence of the virus remained undiminished [ 45b]. 
Introduction VIRULENCE FACTORS Although a case-fatality rate of 60% H5Nl may be an overestimation as subclinical infections seem to occur [ 46], H5Nl is an extremely virulent virus, with the primary cause of death due to H5Nl infection being progressive respiratory failure [47,48]. The mechanism responsible for the virulence of H5Nl in humans is largely unknown. Restriction of the alpha-2,3Gal receptor, to which H5Nl preferentially binds, to the lower respiratory tract in humans might play a role in severe pulmonary disease once infection is established [48]. High viral replication and concurrent induction of an imbalance in the cytokine response with increased production of inflammatory cytokines probably play key roles in the virulence of H5Nl in humans [50,53,54] (Textbox 6.). Textbox 6 In birds, HPAI HSNl pathogenicity is characterized by a broad tissue tropism and systemic replication, which correlates with the presence of a multibasic cleavage site in the HA [reviewed in 49]. In humans H5Nl has been detected outside the respiratory tract [50,51] yet, the role of the multibasic cleavage site in H5Nl pathogenicity in humans remains unclear. Insertion of a multibasic cleavage site in human H3N2 virus on itself seems not enough to confer increased pathogenicity in a ferret model [52]. More likely, multiple viral proteins may be involved in H5Nl pathogenicity in mammals, including HA, PB2 and NSl, and different gene constellations can confer high pathogenicity [49]. STATE OF PANDEMIC ALERT The H5Nl virus capers forced the WHO to raise the pandemic alert to level 3, which is one step away from a beginning pandemic [55]. This situation has remained so from 2004 up to today. The pandemic alert level was only altered by the arrival of the 2009 pandemic and raised to level 6, to fall back to level 3 again afterwards. Yet, the only obstacle separating the world from a beginning H5Nl pandemic on the WHO scale is sustained human-to-human transmission, and the high fatality rate of H5Nl infection makes one fear for the worst if this virus 
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would set off a pandemic [56]. This ongoing H5Nl pandemic threat urges the 
development of effective pandemic mitigation strategies. Antivirals and vaccines 
Use of vaccines and antiviral drugs plays a key role in pandemic mitigation 
[57,58]. This type of intervention is considered clearly efficacious in preventing 
infection and treating illness, where the role for other measures like closing 
schools, wearing face masks, and isolating infected people from the uninfected 
still needs further investigation [59] (Textbox 7.). ANTIVIRAL DRUGS 
Two types of antiviral drugs are registered for use against influenza, M2 proton 
channel inhibitors (amantadine and rimantadine) and NA inhibitors (oseltamivir 
and zanamivir). 
Although highly resistant to M2 inhibitors [49], HPAI H5Nl was found susceptible 
to NA-inhibitors in vitro [60,61]. The therapeutic merits of oseltamivir were, 
however, doubtful in the first H5Nl patients [40], but early treatment may be 
beneficial for the clinical outcome and improve survival [62]. Oseltamivir may be 
used as a prophylaxis, as it was proven to prevent the initiation of influenza virus 
infection of airway epithelial cells in vitro [63]. However, prophylactic use of 
antiviral drugs provides only short-term protection and there is a risk of 
emergence (and selection) of oseltamivir resistant strains by improper drug use 
[64-66]. Especially in the early phase of a pandemic, antiviral drugs may be the 
primary pharmaceutical resource to rely on, in expectation of suitable vaccines 
[49]. However, if containment fails, prophylactic application of antivirals will 
become a very inefficient way to use the limited resources [67]. INFLUENZA VACCINES 
In contrast to antivirals influenza vaccines provide long term protection against 
infection, and are the mainstay of prevention and control of epidemic and 
pandemic influenza [68,32]. 
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Introduction Current vaccine formulations 
Currently licensed influenza vaccines can be roughly divided in inactivated 
vaccines and live attenuated vaccines. Inactivated vaccine formulations include 
whole inactivated virus (WIV) vaccine, split-virus vaccine, subunit-vaccine and 
virosomal vaccine. Live attenuated HSNl vaccines have been developed, but are 
not likely being used until the virus is wide-spread, in order to keep the 
introduction of new influenza genes in the human population at the lowest level. 
Consequently, development of HSNl vaccines has been largely focused on the 
inactivated vaccine formulations [69]. Other types of influenza vaccine in 
development include virus-like particles, DNA-vaccine, and recombinant-HA 
vaccine [70]. Inactivated vaccine production 
Production of inactivated influenza vaccines basically starts with bulk production 
of influenza virus, which is grown in embryonated chicken eggs or cell culture. To 
this end a seed-virus is used that carries a combination of genes which encode for 
the specific antigens, and genes which promote high-yield growth. 
Conventionally, a seed-virus is a reassortant obtained by simultaneously infecting 
chicken eggs with the specific virus and an egg-adapted strain [70]. 
After bulk production of vaccine virus, the virus particles are purified and 
inactivated, using formaldehyde or beta-propiolactone. These particles can be 
used directly as a WIV vaccine. Alternatively, the virus particles may be degraded 
by treatment with detergent and/ or ether to produce a split-virus vaccine. Further 
purification of the HA and NA proteins yields a subunit vaccine [71]. A virosomal 
vaccine is produced by detergent treatment, followed by removal of the 
nucleocapsid containing the viral RNA, and reconstitution of the viral envelop 
membrane bearing the HA and NA proteins [72]. Vaccine immunogenicity 
The protective efficacy of a vaccine is primarily determined by the induction of 
neutralising antibodies against the viral HA surface protein. Antibodies against 
NA play a secondary role but may contribute to protection and may lessen the 
severity of infection [73]. Consequently these antigens are the essential 
components of all inactivated influenza vaccines. A sufficient amount of vaccine­
induced serum anti-HA antibodies, indicated by a serum hemagglutination 
inhibition (HI) titre >40, is generally accepted as the most important correlate of 
19 
Chapter 1 protection [74,75]. In addition, cytotoxic T lymphocyte (CTL) induction may play a role in cross-protective immunity and could aid by reducing disease severity and mortality in a pandemic [75]. 
Textbox 7. Mathematical models have been employed to predict the result 
of different containment measures including chemo-prophylaxis, 
household quarantine and pre-vaccination on the outcome of an emerging 
HSNl pandemic in South-East Asia. [76,77]. All three measures applied 
together and well in time could contain a pandemic at the source when the 
RO (mean number of secondary cases infected by one infected person) is as 
high as 2.4. This would impose controllability over potential pandemic 
viruses, as infectious as the 1918 virus with an estimated RO of 2 to 3, and is 
an argument for the stockpiling of oseltamivir and pre-pandemic vaccines 
for containment actions [78,79]. 
Pandemic vaccine The ideal vaccine against an influenza pandemic would be one that is available at the onset of the pandemic, in quantities sufficient to vaccinate the majority of the world population, and sufficiently potent to allow for one immunization for protection. Although influenza vaccines have been in development for a long time, starting in the 1940s, such vaccine does not exist. CHALLENGES IN PANDEMIC VACCINE PRODUCTION Knowledge about the exact virus subtype and strain is crucial to produce a protective vaccine [73], but will only become available once the pandemic has started. Then, it will take 4 to 6 months of production time before the first vaccines become available, while it may take only 2 months for the virus to spread worldwide [79, 80]. Speeding up the production process is therefore paramount (this problem was evident in the 2009 pandemic [81]). H5Nl's lethality to humans and chickens poses a safety concern, and hampers the production on chicken eggs. The global production capacity is limited and owned by only a few industrialized countries, which creates a vaccine shortage and may lead to uneven distribution 
20 
Introduction [56] (and in fact did so during the 2009 pandemic [82]). Besides the search for ways to expand production capacity, high priority should therefore be given to the investigation of strategies that economise on the use of antigen [83]. As a complicating factor, H5Nl virus processed into conventional vaccines is only weakly immunogenic in un-primed humans [71,84]. Furthermore, because there is no pre-existing cross-protective immunity in the population to H5Nl, an extra priming dose is required [84]. Vaccines produced and stockpiled in anticipation of a pandemic need to be cross-protective, because the strain that actually causes the pandemic may have drifted away from the vaccine strain [79]. Also, because it is unknown when the next pandemic will occur, the stability of the stockpiled vaccines over time is an important issue. Rapid production of low-pathogenic, high-yield seed strains The majority of the vaccines are produced on embryonated chicken-eggs, which are killed by the H5Nl virus. A new technique called reverse-genetics made it possible to delete the nucleic acid sequences that confer the pathogenicity traits (at least for chickens and eggs) from the HA gene, and reconstruct a virus de novo using DNA plasmids, which provide the genetic information for the RNA segments of the viral genome. [85]. By combining the modified H5Nl HA and the NA gene with the other genes of an attenuated strain (PR/8) which has been extensively used in vaccine production, a high-yield non-pathogenic vaccine virus can be created with on its surface the HA and NA proteins of H5Nl. This way, recombinant seed viruses for vaccine production can be readily made and this strategy has been used to produce H5Nl pre-pandemic vaccines [86-88]. Using reverse genetics to produce a seed virus will also speed up vaccine production in response to a pandemic. Normally, an 8-12 week period is necessary to produce a safe vaccine strain from the wild type virus, through reassortment in double infected embryonated chicken eggs [89, 70]. With reverse genetics a vaccine virus can be generated in less than 4 weeks [90]. Availability of vaccines will also be accelerated by fast tract licensure based on the experience with mock-up vaccines using a comparable virus that simulates the novelty of a pandemic virus [89]. Limitations in mass vaccine production and low vaccine immunogenicity In a standard dose of seasonal subunit vaccine 15 µg of HA of a particular subtype is incorporated, providing 70-90% protection in healthy adults [90]. In contrast, 21 
Chapter 1 
two doses of 90 µg of H5Nl subunit vaccine were needed to reach seroprotection 
in >50% of the recipients [84, 91]. The low immunogenicity of H5Nl combined 
with a limited global vaccine production capacity necessitates the development of 
dose-sparing strategies. Possible dose-sparing strategies include the use of WIV 
vaccines and addition of adjuvants. 
WIV vaccines became outdated for epidemic use, due to the development 
of lower reactogenic split-virus and subunit vaccines, they are however more 
immunogenic in un-primed individuals than unadjuvanted split-virus and 
subunit vaccines [92-94], and the production process is less complicated and could 
potentially be faster. 
Adjuvants in potential augment the immunogenicity of a vaccine. 
Currently, few adjuvants are licensed for use in humans. Only aluminum 
hydroxide is US FDA approved. The European Medicines Agency has however 
approved the newer and stronger adjuvants MF-59 in combination with 
inactivated influenza vaccines (in 1997), and ASO3 (in 2009) in combination with 
HlNl pandemic vaccines [89]. Dealing with absence of pre-existing immunity 
In case of the 2009 HlNl pandemic, vaccination with a single dose of 15 µg HA 
seemed sufficient to induce protective antibody responses in >93% of healthy 
young adults [95,96]. Previous exposure to related virus strains may have primed 
the immune system for a rapid and effective antibody response [73]. In case of 
H5Nl, there is no pre-existing immunity, because this virus is only remotely 
related to the human influenza strains and is not frequently encountered in 
humans. Clinical studies with H5Nl vaccines have shown that two immunization 
are necessary for a protective antibody response [84,86-88]. For pandemic 
mitigation this is unfavourable as it will cost time and valuable vaccine doses. One 
way to deal with this problem is to use stockpiled pre-pandemic vaccines and 
administer the first dose as early in the evolving pandemic as possible. 
There is, however, a fair chance that stockpiled H5Nl pre-pandemic as well 
as pandemic vaccines may not match the actual pandemic virus, due to the 
evolution of drift variants. Since 1997, 10 antigenically distinct H5Nl clades have 
evolved (numbered from 0-9) [62] of which multiple clades (0, 1, 2 (subclade 2.1 to 
2.3), and 7) have caused disease in humans. Promisingly, pre-pandemic H5Nl 
vaccines containing whole virus particles or oil-in water adjuvants have been 
shown to induce significant cross-protective antibody response against viruses 
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I ntroduction from different HSNl clades [86,87,98-102]. Also, there is some evidence that a poorly-matching pre-pandemic vaccine could prime for the correct matching vaccine and may be administered in advance of the pandemic wave [97]. Using this strategy protective antibody levels can be reached earlier, and matching vaccines are being spared. Limited storage stability Pre-pandemic vaccines seem to have a role in pandemic mitigation due to their cross-protective activity and potential to serve as a priming agent. These features promote the stockpiling of pre-pandemic vaccines. In the past decade HSNl vaccines have been stockpiled by nations as well as the WHO for containment purposes and resource-poor countries [79]. The shelf live of a vaccine is however limited and vaccines stockpiled some years ago may already have reached the expiry dates. For long-term storage and minimal vaccine wastage vaccine stability is an important issue. Additionally, because of their immediacy and world-wide application pre-pandemic as well as pandemic vaccines preferably need to be temperature stable, with a minimal requirement for cold-chain handling and storage [89]. IMPROVING PANDEMIC VACCINES To tackle some of the challenges of pandemic vaccine development, new approaches to vaccine immunogenicity and stability may be explored. Enhancing the quality of the antibody response The efficacy of a vaccine is traditionally measured by the level of serum HI antibodies induced by the vaccine. However, also the type of immune response induced, in terms of Thl or Th2 type response, may be important for protective immunity. Influenza virus infection naturally induces a Thl type response which coincides with production of specific subtype antibodies [103]. This response-type best provides protection against reinfection with influenza virus [104]. In mice Thl type antibodies have been shown to protect better against infection than Th2 type antibodies [105,106]. In some cases a wrong response type can be detrimental. A biased Th2 type response to a Respiratory Syncytial Virus (RSV) vaccine has been associated with vaccine-enhanced disease after RSV infection [107]. Differentiation into either Thl or Th2 cells, after the activation of T cells by dendritic cells, 
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Chapter 1 strongly depends on the presence of Thl-inducing cytokines, like interleukin 12 (IL-12) and interferon a (IFNa), or Th2-inducing cytokines, like IL-4 and IL-10, respectively [108]. Exploiting innate immunity In the past decade there has been a growing interest in mechanisms by which the innate immune system steers the adaptive immune responses [108]. Upon invasion, microbes are first recognized by pattern recognition receptors (PRR) of the innate immune system that sense microbial components, known as pathogen associated molecular patterns (PAMP) [109]. Viral nucleic acids are important PAMPS, with their PRRs being Toll-like receptors (TLR), which are located in the endosomes, and intracytoplasmic receptors like retinoic-acid-inducible protein I (RIG-I), melanoma differentiation associated gene 5 (MDAS) and DNA-dependent activator of IFN-regulatory factors (DAI) [110]. Intracytoplasmic PRRs are ubiquitously expressed and generally recognize viral nucleic acids produced during viral replication. The TLRs are restricted to specific cell subsets of the immune system, like dendritic cells (DC), NK cells, T cells and B cells, and recognize viral double stranded (ds) RNA (TLR3), single stranded (ss) RNA (TLR7 and TLR8), and DNA (TLR9) [110]. PRR activation by invading virus induces a signalling cascade resulting in activation of NF-KB and IRF leading to production of proinflammatory cytokines and type I IFN (IFNa/ f3), of which the latter is a direct inducer of an anti-viral state in the infected and neighbouring cells. [109]. In the TLR signalling cascade, MyD88 is a crucial adapter molecule for all TLRs except TLR3. It has become increasingly clear that activation of TLR is an important factor leading to the induction of the specific cytokine profiles that shape the response type into Thl or Th2 [108]. DC's play a crucial role in linking the innate with the adaptive immune system. TLR7 activation in plasmacytoid dendritic cells (pDC) induces a strong IFNa response, whereas conventional DC (cDC) hardly produce IFNa to TLR7 stimulation, but instead produce IL-6, IL-12 and TNFa [110]. Besides its role as Thl-inducing cytokine, IFN-I is important for antibody class switching of B cells, and stimulates cross-priming [110]. In addition to DC activation TLR7 triggering has a direct effect on antibody production by B-cells [111]. 24 
Introduction Improving vaccine stability 
In general, protein pharmaceutics, like vaccines, in aqueous solution are prone to 
physical and chemical degradation [112]. Liquid influenza subunit vaccine may be 
kept outside the fridge for only a limited time, which is in the order of a couple of 
weeks, before the HA starts to degrade and the shelf-live becomes affected [113]. 
Dry-powder vaccines are more stable, and can be stored at ambient temperature 
for considerably longer periods [114,115]. Such increased stability would benefit 
pandemic use. 
Freeze-drying is a method that has been successfully used to produce dry­
powder influenza vaccines, including WN, split-virus, subunit, and virosomal 
vaccine [116-119]. To avoid detrimental stresses on the HA during freezing and 
drying and to stabilize the vaccine during storage, disaccharide or oligosaccharide 
sugars can be added [reviewed in 120]. When the sugar solution containing the 
vaccine is rapidly frozen (in liquid nitrogen), water crystals will form whereas the 
crystallization rate of the sugar is too slow to form crystals. This leads to (freeze-) 
concentration of the sugar (and vaccine compound) and consequently further 
depression of the freeze-point of water by the solute. When the freeze­
concentration reaches its maximum, which is at the glass-transition temperature, 
viscosity dramatically increases and an amorphous glass is formed in which water, 
sugar and the vaccine compound are immobilized, and in which water is 
prevented from crystallization, during further lowering of the temperature. 
Subsequently all water, including crystals that have been formed, is removed by 
sublimation in a vacuum. During drying the temperature needs to remain below 
the transition point to a 'rubbery' state (Tg'), where the stabilization by the glassy 
matrix becomes compromised, and crystallization of the sugar may occur. The Tg' 
depends on the water, sugar, and vaccine compound in the glass, and increases 
with the loss of water. In the end a dry amorphous sugar glass is formed in which 
the vaccine compound is captured. This can be stored at higher temperatures, as 
long as it is kept below its transition temperature (Tg), which is primarily 
determined by the sugar used. The sugar glass is thought to confer stability to the 
vaccine due to immobilization, the replacement of water molecules and their 




Outline of the thesis The first aim of the thesis is to identify the basic vaccine formulation which is most fit for pandemic use, primarily in terms of immunogenicity, and to unravel its immunogenic mechanisms. Such knowledge may be used for the rational development of improved influenza vaccines for future pandemics and epidemics. The second aim is to further increase vaccine immunogenicity, by use of a conventional adjuvant, and to increase vaccine stability using sugar glass technology. We first compared the immune responses to whole inactivated virus vaccine (WIV), subunit vaccine, and a virosomal vaccine in a mouse model, using a H3N2 vaccine virus (Chapter 2). Quantitative as well as qualitative differences in the antibody response, T helper cell activation and cytokine production were assessed in mice with different genetic backgrounds. Irrespective of the genetic background of the recipient, WIV induced high levels of Th-1 type antibodies and performed better than subunit or the virosomal vaccine, which correlated with the capacity to induce IFNa production by pDC, and proinflammatory cytokines by cDC in vitro. Because viral RNA, present in WIV but not in subunit or virosomal vaccine, activates TLR7 leading to IFNa production, we assessed the role of TLRs in the adaptive response to different vaccine formulations (Chapter 3). To this end, TLR7 deficient and MyD88 /Trif deficient mice were immunized with HSNl WIY, split­virus or subunit vaccine. TLR7 activation by WIV turned out to play a major role in the differential immune responses exerted by these vaccines. It has been suggested by others that viral membrane fusion may be important for TLR7 signalling. Fusion activity may therefore be a feature that needs to be preserved in WIV preparation, as it might influence WIV induced immunity. To test this hypothesis we immunized mice with fusion-active and fusion-inactive HSNl WIV (Chapter 4). Our data shows that fusion activity does not seem to play a major role in the antibody response to WIV. The use of WIV vaccines and vaccine/ adjuvant combinations have both been suggested as dose-sparing strategies. We investigated the combination of these two strategies by immunizing mice with Aluminium hydroxide (Alum)­adjuvanted HlNl WIV (Chapter 5). Alum had a clear adjuvant effect on the quantity of the antibody response to WIY, but changed the induced immune phenotype. Remarkably, in a virus challenge experiment the addition of Alum to WIV had a deteriorating effect on the protective immunity induced by vaccination. 26 
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Chapter 2 Abstract Background: For protection against (re-)infection by influenza virus not only the magnitude of the immune response but also its quality in terms of antibody subclass and T helper profile are important. Information about the type of immune response elicited by vaccination is therefore urgently needed. Objectives: This study aims at evaluating in detail the immune response elicited by three current influenza vaccine formulations and at shedding light on vaccine characteristics which determine this response. Methods: Mice were immunized with whole inactivated virus (WIV), virosomes (VS), or subunit vaccine (SU). Following subsequent infection with live virus, serum antibody titers and Th cell responses were measured. The effects of the vaccines on cytokine production by conventional and plasmacytoid dendritic cells were investigated in vitro. Results and Conclusions. In Balb / c mice (Th2 prone) as well as in C57Bl/ 6 mice (Thl prone) WIV induced consistently higher hemagglutination-inhibition titers and virus-neutralizing antibody titers than VS or SU. In contrast to VS and SU, WIV stimulated the production of the antibody subclass IgG2a (Balb / c) and IgG2c (C57BL/6) considered to be particularly important for viral clearance and activation of IFNy producing T cells. Similar to live virus WIV stimulated the production of proinflammatory cytokines by conventional dendritic cells and IFNa by plasmacytoid cells while VS and SU had little effect on cytokine synthesis by either cell type. We conclude that vaccination with WIV in contrast to VS or SU results in the desired Thl response presumably by induction of type I interferon and other proinflammatory cytokines. 
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Influenza remains one of the major infectious diseases with 3 to 5 million severe 
cases of illness and 250-500.000 deaths per year in industrialized countries only 
according to estimates of the World Health Organization [l]. Next to the yearly 
epidemics there is the eminent threat of a new influenza pandemic with an 
estimated attack rate of 10-30% and possibly a very high death toll [2,3]. 
Vaccination has been and will be the cornerstone of influenza control in epidemic 
and pandemic situations. 
Among the available vaccine formulations split and subunit vaccines are 
most frequently used for immunization against the yearly influenza epidemics [4]. 
Split vaccines consist of inactivated virus particles which are disrupted by 
treatment with detergent and/ or ether. Subunit vaccines (SU) consist of the viral 
surface antigens purified from detergent-disrupted virus particles. Virosomal 
vaccines (VS) which have been introduced on the market recently are reconstituted 
viral membranes consisting of the viral surface antigens inserted in a lipid bilayer 
thus mimicking the viral envelope [5,6]. In the early years of influenza vaccination, 
whole inactivated virus (WIV) has also been used as influenza vaccine. However, 
the use of WIV vaccines was largely abandoned due to a higher incidence of side 
effects as compared to the other formulations. Recently, WIV has regained interest 
in the context of pandemic vaccine development as a simple and highly 
immunogenic vaccine formulation. Reactogenicity of modem WIV appears to be 
comparable to other vaccine formulations possibly due to improved methods for 
virus production and purification [7-11]. 
For the evaluation of vaccine efficacy the serum hemagglutination­
inhibition (HI) titer achieved by vaccination is currently used as the only correlate 
of protection. An HI titer of 40 is estimated to be associated with a 50% reduction 
of the risk of contracting influenza and is used as the basis for the EMEA criteria to 
which influenza vaccines have to comply [4]. This 50% protective titer was 
calculated from a number of clinical studies in which immunity was achieved by 
either natural infection or by vaccination with inactivated or live-attenuated 
influenza vaccines. Since infection as well as vaccination will induce a plethora of 
immune reactions it is unclear whether HI antibodies themselves provide 
protection or whether their presence is simply an indication for the immune status 
to influenza virus [12]. 
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Chapter 2 Recent evidence suggests that in addition to the magnitude of the immune reaction also the quality of the immune response is important for protection. The antibody response to natural infection by influenza virus and other viruses in mice is dominated by IgG2a (or in C57BL/6 mice IgG2c) [13-16]. By virtue of its Fe domain murine IgG2a/2c interacts very efficiently with complement factors and activatory Fe receptors [17-19]. Thereby, IgG2a/2c contributes to viral clearance by activation of the complement system, stimulation of antibody dependent cellular cytotoxicity and clearance of opsonized virus by macrophages [16, 20,2J]. In contrast, IgGl does neither activate complement efficiently nor has it a high affinity for activatory Fe receptors [18,19]. Recently, it was shown that IgG2a alone protects mice as efficiently from lethal challenge as a mixture of IgGl and IgG2a. In contrast, IgGl alone only protects from mild virus challenge but provides insufficient protection upon high dose challenge [22]. The relative contribution of Thl and Th2 cell-mediated effector mechanisms to protection from influenza virus-induced lung damage and to virus clearance is still under investigation. T helper cell responses to influenza infection involve IFNy producing Thl cells as well as IL4 producing Th2 cells but Thl responses are strongly dominant [23]. Evidence is accumulating that Thl cells are superior to Th2 cells in providing protection against viral infection and do so by secretion of IFNy and by stimulation of B cells and CDS+ T cells but also by direct perforin­dependent cytolysis [24-29]. On the other hand, Th2 cells are necessary to prevent excessive lung inflammation caused by an overwhelming Thl response [27]. In the absence of antibodies, T helper cells can provide a certain degree of cross­protective immunity possibly by secretion of IFNy which activates macrophages or by direct cytolysis of infected cells [25,26,29]. Since epitopes recognized by T helper cells are more conserved than those recognized by antibodies vaccine­induced T helper responses might contribute decisively to the cross-protective potential of influenza vaccines [29]. In order to shed more light on the quality of the immune response to different influenza vaccine formulations we immunized mice with wrv, VS or SU vaccines and measured the induced HI titers, virus-neutralizing antibody titers, virus specific IgGl and IgG2a/2c and determined the Thl/Th2 balance by enumeration of IFNy and IL4 producing T helper cells. Since the genetic background of mice is known to have a large effect on the immune response, the vaccination experiments were performed in Thl prone C57BL / 6 mice as well as in Th2 prone Balb / c mice. To obtain insight into the mechanisms responsible for the 
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Whole Inactivated Vaccine i s  Superior to Subun it Vacci ne differential reactions to the vaccines we studied the effect of the vaccine formulations on conventional and plasmacytoid dendritic cells in vitro. These cell types are considered as the most important switches between the innate and the adaptive immune system and are essential for the induction and control of specific immune responses. Our results show that in contrast to VS and SU vaccine, WIV induces a strong immune response qualitatively resembling the response obtained after virus infection irrespective of the genetic background of the recipient. The immune response to the vaccines in vivo is likely to be related to their capability to induce the production of proinflammatory cytokines by conventional DCs and IFNa by plasmacytoid DCs. 
Material & Methods 
MICE Ten to twelve week old female Balb / c mice or C57BL / 6 mice, purchased from Harlan Netherlands B.V. (Zeist, The Netherlands), were used for the immunization study or alternatively for isolation of spleen cells and bone marrow cells for in vitro stimulation experiments. Animal experiments were conducted according to the guidelines provided by the Dutch Animal Protection Act, and were approved by the Committee for Animal Experimentation (DEC) of the University of Groningen. 
VIRUSES AND VACCINES Egg-derived A/Panama/2007 /99 (H3N2) virus and subunit vaccine produced from this strain were a kind gift from Solvay Pharmaceuticals, Weesp, The Netherlands. Whole inactivated virus vaccine (WIV) was produced by inactivation of virus with 0.1% (3-propiolactone (Acros Organics, Geel, Belgium) for 24 hours at 19-21 °C, followed by dialysis and filtration (0.45 µm). Virosomes were produced as described previously [5,6]. In short, membrane lipids of (3-propiolactone inactivated virus were solubilized with detergent octa (ethyleneglycol)-n-dodecyl monoether (C12Es) (Nikkol, Tokyo, Japan). Nucleocapsids were removed by ultracentrifugation and membranes were reconstituted by extraction of C12Es using Biobeads (Bio-Rad, Hercules, CA). So formed virosomes were concentrated by ultracentrifugation on a 50 % sucrose cushion in Hepes buffered saline/ EDTA buffer (HNE), followed by dialysis and filtration. 
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Chapter 2 IMMUNIZATIONS AND INFECTIONS 
Mice were infected intranasally with 150 hemagglutination units (HAU) live A/ 
Panama virus or were intramuscularly immunized in the hind leg with 30 µl  of  the 
different vaccine formulations each containing 5 µg viral hemagglutinin protein 
(HA) in HNE buffer or received buffer only. After 28 days serum samples were 
collected prior to an intranasal boost with 150 HAU live influenza virus in 10 µl 
divided over both nostrils. Three days hereafter mice were bled to death and 
spleens were collected for T helper cell evaluation. HEMAGGLUTINATION-INHIBITION ASSAY 
A standard HAI assay was performed. In short, 75 µl serum was inactivated at 56 
�C for 30 min and absorbed to 225 µl 25 % kaolin/ PBS (Sigma-Aldrich, Inc., St. 
Louis, MO) solution for 20 min at room temperature (RT). After centrifugation 50 
µl supernatant was added to 50 µl PBS in duplicate in a round-bottom microtiter 
plate ( Costar, Coming Inc., Coming, NY) followed by two-fold serial dilutions. 4 
hemagglutination units (HAU) of virus in 50 µl PBS were added to each well and 
the mixtures were incubated for 40 min at RT. Finally, 50 µl of 1 % guinea pig 
erythrocytes (Harlan) in PBS was added to each well and HAI titers were 
determined after 2 hours incubation at RT. HAI titers represent the reciprocal of 
the highest serum dilution yielding complete inhibition of hemagglutination. HAI 
titers below the detection limit were assigned with half the value of the lowest 
serum dilution. VIRUS-NEUTRALIZATION ASSAY 
Virus-neutralizing (VN) serum antibodies were assessed by a VN assay described 
previously [30]. Briefly, quadruplicates of two-fold serum dilutions in (serum free) 
cell culture medium were incubated with an equal volume containing 6.25 TCID50 
virus, at 37 °C for 2 hours before 100 µl of this mix was added to Maden Darby 
canine kidney (MDCK) cell monolayers in a microtiter plate (Costar, Coming Inc.). 
After overnight incubation in a humidified CO2 incubator at 37 °C, cells were fixed 
with 80% acetone in PBS and the amount of intracellularly produced viral 
nucleoprotein (NP) was determined by ELISA. Blocking was performed with 150 
µl of 4% BSA (Sigma-Aldrich) in 0.05% Tween 20 /PBS (PBS/T), 45 min at RT, 
followed by washing with PBS/T. Subsequently, 100 µl of anti-NP monoclonal 
antibody (mAb) (Instruchemie, Delfzijl, The Netherlands), diluted 1:8000 in 
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Whole I nactivated Vaccine is Superior to Subun it Vaccine 1%BSA/0.1%Tween 20/PBS, was added for 1 hour at RT, followed by washing. Bound anti-NP mAb was detected by incubation with 100 µl goat anti-mouse IgG­horseradish peroxidase conjugate (Southern Biotech, Birmingham, Alabama), diluted 1:8000 in 1% BSA/0.1%Tween/PBS, 1 hour at RT, followed by washing and subsequent staining with o-phenylene-diamine-dihydrochloride (OPD) (Eastman Kodak Company, Rochester, NY). Absorbance at 492 nm (A,m) was measured with an ELISA reader (Bio-tek Instruments, inc., Winooski, VT). VN titers were expressed as the reciprocal of the highest dilution yielding an average A492 above the end-point value resulting from the equation: [(average A492 of the positive controls (infected cells) minus average A492 of the negative controls (non infected cells)) divided by 2] plus the average A492 of the negative controls. lSOTYPE ELISA For detection of virus specific serum antibodies of different isotypes microtiter plates (Greiner, Alphen a/ d Rijn, The Netherlands) were coated with 0.2 µg influenza subunit vaccine in 100 µl 0.05 M carbonate-bicarbonate coating buffer (pH 9.6-9.8) per well, overnight at 37 °C, followed by blocking with 2% milk in coating buffer for 45 minutes at 37°C. After washing with coating buffer and 0.05%Tween 20/PBS (PBS/T), 100 µl of serum diluted in PBS/T was applied in duplicate to the first well and serial twofold dilutions were made. A subsequent incubation for 1.5 hours at 37°C was followed by washing and incubation with 100 µl of horseradish peroxidase conjugated goat anti-mouse IgG-isotype antibody (Southern Biotech) for 1 hour at 37°C. Plates were washed and stained with OPD (Eastman Kodak Company). Absorbance at 492 nm (Ait92) was read with an ELISA reader (Bio-tek Instruments, inc.). After subtraction of background levels, serum antibody concentrations were calculated by means of appropriate isotype standards (Southern Biotech) using linear regression. ELISPOT IFNy and IL4 ELISPOT asays were performed as described before [31] with some adaptations. In short, erythrocyte-depleted splenocytes (5x105 cells per 100 µl 5% FCS/50 µM (3-mercaptoethanol/IMDM medium (Gibco, Paisley, UK)) were seeded in triplicate on a microtiter plate (Greiner), pre-coated with anti-IFNy or anti-IL4 capture antibodies (Pharmingen, San Diego, CA) and blocked with 4% BSA/PBS (Sigma-Aldrich). Cells were stimulated with 1 µg A/Panama virosomes per well, overnight in a humidified CO2 incubator at 37 °C. Plates were treated 
43 
Chapter 2 with 100 µl of H2O per well and kept on ice to lyse the cells. After washing with 0.02% Tween 20/PBS, biotinylated anti-IFNy or anti-IL4 antibody (Pharmingen) was added at a concentration of 0.125 µg/ ml in 2% BSA/PBS (Sigma-Aldrich), 50 µl / well, and incubated for 1 hour at 37 °C. After washing and incubation with alkaline phosphatase conjugated streptavidin (Pharmingen), 1:1000 diluted in 2% BSA/PBS, 100 µ1/ well for 1 hr at 37°C, spots were visualized with a 5-bromo-4-chloro-3-indolylphosphate (Sigma-Aldrich) substrate reaction immobilized in solidified agarose. Plates were scanned and spots were counted manually. C ULTURE OF CONVENTIONAL DCS Femurs from Balb/ c mice were dissected and flushed with IMDM (Gibco) to collect bone marrow (BM). BM leukocytes were seeded at 2x106 cells in a 100 mm bacteriological petri dish ( Corning) in the presence of 200 U / ml recombinant mouse (rm) GM-CSF (Peprotech, London, UK) as described in detail by Lutz and colleagues [32]. After 9 days of culture, the non-adherent cells were collected by gentle pipetting, and centrifugation at 300 g for 5 minutes at RT. FACS analysis showed over 70% of these cells to be CDllc positive, representing cDCs. l.5x107 cells were seeded per culture dish (100 mm, Coming) in 10 ml fresh medium containing 100 U /ml rmGM-CSF. To induce maturation and cytokine production, cDCs were exposed to active virus with a multiplicity of infection (MOI) of 1.5, or to different inactivated vaccine formulations (10 µg HA per ml). After 4, 12 and 24 hours incubation in a humidified CO2 incubator at 37 °C supematants were collected for cytokine quantification by Luminex multiplex immunoassay. L UMINEX ASSAY The multiplex technology (Luminex Corp., Oosterhout, The Netherlands) combines the principle of a sandwich immunoassay with fluorescent bead-based technology, allowing individual and multiplex analysis of up to 100 different analytes in a single microtiter well [33]. The multiplex assay for 6 cytokines [1Llf3, IL6, ILl0, IL12p70, TNFa, IFNy] was performed in 96-well microtiter plate format according to the manufacturers protocol (LINCO Research, Inc, Missouri, USA). Samples were analyzed on a Luminex 100 apparatus, and calculations were performed using STarStation software (Applied Cytometry Systems, Sheffield, UK). 
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Whole Inactivated Vaccine is Superior to Subunit Vacci ne PLASMACYTOID DENDRITIC CELLS Single splenocyte suspensions were produced as described in the ELISPOT section and enriched for plasmacytoid DCs (pDCs) by depletion of T cells, B cells, NK cells and macrophages by magnetically labeling and separating CD3, CD19, CD llb and CD49b positive cells (Miltenyi Biotech GmbH, Germany). Labeling of pDCs with anti-mPDCA-1-PE antibody (Miltenyi) for FACS analysis, revealed a final pDCs population constituting approximately 6 % of the enriched cell population. Cell suspensions containing 1-2x105 pDCs in 100 µl were seeded in a microtiter plate and stimulated in triplicate with an equal volume containing the appropriate amount of vaccine or live virus for 20 hours in a humidified CO2 incubator at 37 °C. Culture supematants were collected and subjected to the IFNa ELISA . IFNa ELISA Two fold serial dilutions of culture supematants, starting from a 4 fold primary dilution, were subjected in duplicate to an IFNa ELISA previously described by Lund et al. [34], except that the staining was performed with OPD (Eastman Kodak Company) and absorbance was read at 492 nm. IFNa concentrations were calculated from a recombinant IFNa standard curve performed in quadruplicate (HyCult, Biotechnology, Uden, The Netherlands) using linear regression, and expressed in units per ml. STATISTICAL ANALYSIS Statistical analysis on antibody titers was performed using the unpaired Student's t test. P values of p<0.05 and p<0.01 were considered as statistically significant or highly significant, respectively. Results In order to elucidate the effect of vaccine formulation on the magnitude and the quality of the elicited immune response, mice were immunized once with 5 µg HA derived from A/Panama/2007 /99 (H3N2) formulated as WI\!, VS, or SU vaccine. Serum samples were taken four weeks after immunization and the hemagglutination-inhibiting (HAI) and virus-neutralizing (VN) capacity of the sera was determined (Table 1). In Balb / c mice, all three vaccines induced HAI titers > 40, with WIV producing the highest responses. In C57BL / 6 mice, HAI 
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titers after immunization with WIV were similarly high as in Balb / c mice but were 
low (<40) after immunization with VS or SU. The neutralizing activities of the sera 
correlated with the HAI titers. In both mouse strains they were highest after WIV 
immunization. Immunization with VS  or SU vaccine induced measurable virus­
neutralizing activity in Balb / c mice, whereas this activity was under the detection 
limit of 80 in C57BL / 6 mice. Table 1: Hemagglutination-inhibition titers and virus-neutralization titers after a single immunization. Balb/c C57Bl/6 
HAI VN HAI VN 
HNE <8 <80 <8 <80 
WIV 256 691 ** (577-823) 256 1493** (959-2457) vs 128 1 60* ( 125-200) 16  <80 
SU 128 148* (87-234) 16 <80 Mice were immunized once i.m. with buffer only (HNE) or with 5 µg HA formulated as WTV, VS, or SU. On day 28 serum samples were taken. For HAI determination serum samples were pooled per group (11=9). For determination of VN titers sera from individual mice were tested. Titer is given as geometric mean, the 95% confidence interval is indicated. Statistical significant differences (P<0.01) are as indicated: ** compared to VS, SU or HNE, * compared to HNE. 
Twenty-eight days after immunization the mice were infected intranasally 
with live A/ Panama virus and early memory responses were determined three 
days later. Infection with A/Panama virus does not lead to symptomatic disease in 
mice but induces nevertheless humoral and cellular immune responses. Intranasal 
administration of live A /Panama virus boosted the vaccine-induced HAI and VN 
titers in either mouse strain (Fig. 1). In Balb / c mice immunization with all three 
vaccines resulted in high HAI titers and VN titers after virus exposure (Fig. 1, left 
panels). Yet, titers in WIV-immunized mice were higher than in VS- and SU­
immunized animals. These differences were statistically significant for HAI titers 
after WIV- vs SU immunization (p<0.05) and for VN titers compared between WIV 
and VS as well as SU (p<0.01). In C57BL / 6 mice only WIV induced consistently 
high HAI and VN titers in all immunized mice whereas VS or SU resulted in 
measurable HAI and VN titers in only some of the immunized animals (Fig. 1, 
right panels). Differences in titer between WIV- and VS- or SU-immunized mice 
were highly significant (p<0.01) in all cases. Taken together these results show that 
WIV is more immunogenic than VS or SU irrespective of the mouse strain studied. 
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HNE WIV vs SU HNE WIV vs SU Figure 1: HAI titers and VN titers after immunization followed by virus challenge. Mice (9-10/experimental group) were injected i.m. with buffer (HNE) or were vaccinated by i.m. injection on day 0 with 5 µg HA derived from strain A/Panama/2007/99 (H3N2) formulated as WTV, VS or SU vaccine and were i.n. infected on day 28 with A/Panama virus. Three days later mice were sacrificed. HAI titers and VN titers were determined in individual sera as described in Material & Methods. Results are given as log2 titers. The detection limit was 2 for HAI determination and 5.3 for VN determination, respectively. Significant (p<0.05) and highly significant (p<0.01) differences beh.veen WIV and the other vaccine formulations are indicated by * and **, respectively. The quality of the vaccine-induced immune response was investigated by determination of the IgG subclass profile and enumeration of IFNy- and IL4-producing T helper cells. As a reference, we included in these studies mice that were immunized by exposure to live virus 28 days prior to virus challenge. Determination of IgG subclasses by ELISA revealed that Balb / c mice which had been earlier exposed to live virus produced similar amounts of IgGl and IgG2a. Immunization with WIV resulted in the production of substantial amounts of IgG2a but little IgGl (Fig. 2). Production of antibodies in response to immunization with VS or SU vaccine was lower and the antibodies synthesized were almost exclusively of the IgGl subclass. C57BL / 6 mice express the antibody 
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Virus WIV vs SU Virus WIV vs SU Figure 2: IgG subtypes after immunization and subsequent virus challenge. Mice were treated as described in the legend to Fig. 1 .  An additional group of mice was i.n. infected on day O with 150 HAU of live A/Panama virus (virus) and received a second dose of virus 150 HAU on day 28. IgGl (black diamonds) and IgG2a (light gretJ diamonds) or IgG2c (dark gretJ diamonds) were determined by ELISA and amounts were calculated using IgGl, IgG2a, and IgG2c standards. Responses significantly lower or higher than those induced btj WIV (p<0.05) are indicated by # and *, respectively. 
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Virus WIV vs SU Virus WIV vs SU Figure 3: T helper responses after immunization followed by virus challenge. Splenoe1 tes obtained from the mice described above were used to perform ELISPOT assays for enumeration of IFNy- (black triangels) and IL4- (gretJ triangels) producing T helper cells. Cells were stimulated overnight before lysis and detection of the respective cytokines. Responses significantly lower or higher than those induced by WIV (p<0.05) are indicated btJ # and *, respectively. 
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To obtain further insight into the quality of the immune response induced by the 
three different vaccines in relation to virus exposure, T helper responses were 
measured (Fig. 3). After earlier virus exposure or immunization with wrv, Balb/ c 
mice as well as C57BL / 6 mice generated large numbers of IFNy-producing cells 
after challenge. IL4-producing cells were also detected although in much lower 
amounts. In contrast, the T helper responses to VS and SU vaccine were either 
balanced or dominated by IL4-producing cells. The number of IFNy-producing 
cells in VS- or SU-immunized mice was significantly lower than in WIV­
immunized mice except for VS-immunized Balb/ c mice (p<0.01 in all cases). IFNy 
and IL4 are regarded as signature cytokines of Thl and Th2 cells, respectively. We 
therefore used the results of the ELISPOT assays to calculate ratios of Thl -type 
cytokine and Th2-type cytokine producing cells (Thl /Th2 ratios). Ratios were 
calculated for individual mice and the average and standard deviation were 
determined per experimental group (Fig. 4). As was found for virus-exposed mice 
the mean Thl /Th2 ratio was >> 1 for all mice immunized with WIV with mean 
ratios of 2.68 for Balb / c mice and 3.51 for C57BL / 6 mice. In contrast, Thl /Th2 
ratios in VS- and SU-immunized mice were close to 1 or lower than 1 and in each 
of these experimental groups a minority of the mice showed ratios > 1. Taken 
together the results of the immunization experiments indicate that immunization 
with WIV induces a Thl response with induction of IgG2a and IFNy-producing T 
helper cells. At least with respect to the T helper cells this response resembles that 
observed after exposure to live virus. In contrast, VS and SU vaccines induce Th2 
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incubation time (h] Figure 5: Cytokine production of conventional DCs upon exposure to virus or vaccines. Bone marrow cells were cultured for 9 days with GM-CSF to obtain cDCs. On day 9 cells were exposed to live influenza virus (closed circles), WIV (open circles), VS (closed triangles) or SU (open triangles) for the periods indicated or were left untreated (black squares). Supernatants were harvested and e1;tokines were determined using Luminex technologi;. Results shown are the mean of two independent experiments. Each supernatant was measured in duplicate. 
pDCs have been described as the major producers of type I interferon during virus 
infection [36]. A pDC-enriched cell population was prepared from splenocytes of 
naYve Balb/ c mice and the cells were incubated with 0.01, 0.1, 1, or 10 µg HA 
formulated as active virus or WlV, VS or SU vaccine, respectively (Fig. 6a). Cells 
incubated with active virus or WIV produced substantial amounts of IFNa. These 
amounts peaked at a HA concentration of 0.1 µg / ml but were lower for lower as 
well as higher antigen doses. In contrast, pDCs incubated with VS or SU vaccine 




used. IFNa production in reaction to WIV was also observed in crude splenocyte 
preparations but amounts increased significantly upon pDC enrichment indicating 
pDCs as a major source of IFNa (Fig. 6b ). Similar to spleen-derived pDCs from 
Balb/c mice, pDCs derived from bone marrow of C57BL / 6  mice by culture with 
Flt3 ligand produced IFNa upon exposure to WIV but not to SU vaccine (Fig. 6c). 
These data indicate that the differential reaction to the different vaccine 
formulations is independent on the source of the pDCs and the strain of mice. In 
conclusion, WIV is superior to VS and SU in activating cDCs as well as pDCs to 
produce cytokines that can modulate the extent and the phenotype of adaptive 
immune responses. 
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µg HA 0 0 Figure 6: Production of IFNa by plasmacytoid DCs after exposure to virus or vaccines. (A) Splenocytes derived from Balb/c mice were enriched for pDCs as described in Material & Methods. Cells were incubated for 20 hours with the indicated amounts of HA using either live virus (filled circles), WIV (open circles), VS (filled triangles), or SU vaccine (open triangles). Supernatants were harvested and IFNa was determined by sandwich ELISA. Results of a representative experiment are shown. (B) Crude splenocytes (black bar) and splenoci;tes enriched for pDCs as above (gretJ bar) were incubated for 20 hours with 0.1 µg WIV. Supernatants were analyzed for IFNa as above. (C) Flt3 ligand cultured bone marrow cells were exposed to 0.1 µg WIV (white bar) or SU vaccine (black bar for 20 hours and IFNa in the supernatants was analyzed as above. 
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Whole Inactivated Vaccine is Superior to Subunit Vaccine Discussion In this paper we show that, using the same amount of HA, immunization of mice with WIV results in higher HAI and VN titers than immunization with VS or SU. Moreover, the quality of the response to the vaccines differs profoundly. While WIV elicits a Thl response reminiscent of that found after virus infection, VS and SU induce typical Th2 responses. The observed differences in the amounts and subtypes of the induced antibodies and the phenotypes of the T cell responses to the different vaccine formulations were independent of antigen dose as revealed by dose-response studies using antigen amounts as low as 0.04 µg (results not shown). The responses found in vivo reflected the effects of the vaccines on dendritic cells in vitro. Similar to active virus WIV induced the synthesis of various cytokines by cDCs and stimulated the production of type I interferon by pDCs. In contrast, VS and SU had only moderate to low effects on DCs in vitro. Similar to the results obtained in the murine system reported here, higher HAI titers in response to WIV as compared to the other formulations have also been reported from human clinical trials especially when the study population was naive to the vaccine strain used [7,37-39]. The superior immunogenicity of WIV could be of great importance in a pandemic situation when protective immune responses against a new virus variant have to be achieved with a minimum amount of antigen. Evidence is accumulating that not only the magnitude of the immune response but also its quality is important for protection. In the murine system IgG2a was found recently to have a greater protective potential than IgGl [22, Bungener et al, unpublished observations]. Moreover, Thl cells can protect from lung damage while Th2 cells can be deleterious [24, 26-28]. These observations imply that the vaccine-induced immune response should ideally be of a type I phenotype. In the murine system, the current study and studies of others show that only WIV but not split, VS, or SU vaccine can induce the desired type I response [40-43]. In the human situation the quality of the evoked immune response has so far largely been neglected. HAI titers, and for HSNl trials VN titers, are usually the only correlates of protection measured in clinical studies. Since vaccines can differ profoundly in the type of response they evoke and since this type can have important implications for protection we strongly recommend including the determination of immune response quality in future clinical studies. 
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Chapter 2 Interestingly, the differences we found in the immune response to active virus and WIV on the one hand and VS and SU on the other hand correlated with the effect of these agents on dendritic cells in vitro. DCs are considered as the most important antigen presenting cells and are the only cells that can activate naive T cells [for reviews see 44-46]. Moreover, they are involved in the polarization of naive T cells to a Thl or Th2 phenotype, respectively, and do so by the secretion of defined cytokines [for review see 47]. We used bone marrow cells cultured with GM-CSF to generate cDCs in vitro. Only when incubated with active virus or WIV these cells produced substantial amounts of cytokines. These included IL12 which is considered as necessary to activate IFNy production by Thl cells [35]. Virus and WIV also induced the production of the proinflammatory cytokines IL1[3, IL6 and TNFa. These cytokines were also found to be upregulated in human DCs incubated with live influenza virus [48]. Notably, ILl0 which is involved in the control of the immune response and considered as a Th2 cytokine was also induced by virus and WIV although at later time points as the proinflammatory cytokines. cDC-derived cytokines are very important for activating, directing and controlling adaptive immune responses. The higher and qualitatively different immune responses evoked by WIV as compared to the other vaccines might therefore - at least partly - be explained by stronger effects of WIV on cDCs. pDCs are less active in antigen presentation than cDCs. However, they are highly important in the innate defense of virus infections since they can produce large amounts of type I interferons, particularly IFNa upon exposure to virus [36,49,50]. In our assays, pDCs exposed to active virus and WIV produced similar amounts of IFNa whereas neither VS nor SU induced any IFNa synthesis. Type I interferons are major inducers of activation of immature DCs and lead to the upregulation of MHC molecules, chemokines, chemokine receptors and co­stimulatory molecules [SO]. Moreover, they exert direct effects on B and T cells thus affecting antibody secretion and antibody class switching [51]. Type I IFNs have been described as natural adjuvants. When added during immunization with influenza vaccine, type I IFN enhanced IgGl but especially IgG2a responses and significantly improved survival of the mice after virus challenge [52]. We therefore consider it likely that IFNa presumably produced by pDCs, upon immunization with WIV but not VS or SU vaccine is responsible for the enhanced immune response and the dominant Thl reaction. Together with studies of others comparing split vaccine with WIV [41-43] our current investigations allow interesting conclusions on the parameters which 
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determine vaccine immunogenicity. Split vaccine and WIV both contain all the 
viral components yet they elicit very different immune responses indicating that 
not only vaccine composition but also the physical structure of the vaccine 
(soluble vs particulate) is important. On the other hand, virosomes and WIV 
sharing the particulate structure but differing in their composition also induce 
very different responses. From these results we conclude that it is the combination 
of vaccine components present and their physical organization which determines 
the immunological properties of a vaccine. Interestingly, WIV and active virus 
elicited quantitatively and qualitatively similar responses indicating that the 
structural integrity of the virus particles is more important for the immune 
response than the presence or absence of virus replication. The exact mechanisms 
by which active virus and the vaccines induce the differential production of DC 
cytokines are so far unclear. It is tempting to speculate that stimulation of 
pathogen associated molecular pattern (PAMP) receptors is involved. Elucidation 
of these mechanisms is highly interesting in the context of rational vaccine 
development and will be approached in a follow-up study. 
In conclusion, we showed that WIV vaccine induces a stronger and more 
Thl-skewed immune response than VS and SU vaccines most probably due to 
direct action of the vaccine on conventional as well as plasmacytoid DCs. Due to 
its enhanced immunogenicity WIV can induce protective immune responses at 
lower antigen doses. Moreover, the type of the immune response elicited by WIV 
has proven to provide better protection in animal models. We therefore consider 
WIV as a highly attractive vaccine candidate especially in a pandemic situation. 
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Chapter 3 Abstract 
In the case of an influenza pandemic, the current global influenza vaccine 
production capacity will be unable to meet the demand for billions of vaccine 
doses. The ongoing threat of an HSNl pandemic therefore urges the development 
of highly immunogenic, dose-sparing vaccine formulations. In unprimed 
individuals, inactivated whole virus (WIV) vaccines are more immunogenic and 
induce protective antibody responses at a lower antigen dose than other 
formulations like split virus (SV) or subunit (SU) vaccines. The reason for this 
discrepancy in immunogenicity is a long-standing enigma. Here, we show that 
stimulation of Toll-like receptors (TLRs) of the innate immune system, in 
particular stimulation of TLR7, by HSNl WIV vaccine is the prime determinant of 
the greater magnitude and Thl polarization of the WIV-induced immune 
response, as compared to SV- or SU-induced responses. This TLR dependency 
largely explains the relative loss of immunogenicity in SV and SU vaccines. The 
natural pathogen-associated molecular pattern (PAMP) recognized by TLR7 is 
viral genomic ssRNA. Processing of whole virus particles into SV or SU vaccines 
destroys the integrity of the viral particle and leaves the viral RNA prone to 
degradation or involves its active removal. Our results show for a classic vaccine 
that the acquired immune response evoked by vaccination can be enhanced and 
steered by the innate immune system, which is triggered by interaction of an 
intrinsic vaccine component with a pattern recognition receptor (PRR). The 
insights presented here may be used to further improve the immune-stimulatory 
and dose-sparing properties of classic influenza vaccine formulations such as WIY, 
and will facilitate the development of new, even more powerful vaccines to face 
the next influenza pandemic. 
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TLRs Determine Influenza Vaccine lmmunogenicity Author Summary The rise and spread of the highly pathogenic avian HSNl influenza virus has seriously increased the risk of a new influenza pandemic. However, the number of vaccine doses that can be produced with today's production capacity will fall short of the demand in times of a pandemic. Use of inactivated whole virus (WN) vaccines, which are more immunogenic than split virus or subunit vaccines in an unprimed population, could contribute to a dose-sparing strategy. Yet, the mechanisms underlying the superior immunogenicity of WN vaccine formulations are unknown. Here, we demonstrate that the viral RNA present in inactivated virus particles is crucial for the improved immunogenic properties of WN in mice. By triggering Toll-like receptor 7 (TLR7), the viral RNA activates innate immune mechanisms that augment and determine subsequent adaptive responses. Efficient TLR7 signalling is lost in split virus and subunit vaccines with the processing steps that lead to disruption of the integrity of the virus particle and exclusion of the RNA. Our results prove for the first time to our knowledge that the immune-potentiating mechanism of a classic vaccine is based on activation of the innate immune system by one of its structural components. These findings may reflect a general principle for viral vaccines and provide a rational basis for further improvement of influenza vaccines, which are urgently needed in the face of the current HSNl pandemic threat. 
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Chapter 3 Introduction The first cases of human infection with highly pathogenic avian influenza (HPAI) H5Nl virus occurred in 1997 during an outbreak in Hong Kong [1]. Since then HPAI H5Nl has spread across Asia, Europe, Africa and the Pacific, and has caused a cumulative number of 338 laboratory confirmed human cases of infection, with a fatality rate of >60% [2]. Although no sustained human to human transmission has been observed yet, the threat of an imminent H5Nl pandemic requires maximum preparedness [3]. Vaccination is considered the cornerstone of protection against epidemic and pandemic influenza. However, an anticipated scarcity of the antigenic vaccine components and a narrowed time window between vaccine production and deployment puts special constraints on the vaccine formulation to be used in a pandemic situation [4],[5]. Consequently, pandemic vaccine formulations should ideally be dose sparing and uncomplicated to produce [6],[7]. Whole inactivated virus (WIV) vaccines consisting of formalin-inactivated whole virus particles were the first registered influenza vaccines licensed in 1945 in the United States [8]. However, the use of this vaccine formulation caused a relatively high incidence of adverse events, including local reactions at the site of injection and febrile illness, particularly among children [9],[10]. In the 1960 and 1970s, WIV vaccines were therefore largely replaced by less reactogenic split virus (SV) and subunit (SU) formulations [8]. SV and SU vaccines contain detergent­and / or ether-disrupted (split) virus particles or purified viral haemagglutinin (HA) and neuraminidase (NA) proteins, respectively. Apparently, disruption of whole inactivated influenza virus particles diminishes the reactogenicity of the vaccines. In primed individuals, unadjuvanted WN, SV, and SU vaccines in general induce similar immune responses in terms of haemagglutination inhibition (HI) titres (for a meta-analysis over 24 studies see[ll]). However, in individuals that have not been exposed to the vaccine antigens before, WIV vaccines are more immunogenic than SV and SU vaccines [9],[ll],[12]. Similarly, in naYve animals immunization with WIV raises stronger immune responses than immunization with SV or SU [13]-[15], especially after a single administration. In the case of an H5Nl pandemic, the majority of the population is expected to be immunologically nai:ve to the H5Nl subtype. In this scenario, use of WIV as basis for an optimized vaccine may be of advantage, for its immunogenic superiority seems to rely on the 
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TLRs Determine Influenza Vaccine l m munogenicity ability to activate unique mechanisms in the priming event of the immune response. Thus, WIV seems to harbour an intrinsic immune-potentiating component that is lost during processing of inactivated virus particles to SV and SU vaccine formulations. In earlier experiments, we and others observed that immunization of mice with WIV vaccine results in a Thl-skewed immune response and strong antibody induction with high levels of IgG2a antibodies [14]-[16]. This response type was found irrespective of the murine genetic background or subtype of virus (either HlNl or H3N2) and conferred protective immunity against challenge with homologous virus [15],[16]. By contrast, immunization with SU vaccine yielded responses of a Th2 phenotype with lower antibody levels mainly consisting of the IgGl subtype, which did not lead to protection. "Empty" reconstituted viral envelopes (virosomes) resembling intact virus particles but devoid of the viral nucleocapsid elicited responses similar to those after vaccination with SU formulations [15]. This identifies the viral nucleocapsid which contains the viral genomic ssRNA as the immune-potentiating component of WIV. In the past decade, it has become increasingly clear that the acquired immune response to microbial infection is regulated through recognition of pathogen-associated molecular patterns (PAMPs) by Toll-like receptors (TLRs) and other pattern recognition receptors of the innate immune system [17]-[20]. However, the importance of TLR signalling in immune responses to vaccines remains largely unclear. A recent study showed that TLR signalling is not important for the antibody-enhancing effect of classical vaccine adjuvants such as Complete Freund's adjuvant (CFA) [21]. Since CFA contains dried mycobacteria, and therefore mycobacterial PAMPs [17], this observation casts doubt on the importance of PAMPs and TLRs in augmenting immune responses to vaccination. Influenza viral genomic ssRNA is a natural PAMP recognized by TLR7 [22]. Here, we investigate whether PAMP recognition by TLRs, in particular recognition of viral ssRNA by TLR7, is responsible for the superior response to WIV vaccines compared to SV and SU influenza vaccine formulations. Results/ Discussion To analyze the role of ssRNA and other PAMPs in the response to influenza vaccines in detail, we immunized wild-type C57BL/ 6 mice, TLR7 knock-out mice, and MyD88 /TRIF double knock-out mice with different vaccine formulations. MyD88 (myeloid differentiation factor 88) is an adaptor molecule which functions 
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Chapter 3 downstream of all known TLRs and ILlR family members with the exception of TLR3, which instead recruits a MyD88-related adapter molecule, TRIF (TIR domain-containing adaptor protein inducing interferon f3) [17]. Consequently, a deficiency of both MyO88 and TRIF excludes signalling by all TLRs. Mice were immunized intramuscularly with f3-propiolactone-inactivated H5Nl (NIBRG-14) WI\T, SV, or SU vaccine. Quantitative PCR using primers specific for segment 7 of the viral genome revealed that WIV contained per vaccine dose at least 5x108 copies of viral RNA, the natural ligand of TLR7. In SU or SV vaccine the amount of RNA was 500 and 5,000 times lower than in WI\T, respectively. Four weeks after immunization, serum and spleen cells were collected for evaluation of humoral and cellular immune responses. Serum HI titres in WIV-immunized TLR7-/- mice and MyDBB-1-/TRIF-I - mice were found to be significantly lower than in WIV-immunized wild-type mice (Figure lA; p = 0.021 and p = 0.001, respectively). Although sera from TLR7-/ - mice immunized with WIV showed a higher geometric mean titre (GMT) than sera from WIV-immunized MyDBB-I- JTRIF-1- mice, this difference was not significant (p = 0.053). Most of the HI titres of SV- and SU-immunized wild-type mice were below detection level, precluding evaluation of the effect of the knock­out mutations on the HI responses to these vaccines. 
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WIV sv SU Figure 1. TLRs contribute to the efficacy of H5N1 WIV vaccine. Four weeks after immunization of wild-hJpe, TLR7-/-, and MyDBB-/-/TRIF-/- mice with WIV, SV, or SU vaccine (5 µg HA), serum HI titres (A) and HSNl-specific IgG titres (B) were determined for the individual mice. Titres below the detection limit were assigned with half the value of the lowest detectable serum dilution, which was 8 in the HI assay and 100 in the IgG ELISA. Significant (p<0.05) and highly significant (p<0.01) differences between wild-type mice and mutant mice receiving the same vaccine are indicated mJ * and **, respectively. GMT indicates geometric mean titter. 
Similar to the HI titres, virus neutralization (VN) titres of pooled serum samples 
from mice immunized with WIV were lower in the knock-out groups than in the 
wild-type group (Table 1). These results clearly show that TLR signalling is 
critically involved in the response to WIV immunization. Yet, in the knock-out 
groups, VN titres obtained after immunization with WIV were still modestly 
higher than those obtained after vaccination of wild-type mice with the other 
vaccines. This points to TLR-independent pathways contributing to the superior 
antibody response to WIV vaccine. 
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Chapter 3 Table 1. TLR-dependent and -independent mechanisms contribute to virus neutralization titres induced by WlV. 
Vaccine Mouse Strain VN Titre 
wt 640 
WIV TLR7_,_ 80 
MyDss-/-/TRIF_,_ 80 
wt 20 
sv TLRT1- 20 
MyD88_,_ /TRIF_,_ 40 
wt 40 
SU TLRr'- 20 
MyD88_,_ /TRIF_,_ 20 
Mouse sera were collected 4 wk after immunization with different vaccine 
formulations and pooled per immunization group (n = 8 per group, except for 
SU immunized MyD88_,_ /TRIF_,_ mice: n = 7) and subsequently submitted to 
the VN assay. Serum titres of H5Nl -specific IgG were determined by ELISA. In accordance with the HI and VN results, IgG titres were significantly decreased in WIV-immunized TLR7-/- and MyDBs-1-/TRIF-1- mice compared to wild-type mice (Figure lB; p = 0.010 and p = 0.001, respectively). However, like the VN titres, the IgG titres in the WIV-immunized mutant mice were still significantly higher than those induced by SV (TLR7-I-: p = 0.001; MyDBB-1-/TRIF-I-: p = 0.005) or SU (TLR7-/ -: p = 0.005; MyDBB-I-/TRIF-1-: p = 0.021) immunization again indicating involvement of TLR-independent pathways. The relative contributions of TLR­dependent and -independent mechanisms to the superior IgG response to WIV can be estimated by comparing the difference in geometric mean titre (GMT) between WIV-immunized wild-type and MyD88/TRIF-deficient mice with the difference between WIV-immunized wild-type mice and SV- or SU-immunized wild-type mice. Using this procedure the TLR-dependent contribution was calculated to be 73% and 83% for WIV versus SV and WIV vs SU, respectively (for calculation, see Text S1). The IgG responses to SV and SU vaccine in both TLR7-/ - or MyDBB-1-/TRIF-I- mice did not differ from those in wild-type mice, except for the IgG response to SU in TLR7-/- mice, which was slightly but significantly decreased (p = 0.038; Figure lB). Together with the HI and VN results, these findings demonstrate that the superior antibody response to WIV is 
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predominantly regulated by TLRs, TLR7 in particular, while TLRs do not seem to 
play a prominent role in SV and SU antibody responses. 
We next investigated the role of TLRs in the Thl polarization of the 
response characteristically found after WIV vaccination. We first assessed numbers 
of IFNy- and IL4- producing T cells (Thl and Th2 cells, respectively) in a cytokine­
specific Elispot assay, after re-stimulation of spleen cells from immunized mice 
with HSNl SU vaccine. Numbers of Thl cells were significantly decreased in WIV­
immunized knock-out mice compared to wild-type mice (p = 0.003 and p = 0.010 
for TLR7-/- and MyDBB-1-/TRIF-I- mice, respectively), and matched those found 
in SV- and SU-immunized wild-type mice (Figure 2). No difference was found 
between TLR7-/- and MyDBB-1-/TRIF-1- mice. Numbers of influenza-specific IL4-
producing cells were extremely low in all animals for all vaccine formulations 
without significant differences between knock-out and wild-type mice (not 
shown). These data indicate that stimulation of TLR7 by ssRNA is the 
predominant determinant of the strong Thl-type cellular response induced by 
WIV. 
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SU Figure 2. Induction of IFNy-producing T cells by H5N1 WIV vaccine depends on TLR7 signalling. Spleen cells of wild-h;pe mice and mutant mice immunized with WTV, SV, or SU vaccine were re-stimulated in vitro with SU vaccine, and numbers of IFNy-producing cells were determined by Elispot assay. Bars represent the average values of triplicate determinations per mouse for each mouse hJpe and immunization group (n = 8; MyDBB-/-/TRlF-/-1 SU, n = 7), with standard deviation. Significant (p<0.05) and highly significant (p<0.01) differences between wild-type mice and mutant mice receiving the same vaccine are indicated by * and **, respectively. 
We further determined the subtype profiles of HSNl -specific serum IgG by ELISA 
(Figure 3). IFNy is known to stimulate production of IgG2a subtype antibodies by 
activated B cells, while IL4 stimulates IgGl secretion [23] . In C57BL/ 6 mice, 
however, the IgG2c subtype is produced instead of IgG2a[24],[25]. Hence, a 
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- MyDaa·1·1TRIF·1• Figure 3. H5N1 WIV vaccine induces Th1-type antibody responses via TLR7 signalling. Serum titres of H5N1-specific IgGl subtype (Th2-type antibody), and IgG2c, IgG2b, and IgG3 subhJpes (Thl-type antibodies) were determined by ELISA. Geometric mean titres are plotted for each group of wild-type mice or mutant mice (11 = 8; MyDBB-/-/TRIF-/-/SU, 11 = 7) immunized with WTV, SV, or SU vaccine. Significant (p<0.05) and highly significant (p<0.01) differences between wild-type mice and mutant mice receiving the same vaccine are indicated by * and **, respectively. 
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The response characteristics of the different H5Nl vaccines in wild-type mice were 
well in line with those previously found for other influenza subtypes [15],[16]. 
This consistency is supportive of a general mechanism underlying the differences 
in responses to wrv, SV and SU vaccine, which operates irrespective of the virus 
subtype used to vaccinate. 
The above results demonstrate that TLR signalling plays an important role 
in the magnitude and Thl skewing of the response to WIV influenza vaccines. Yet, 
in TLR-ko mice, WIV remained more immunogenic than SV and SU vaccines, 
inducing significantly higher titres of total IgG (Figure lB) and Thl-type antibody 
subtypes (IgG2b, IgG2c, IgG3; Figure 3; p<0.05 for all comparisons). Thus, next to 
TLR-dependent mechanisms, a (minor) TLR-independent factor seems to 
contribute to the superior magnitude and Thl-skewing of the immune response to 
WIV. Type I interferons, including IFNa, have been shown to stimulate antibody 
responses and isotype switching to IgG2a when added to influenza subunit 
vaccine or other protein antigens [26],[27], even without the need for additional 
TLR stimuli. We have previously shown for an H3N2 influenza virus strain that, 
unlike SU vaccine, WIV vaccine efficiently induced interferon a (IFNa) production 
in plasmacytoid dendritic cells (pDCs) in vitro [15]. We therefore evaluated the 
induction of IFNa by the H5Nl influenza vaccine formulations used in this study 
and its TLR7 dependency in vitro. In pDCs of wild-type mice cultured from bone 
marrow cells (Figure 4A, black bars) or enriched from splenocytes (Figure 4B, 
black bars) WIV but not SV or SU induced IFNa production. In bone marrow­
derived pDCs from TLR7-/- mice, IFNa production upon incubation with WIV 
was strongly decreased as compared to wild-type DCs (Figure 4A), confirming the 
results of others [22]. However, spleen-derived pDCs from TLR7-/- mice exposed 
to WIV produced similar amounts of IFNa as compared to pDCs from wt mice 
(Figure 4B). Thus, while in pDCs cultured from bone marrow induction of IFNa 
production by WIV is strictly dependent on TLR7, in pDCs enriched directly from 
spleen cells it is independent of TLR7. This implies that bone marrow pDCs and 
spleen pDCs are not completely identical. In line with this notion, bone marrow 
pDCs and spleen pDCs were earlier found to respond differently to HSV virus 
infection with respect to the TLR9 dependency of the IFNa response [28] . Our 
results show that WIV is indeed able to induce IFNa in a TLR7-independent way. 
This may also be the case in the in vivo situation, where in accordance with its 
well-described adjuvant functions IFNa may lead to the production of Thl type 
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ctrl WIV sv SU CpG ctrl WIV sv SU CpG Figure 4. Induction of IFNa by WIV is TLR7-dependent in bone-marrow derived pDCs, but not in spleen-derived pDCs. Bone-marrow cells cultured with FLT3L (containing 20-30% pDCs) (A), or pDC-enriched spleen cell cultures (containing 62%-68% pDCs) (B) of wild-hJpe mice (black bars) and TLR7-/- mice (white bars) were incubated overnight with WTV, SV, or SU vaccine. IFNa was measured in cell supernatants by sandwich ELISA. Bars represent average values of triplicate determinations with standard deviation, and are representative of three independent experiments. Possible TLR-independent pathways activated by WIV may involve the retinoic acid-inducible gene(RIG-I) [29]-[32]. RIG-I is a cytoplasmic RNA-helicase that recognizes influenza virus by binding viral ssRNA bearing 5'-triphosphates which leads to IFNa production [33],[34]. The inactivated virus particles in WIV vaccine retained their membrane-fusion property (Text S2) and part of the viral genomes could therefore have entered the target cell cytoplasm to be sensed by RIG-I. Taken together our observations show that the superior immune response to WN, relative to that to SV or SU vaccines, is driven primarily by TLR­dependent mechanisms. Herein the presence of the viral RNA in the vaccine seems to play a crucial role. In contrast to SV and SU vaccines WIV contains substantial amounts of viral RNA. Removal of ssRNA from WIV by detergent solubilization and ultracentrifugation followed by reconstitution of the viral membrane envelopes to virosomes abolishes the capacity of the vaccine to induce production of IFNa by pDCs in vitro (Text S3 and Figure SlA) and type 1 immune responses in vivo [15]. On the other hand, ssRNA purified from WIV and condensed with polyethylenimine (PEI) did induce IFNa production in vitro (Text S3 and Figure S18). Obviously, exposure of the viral RNA to �-propiolactone in the course of virus inactivation leaves the RNA intact to trigger TLR7-mediated signaling pathways (Figure 4), which translates into a strong and Thl-skewed antibody response to WIV in wild-type mice. In addition, the viral RNA may contribute to 72 
TLRs Determ ine Influenza Vaccine lmmunogen icity the TLR-independent part of the response to WIV since TLR7-independent production of IFNa could only be induced in pDCs by WIV and not by formulations (SV, SU, or reconstituted viral envelopes) which lack viral RNA (Figure 4B) [15]. These lines of evidence point to the ssRNA in WIV as the key component that enhances and steers the adaptive immune response by involvement of innate immune mechanisms. IFNa induction in pDCs clearly discriminates WIV from SV and SU vaccines but seems to occur independent of TLR7. The fact that the immune response to WIV is predominantly dependent on TLR7 then suggests that other TLR7-mediated mechanisms, possibly involving conventional DCs and B cells, critically contribute to the immune reaction. Recently, an in vitro study on B cells showed that TLR7 stimulation or CD40-CD40L binding by itself triggers IgGl antibody production, but when simultaneously present induce proliferation and a switch to IgG2a production [25]. Additional stimulation of IFNa/�  receptors on the same cells further drives the production of IgG2a at the expense of IgGl antibodies [25]. Although this model might represent an over-simplification of the in vivo situation, it is in line with our data. The different scenarios encountered upon immunization of wild-type and mutant mice with wrv, SV, or SU are summarized in Table 2. WIV provides the ssRNA for direct triggering of TLR7 in B cells as well as the CD40 ligand for CD40 stimulation on B cells through strong T helper cell induction, which was shown also to depend on TLR7 signalling. Together with IFNa produced by TLR7-mediated and/or TLR7-independent mechanisms, these signals will lead to the enhanced and strongly polarized Thl­type antibody responses characteristic for WIV. In the absence of TLR7, WIV­induced IFNa can still stimulate moderate production of Thl type antibodies and increase the total IgG. In contrast, SV and SU vaccines are poor inducers of T helper cells and IFNa, and cannot stimulate B cells directly via TLR7. Consequently, SV and SU vaccines induce lower and more Th2-polarized antibody responses. 
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Table 2. Putative vaccine effects contributing to different adaptive immune responses 
based on the model proposed by Heer et al. [25]. 
Vaccine Mouse Strain Direct Vaccine Effects Result 
RR7-Mediated 8-Cell Antibody 
IFNa Production Th Cell Induction Stimulation Response Phenotype 
WIV wt + ++ + +++ Thl 
TLR7+ + + ++ Th1/Th2 
SV/SU wt + + Th2 
TLR7+ + + Th2 
Differences in responses induced in either wild-type or TLR7-deficient mice by WIV and SV or SU vaccine are given semiquantitatively for each of the indicated facets of 
the innate or adaptive response. 
Our data provide mechanisms which explain the superiority of WIV vaccine to 
prime HA-specific immune responses in mice. Whether similar mechanisms are 
operational in humans and contribute to the stronger immunogenicity of WIV 
compared to SV or SU in unprimed individuals remains to be elucidated. Despite 
the favourable immunogenic properties of WIY, recent clinical trials performed in 
the context of pandemic vaccine development show that even with WIV at least 
two immunizations with a substantial amount of antigen (15-30 µg) and/ or the 
addition of adjuvants will probably be required to achieve immune responses that 
comply with the CPMP criteria. If TLRs are involved in the priming of humans 
with WIY, their role during recall responses may be less critical, given the fact that 
in general WIY, SU, and SV induce similar HI titres in primed populations [11]. 
Use of WIV derived from wild-type virus instead of recombinant vaccine strains 
resulted in good antibody titres even without the addition of adjuvants and might 
thus be an option to obtain satisfying immune responses [35]. Evaluation of 
adjuvants in combination with WIV in clinical trials is so far restricted to 
aluminium salts. However, where adjuvanted and non-adjuvanted WIV were 
compared side-by-side, effects of this Th2 adjuvant on vaccine efficacy were 
absent, poor, or inconsistent [36]. So, better adjuvants have to be found that work 
synergistically with WIV in order to exploit the full potential of intact inactivated 
virus particles as vaccines. 
In conclusion, our data reveal, for the first time to our knowledge, that 
TLRs play an eminent role in the immune responses to a classic influenza vaccine. 
Of the three influenza vaccine formulations studied here, only WIV efficiently 
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triggered TLR7-mediated mechanisms leading to superior immune responses. 
Processing of inactivated whole virus particles into SV or SU eliminates the 
immuno-potentiating effect of the viral ssRNA, the primary PAMP in WIV 
vaccine, and results in a loss of quantity and shift in the quality of the immune 
response. Thus, TLR-dependent mechanisms appear to form the basis for WIV 's 
antigen-sparing quality and hence its recognized strong potential as a pandemic 
vaccine candidate [7],[12]. Optimizing TLR7-signalling by rational vaccine design 
may produce even more potent vaccines, which are urgently needed in the face of 
the current influenza pandemic threat. 
Methods VACCINES AND REAGENTS 
HSNl virus (NIBRG-14, a 2:6 recombinant of A /Vietnam/ 1194 / 2004 [HSNl] and 
A/PR/8/34 [HlNl] virus produced by reverse genetics technology) was provided 
by the National Institute for Biological Standards and Controls (NIBSC; Potters 
Bar, UK), propagated on embryonated chicken eggs, inactivated with 0.1% (3-
propiolactone to obtain WIY, and processed into split virus vaccine or subunit 
vaccine according to standard procedures [37],[38]. The haemagglutinin protein 
concentration in the vaccines was determined by single radial immunodiffusion 
(SRID) [39]. Endotoxin levels in all vaccines met the requirements of the European 
Pharmacopoeia standard. (If, nevertheless, contamination of endotoxin [ signalling 
via TLR4] would have played an important role we should have observed 
substantial differences in the response between TLR7-deficient mice [capable of 
signalling via TLR4)]and MyD88/TRIF-deficient mice [deficient in all TLR-derived 
signalling]. However, such differences were not found for any of the vaccines.) 
CpG DNA (ODN D19) was purchased from Eurogentec (Seraing, Belgium). MICE AND VACCINATION 
For immunization experiments, C57BL/ 6, TLR7-/- and MyDBB-1- /TRIF-I- mice 
(generated from MyDBB-1- mice [40] and TRIF-/- mice [41]) were bred at the 
University of Massachusetts Medical School (Worcester, MA). For in vitro studies, 
10- to 12-week-old female C57BL/ 6 mice were purchased from Harlan 
Netherlands B.V. (Zeist, The Netherlands), and TLR7-/- mice (a gift from S. Akira 
and C. Reis e Sousa) were bred at the University Medical Center Groningen. All 
experiments were conducted with approval of the local Institutional Animal Care 
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Chapter 3 and Use Committees. Mouse groups were matched for sex and age. Groups (n = 6--8) of C57BL/ 6, TLR7-I-, and MyD88-/-/TRIF-1- mice were intramuscularly injected with 50 µl of PBS in each calf muscle containing a total of 5 µg haemagglutinin protein per mouse of either wrv, SV, or SU vaccine formulation or no vaccine as a control. At 28 days after immunization, sera and spleens were collected for evaluation. QUANTITATIVE PCR Relative viral RN A content of the different vaccines was determined using a two­step real-time RT-PCR assay amplifying a 193-bp fragment within the Ml gene of influenza A viruses. For this purpose RNA was extracted from wrv, SV, or SU (5 µg HA) with the QIAamp viral RNA Mini Kit (QIAGEN, Venlo, The Netherlands), cDNA synthesis was performed on 5 µl of viral RNA (one-tenth of the final elution volume) using the Verso cDNA kit from ABgene (Westburg, Leusden, The Netherlands), and 1 µM UNI12 primer (5'-AGCAAAAGCAGG-3', corresponding to viral noncoding nucleotides 1 to 12 [42]). Real-time PCR was performed with 200 nM Ml-FOR primer (5'-CCTGGTATGTGCAACCTGTG-3') and Ml-REV primer (5'-AGCCTGACTAGCAACCTCCA-3'); purchased from Eurogentec, and the Absolute QPCR SYBR Green Mix (ABgene). Amplification was performed on a StepOne apparatus (Applied Biosystems), and consisted of 15 min initial activation at 95°C, followed by 40 thermal cycles of 15 sec at 95°C and 60 sec at 60°C. In each experiment, a standard curve (R2>0.99 within the range of lxl02 to lx109copies per reaction) was drawn to convert the respective cycle threshold (Ct) values into the number of viral genome copies. This standard consisted of a pCR2.1-TOPO plasmid construct in which was cloned a 473-bp sequence of influenza A/Puerto Rico/8/34 segment 7. HAEMAGGLUTINATION INHIBITION ASSAY The HI assay was performed as described before [15]. Briefly, heat-inactivated mouse serum was absorbed to 3 volumes 25% kaolin/PBS (Sigma-Aldrich, Inc., St. Louis, MO), 20 min at room temperature (RT). After centrifugation, 50 µl of supernatant was serially diluted two-fold in a round-bottom microtitre plate (Costar, Corning Inc., Corning, NY), in duplicate. Subsequently, 50 µl PBS was added containing 2 HAU of H5Nl (NIBRG-14) virus and incubated for 40 min at RT. We used 2 HAU of virus instead of the standard 4 HAU to increase the sensitivity of the assay. Finally, 50 µl of 1 % guinea pig erythrocytes (Harlan) in PBS 76 
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was added to each well and HI titres were determined after 2 h incubation at room 
temperature. HI titres are given as the reciprocal of the highest serum dilution 
producing complete inhibition of haemagglutination. VIRUS-NEUTRALIZATION ASSAY 
The levels of virus-neutralizing (VN) serum antibodies were determined with a 
VN assay [15],[43]. The VN titre was defined as the reciprocal of the highest serum 
dilution capable of inhibiting 200 TCID50 of H5Nl vaccine strain virus 
(NIBRG-14) from infecting Madin-Darby canine kidney cell monolayers in a 
microtiter plate. Infection was measured by an ELISA on intracellularly produced 
viral NP protein. Inhibition of infection by simultaneous incubation with mouse 
serum was established if the ELISA absorbance value (A,i92) measured was below 
the cut-off value, determined by the equation: [ (average A492 of the positive 
controls (infected cells) minus average A492 of the negative controls (non infected 
cells)) divided by 2] plus the average A492 of the negative controls. Serum samples 
were tested in quadruplicate. lSOTYPE ELISA 
Microtitre plates (Greiner, Alphen a /  d Rijn, The Netherlands) were coated with 0.2 
µg influenza H5Nl (NIBRG-14) subunit vaccine per well in 100 µI coating buffer, 
overnight. After blocking with 2% milk in coating buffer for 45 min, 100 µI of two­
fold serial dilutions of serum samples in 0.05% Tween 20 / PBS (PBS /T) were 
applied to the wells and incubated for 1.5 h, in duplicate. Subsequently, 100 µI of 
horseradish peroxidase-conjugated goat anti-mouse IgG-isotype antibody 
(Southern Biotech, Birmingham, Alabama) was applied for 1 h. All incubations 
were performed at 37°C. Staining was performed using o-phenylene-diamine 
(OPD) (Eastman Kodak Company) and absorbance was read at 492 nm (A,i92) with 
an ELISA reader (Bio-tek Instruments, Inc.). After subtraction of background 
levels, serum dilutions yielding an OD of 0.2 were calculated using linear 
regression, of which the reciprocal of the average of the duplicates represents the 
titre. IFNr AND IL4 ELISPOT ASSAYS 
This assay was performed as described previously [15]. In short, erythrocyte­
depleted splenocytes were seeded at a concentration of 5x105 cells in 100 µI 
medium per well, in triplicate in a microtitre plate (Greiner), which was pre-coated 
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Chapter 3 with anti-IFNy or anti-IL4 capture antibody (Pharmingen, San Diego, CA) and blocked with 4% BSA/PBS (Sigma-Aldrich). Cells were stimulated with 1 µg HSNl (NIBRG-14) subunit vaccine per well, overnight in a humidified CO2 incubator at 37°C. Cells were lysed with 100 µl of H2O per well and plates were washed extensively, after which 100 µl of biotinylated anti-IFNy or anti-IL4 (Pharmingen) in 2% BSA/PBS was added 1 h at 37°C. Subsequently, the plates were incubated with 100 µl of alkaline phosphatase conjugated streptavidin (Pharmingen) in 2% BSA/ PBS for 1 h at 37°C, spots were visualized with 5-bromo-4-chloro-3-indolylphosphate (Sigma-Aldrich) substrate immobilized in solidified agarose. Plates were scanned and spots were counted manually. PLASMACYTOID DENDRITIC CELLS Plasmacytoid DCs were generated from bone marrow cells of C57BL/6 or TLR7-/ - mice by seeding 1-2x106 bone marrow cells per well of a 24-well plate and culturing the cells for one week in Iscove's Modified Dulbecoo's Medium (IMDM) with 10% FCS and 100 ng/ml FLT3L (R&D Systems, Abingdon, UK)[22]. Single splenocyte suspensions were produced by collagenase D (Roche Diagnostics GmbH, Germany) treatment of the spleens, and spleen cell populations enriched for plasmacytoid DCs (pDCs) were obtained after magnetically labelling of pDCs with anti-mPDCA-1 antibody conjugated MicroBeads (Miltenyi Biotech GmbH, Germany) and separation over a MACS Column (Miltenyi), according to the manufacturers protocol. Percentages of pDCs in the positively selected population were determined by FACS analysis using anti-mPDCA-1-PE antibody (Miltenyi) and anti-CDllc-FITC (GeneTec Inc., Canada). Cell suspensions containing 1-2x105 pDCs in 100 µl were seeded in a microtitre plate and stimulated in triplicate with an equal volume containing 1.0 µg HA of either WIY, SV, or SU vaccine, or 1.0 nmol CpG DNA. After 20 h of incubation in a humidified CO2 incubator at 37°C, supematants were collected and subjected to the IFN a ELISA. IFNA ELISA IFNa detection in cell-culture supematants was performed using a sandwich ELISA as described previously [15]. IFNa concentrations were calculated from a recombinant IFNa (HyCult, Biotechnology, Uden, The Netherlands) standard curve performed in quadruplicate using linear regression, and expressed in units per ml. 
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STATISTICS Statistical analysis on HI titres, antibody titres, and Elispot counts was performed with SPSS (SPSS 1202 Inc., Chicago, IL) using the Mann-Whitney U test with a CI of 95%. All p values are two-tailed. Statistical significance was defined as p<0.05. Supporting Information Figure S1. 
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WIV vs CpG WIV RNA/PEI PEI CpG Text S1. Calculation of relative contributions of TLR-dependent and -independent mechanisms to WIV's superior IgG response. The contribution of TLR-dependent and -independent mechanisms to the IgG response was derived using the equation: {(x-y)/(x-z)} *100% , where x is the GMT of WIV immunized wild-hjpe mice (=42,105), y is the GMT of WIV-immunized MyD88-/-/TRIF-/- mice (=11,889) and z is the GMT of SV-immunized wild-hjpe mice (=876) or, when compared to SU vaccine, the GMT of SU-immunized wild-type mice (=5,481). Text S2. H5N1 virus inactivated with {3-propiolactone is fusion-active. Fusion activihJ of H5N1 virus (NIBRG-14), inactivated with 0.1% {3-propiolactone, was evaluated with a Jzaemolysis assay and a fluorescence membrane fusion assay using WIV labelled with octadec1Jl Rlzodamine B (R18), as described previously (Stegmann T, et al. (1993) Biochemistry 32: 11330-11337). The experimental lzaemolysis of human erythroC1Jtes btJ WIV, as a percentage of maximal ltaemolysis btJ water treatment of the enJtlzroC1Jtes, was 45.2% at pH 5.5. Comparatively, haemolysis values for split virus and subunit in the same test were 0.3% and 0.5% respectively. Fusion activihJ, measured with the R18 assay, ranged between 25% and 30% at pH 5.5 for WTV. 
79 
Chapter 3 Text S3. Viral RNA from [3-propiolactone-inactivated WIV vaccine stimulates TLR7. Virosomes (VS) were prepared from [3-propiolactone-inactivated H5N1 virus (NIBRG-14), by solubilization of the viral membrane, followed by removal of the nucleocapsid by ultracentrifugation, and subsequent reconstitution of the viral membrane envelope, as described previously (De Jonge J, et al. (2006) Biochimica et Biophysica Acta 1758: 527-536). Viral RNA was isolated from H5N1 WIV preparations using a RNeasy Kit (QIAGEN, Venlo, The Netherlands) and condensed with polyethylenimine (PEI, Sigma-Aldrich, Inc., St. Louis, MO), as described elsewhere (Diebold SS, et al. (2004) Science 303: 1529-1531). Stimulation experiments were performed as described in the Methods section of the manuscript. In short, bone-marrow derived pDC cultures were stimulated with WIV or VS in a concentration of 5 µg HA per ml, or RNA/PEI complexes in a concentration of 1 µg RNA per ml, or PEI alone, or CpG DNA. The IFNa response is shown in Figure 51. Virosomes (VS) which are virus-like particles devoid of RNA do not induce detectable (nd) IFNa production in pDCs from wild-type mice (black bars) or TLR7-/- mice (white bars) (Fig. 51A). In contrast RNA/PEI complexes induce IFNa production in pDCs from wild-hJpe mice (black bars) but not from TLR7-/- mice (white bars) (Fig. 51B). These experiments confirm that it is the viral genomic RNA in WIV that activates TLR7-mediated pathways, as was shown by others (Diebold 
SS, et al. (2004) Science 303: 1529-1531), and that the inactivation procedure with [3-propiolactone has no effect on the ability of the viral genome to stimulate TLR7. Acknowledgments We thank Professor S. Akira and Professor C. Reis e Sousa for providing the TLR7 knock-out mice. We thank the NIBSC for providing NIBRG-14 influenza virus. The plasmid pCR2.l-TOPO-Ml was a kind gift from Evelien Vanderlinden (Rega Institute, Leuven, Belgium). Wouter ter Veer is acknowledged for excellent technical assistance. 
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Abstract Whole inactivated virus (WIV) influenza vaccines are more immunogenic in unprimed individuals than split-virus or subunit vaccines. In mice, this superior immunogenicity has been linked to the recognition of the viral ssRNA by endosomal TLR7 receptors in immune cells, leading to IFNa production and Thl­type antibody responses. Recent data suggest that viral membrane fusion in target cell endosomes is necessary for TLR7-mediated IFNa induction. If so, virus inactivation procedures that compromise the fusion activity of WIV vaccines, like formaldehyde (FA) treatment, could potentially harm vaccine efficacy. Therefore, we measured the effect of fusion inactivation of H5Nl WIV on TLR7 activation in vitro, and on antibody isotype responses in vivo. Fusion inactivation of WIV reduced, but did not block, TLR7-dependent IFNa induction in murine dendritic cells in vitro. In vivo, fusion-inactive WIV was as potent as fusion-active WIV in inducing total H5Nl-specific serum IgG and IgG2c subtype antibodies in unprimed mice. Both vaccines induced only small amounts of IgGl. However, FA treatment of WIV did reduce the capacity of the vaccine to induce hemagglutination-inhibiting (HI) antibodies. This possibly relates to modification of epitopes that are targets for HI antibodies rather than to loss of fusion activity. Antibody affinity maturation was not negatively affected by fusion inactivation. In conclusion, fusion activity of H5Nl WIV does not play a major role in Thl -type antibody induction. Yet, to preserve the full immunogenicity of WIY, or possibly also other inactivated influenza vaccines, harsh treatment with formaldehyde should be avoided. 
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Aside from yearly epidemics, influenza A viruses occasionally cause pandemics, 
leading to excess morbidity and deaths. Pandemics, at least those in the recent 
past, resulted from the introduction of a new influenza virus originating from 
birds or swine into the human population [1-5]. Avian viruses that incidentally 
infect humans like highly pathogenic H5Nl, H7N7, and H9N2 present a pandemic 
risk, as these viruses might adapt and become transmissible from human-to­
human [6-9]. This potential pandemic threat urges the development of highly 
efficacious influenza vaccines [10]. 
Influenza vaccines containing whole inactivated virus (WIV) particles 
induce stronger immune responses in immunologically naive individuals than 
split-virus or subunit vaccines [11-13]. This feature allows for dose-sparing 
immunization regimens without the requirement for an adjuvant [14]. WIV 
therefore is a promising pandemic vaccine candidate [15]. Additionally, in mice, 
WIV uniquely induces a Thl-type response, characterised by high levels of IgG2a/ 
c antibodies, which correlates better with protection than a Th2-type response, as 
typically induced by (unadjuvanted) split-virus or subunit vaccines [16-19]. 
Recently, a mock-up licensure was granted by the European Medicines Agency 
(EMA) for an H5Nl WIV formulation, which allowed fast-track approval of an 
HlNl WIV vaccine, deployed during the HlNl flu pandemic in 2009 [20,21]. 
In mice, the superior immunogenicity of WIV is largely due to activation of 
Toll-like receptor 7 (TLR7) in immune cells by viral single-stranded (ss) RNA 
present in the inactivated viral particles [22,23]. In addition, TLR7 activation may 
also play a role in antibody affinity maturation, and long-term persistence of 
antigen-specific B-cell and T-cell responses [25]. It is likely that multiple TLR7-
dependent mechanisms act together to produce the Thl-type antibody response 
induced by WIV [23,24,26-29]. TLR7 activation in B-cells on itself stimulates 
antibody production in vitro, and TLR signalling in B-cells has been shown 
essential for augmenting in vivo antibody responses [24,25]. TLR7 is also involved 
in the induction of CD4+ Th-cells [23,29] and IFNa production by plasmacytoid 
dendritic cells (pDC) [27,28]. Th-cells provide CD40L, which together with IFNa 
presents additional signals to activated B-cells, necessary to augment and steer the 
antibody production to predominantly IgG2a in vitro and in vivo [24-26]. 
It has been shown that TLR7-mediated IFNa production by pDCs is 
strongly reduced when endosomal acidification is blocked [27,28]. The low 
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Chapter 4 endosomal pH is the natural trigger for viral membrane fusion and uncoating, and it has been suggested that these viral activities are important for TLR7 signalling [30]. This implicates that treatments which affect the membrane fusion capacity of WIV, for instance virus inactivation protocols that use formaldehyde [31], could affect the vaccine's capacity to trigger TLR7 and therefore impair the immunogenicity of the vaccine. To study the role of viral membrane fusion activity in the immunogenicity of WIV, we used a formaldehyde treatment protocol to inactivate the fusion activity of WIV particles, and measured the effect of this treatment on particle uptake and TLR7 activation in dendritic cells in vitro and on antibody subtype responses in vivo. 
Materials and methods VIRUS, VIRUS INACTIAVTION, AND FUSION INACTIVATION H5Nl virus (NIBRG-14, provided by NIBSC, Potters Bar, UK) was propagated on eggs. Egg-derived H3N2 virus strain A/ Panama/ 2007 / 99 was kindly provided by Solvay Biologicals, Weesp, The Netherlands. WIV vaccine was produced by using 0.1% (3-propiolactone (BPL) to inactivate influenza virus replication [23]. The amount of HA and total viral protein in the WIV vaccine stock was 0.99 µg / µl and 9.88 µg/ µl, as determined by single radial immunodiffusion (SRID) and micro Lowry assay, respectively [23,52]. To inactivate the fusion activity of WIY, purified viral particles were incubated with formaldehyde (FA) using conditions as indicated under Results. Formaldehyde treatment was followed by immediate dialysis against HNE buffer (5 mM Hepes, 0.15 M NaCl, 0.1 mM EDTA, pH 7.4). MICE AND IMMUNIZATION TLR7-/ - mice (a kind gift from Dr. S. Akira and Dr. C. Reis e Sousa) were bred at the animal facility of the University Medical Center Groningen and were used for isolation of bone marrow and subsequent culture of bone-marrow-derived dendritic cells (BMDC) [32]. Female C57Bl/ 6 mice, 6-8 weeks old, were obtained from Harlan (The Netherlands). Mouse experiments were conducted with approval of the local institutional committee for animal care and use. Mice were immunized intramuscularly with 1 or 5 µg of fusion-active or fusion-inactive H5Nl WIV in HNE buffer. Four weeks after immunization, mice were sacrificed and blood was collected. 
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Viral Membrane Fusion and Th l Antibodies DENDRITIC CELLS BMDC cultures, enriched for plasmacytoid dendritic cells (pDC), were established as described by Gilliet et al. [33] with minor modifications [23]. After 8 days of culture, cells were harvested and analysed for pDC's using anti-PDCA-1-PE (Miltenyi Biotec, Bergisch Gladbach, Germany) and anti-CDllc-FITC (Genetex Inc, CA, USA) staining and flow-cytometric analysis. FUSION ASSAYS The fusion capacity of WIV was measured by octadecylrhodamine (R18) dequenching after fusion of R18-labeled WIV with eryhtrocyte ghost membranes and by a hemolysis assay. R18-labeled WIV was prepared by adding R18 (Molecular Probes, Eugene, Oregon, USA) in ethanol to WIV at an amount of 9 mol % of the phospholipid content of WIV ( determined by a phosphate assay [53]),followed by incubation at room temperature (RT) for 1 hr in the dark. Free R18 was separated from viral membrane-bound R18 by gel filtration chromatography on a Sephadex G75 column (Pharmacia, Sweden) and labeled virus was collected. The capacity of R18-labeled WIV to fuse with eryhtrocyte ghost membranes was investigated and calculated as previously described [34]. Fusion activity of WIV determined by hemolysis was determined as described before [35]. IN VITRO UPTAKE OF FUSION-ACTIVE AND FUSION-INACTIVE WIV BY BMDC To study the uptake of fusion-active and fusion-inactive WIV by dendritic cells, WIV preparations were labeled with fluorescein-isothiocyanate (FITC, Sigma), as described previously [36]. FITC-labeled fusion-active or FITC-labeled fusion­inactive WIV was then incubated at concentrations of 0.1, 1, and 10 µg viral protein per ml, with BMDC for 30 min at 37° in 15 ml polypropylene tubes. Next, cells were placed on ice and 2.5 µg/ml of neuraminidase (Clostridium-derived, Type V, Sigma) was added to remove bound virus from the cell surface. After incubation for 1 hr, cells were washed in ice-cold serum free IMDM, incubated for 20 min with anti-CD11c-PE-Cy5 (eBioscience, San Diego, USA) and washed with PBS. Cells were then fixed by a 10 min incubation in FACS lysing solution (BD). After a final wash in PBS/0.02% BSA, cells were analysed on a FacsCalibur (BD) flow cytometer. 
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Chapter 4 IN VITRO INDUCTION OF IFNA IN WIV-STIMULATED BMDC Fusion-active and fusion-inactive WIV in different concentrations, or 1.0 nmol CpG DNA (019; GGTGCATCGATGCAGGGGGG; Eurogentec, Belgium), was added to triplicate wells of BMDCs (1-2x105 BMDC/well) in 96 wells plates. Culture supematants were harvested 16 hr later and assayed for IFNa using an IFNa ELISA as described before [19, 23]. ANTIBODY IGG SUBTYPE ELISA, HEMAGGLUTINATION-INHIBITION ASSAY AND AFFINITY MEASUREMENTS For detection of virus-specific serum antibodies of different subtypes, sera of immunized mice were tested by ELISA, as described before [23]. The presence of hemagglutination-inhibiting (HI) antibodies were determined by employing a standard HI assay [19, 23]. To allow a comparison of affinity of H5Nl-specific IgG antibodies, pooled serum samples from immunized mice were first diluted such that they contained comparable levels of H5Nl-specific IgG. The sera were then incubated in H5Nl-coated ELISA plates for 1.5 hr. After washing with PBS/T, separate sets of wells with bound antibody were washed with different concentrations (ranging from 0.125 to 4 M) of ammonium.thiocyanate (NH4SCN) in phosphate buffer (pH6.0) for 15 min at RT. [37] After three washes with PBS /T, the remaining amount of antibody still bound in the antigen-coated wells was assessed using horseradish peroxidase-conjugated goat anti-mouse IgG as indicated above and expressed as OD at 492 nM. STATISTICAL ANALYSIS Statistical analysis was performed using Graphpad Prism 5.0 ( Graphpad software Inc., La Jolla, CA, USA). Results FUSION INACTIVATION Fusion-active WIV caused lysis of 60% to 83% of human erythrocytes in the hemolysis assay, in case of H5Nl WIV or H3N2 wrv, respectively, at the optimal pH for membrane fusion (pH5.5 for H5Nl, and pH5.2 for H3N2). Viral membrane fusion activity was completely abrogated after incubation of the WIV preparation with 0.5% FA for 30 min at 37°C (Fig lA). The loss of fusion activity by treatment 
90 


























H5N1 H5N1/FA H3N2 H3N2/FA 
,,,' 
,�-----..--,----..----•· .,.-
/ •• •  WIV 
l - WIV/FA . . . . . . , 
10 20 30 40 50 60 
time (sec) 
_:-,�:: 
FITC --+ Figure 1. Inactivation of viral membrane fusion activity. WIV was treated with buffer alone (WIV) or with buffer containing 0.5% formaldehyde (WIV/FA), for 30 min. (A) Fusion activity of WIV and WIV/FA, measured by its capacity to lyse erythrocytes, is given as a percentage of the maximal lysis, determined by hypotonic lysis of the erythrocytes in water. Results are shown for two different virus strains: H5N1 and H3N2, untreated (H5N1,  H3N2) and treated with FA (H5N1/FA, H3N2/FA). (B) Fusion activity, measured by an R18-based fluorometric assay. Given is the percentage of R18-labelled H3N2 WIV particles, either untreated (dashed line) or FA-treated (solid line), that fuse with erythroe1 te ghosts, plotted against the time elapsing after installing the optimal pH (pH 5.2) for triggering viral membrane fusion. (C) The binding and uptake of FITC­labelled fusion-active WIV and fusion-inactive WIV/FA by BMDC is presented by the fluorescence intensity (dashed line, WIV; solid line, WIV/FA) with the mean fluorescence intensity (MFI) given. The grey histogram shows the fluorescence intensity of BMDC incubated with medium alone. The data shown are representative results of two independent experiments. 
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M NH4SCN Figure 4. Effect of fusion-inactivation on antibody affinity maturation. Antibody affinihJ was assessed using increasing concentrations of a chaotropic agent  (NH4SCN) to break antigen­antibody bonds of serum IgG bound to HSNl-coated ELISA plates. Plotted are the optical densities (OD) and standard deviation of triplicate determinations for pooled serum samples of mice immunized with fusion-active WIV (dashed line, WIV) or fusion-inactive FA-treated WIV (black line, WIV/FA), against the concentration of NH4SCN in the washing buffer. The OD represents the amount of IgG that remained bound to the HSNl antigens. Despite the similar ELISA antibody titers for sera from mice immunized with fusion-active WIV or fusion-inactive wrv, HI titers were clearly lower in mice immunized with fusion-inactive WIV (Fig SA). A possible cause for this discrepancy may be the modification of epitopes on the HA by the FA treatment, leading to the induction of antibodies that do not recognize native HI epitopes. Indeed, when FA-treated viral particles were used for hemagglutination instead of untreated particles in the HI assay, a more than two-fold apparent increase in HI titer was observed for the sera from mice immunized with fusion-inactive WIV (Fig SB). This suggests that the 0.S% FA treatment modifies epitopes on HA that are targets for HI antibodies, and that the subsequent reduction in HI titer is probably not due to loss of viral membrane fusion activity. 
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WIV WIV/FA Figure 5. Serum HI titers induced by fusion-active and fusion-inactive wrv. (A) The capacihJ of sera from mice immunized with fusion-active WIV or fusion-inactive WIV (WIV, WIV/FA, respectively; 1 µg or 5 µg HA) to prevent hemagglutination of guinea pig erythrocytes is given for the individual mice, and presented as HI titer. (B) To analyse possible epitope changes mediated by FA treatment, pooled serum samples from mice immunized with either fusion-active or fusion-inactive WIV (WIV, WIV/FA, respectively) were tested in an HI assay. In this assay, untreated viral particles (black bars) or FA-treated viral particles (white bars) were used to agglutinate enJthrocytes. Statistically significant differences are indicated in the figure with asterisks (p<0.01). Discussion 
In this study, we investigated the effect of viral membrane fusion activity on the 
immunological properties of influenza A/HSNl WIV vaccine. We found that 
inactivation of viral membrane fusion had no effect on the uptake of WIV particles 
by antigen-presenting cells and a modest effect on TLR7-mediated IFNa 
production by DCs. In vivo, fusion inactivation of WIV did not have a major effect 
on the capacity of WIV to induce anti-HA antibodies as measured by ELISA. 
Induction of HI antibodies was reduced by fusion inactivation of WIV, but this 
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Chapter 4 may be explained by a modifying effect of FA on HA epitopes, rather than a loss of membrane fusion activity. We previously reported that TLR7 signalling plays an important role in the stimulation of the immune response to influenza WIV [23]. Wang and coworkers earlier postulated a role for viral membrane fusion and virus uncoating in TLR7 signalling [30]. Their hypothesis was based on the observation that prevention of fusion of (influenza) virus with the target cell endosomal membrane by raising the endosomal pH, resulted in a strong reduction of TLR7 signalling. We were able to study the role of membrane fusion in a direct way by selectively eliminating the fusion capacity of the virus particle itself, rather than by modifying the endosomal pH. We destroyed viral membrane fusion activity of WIV by a short treatment with 0.5% FA. Other methods that can inhibit the fusion activity of WIV include low-pH pretreatment, or fusion-blocking antibodies. Low-pH treatment, however, induces conformational changes in the HA affecting its receptor binding capacity or change the exposure of certain antibody epitopes for B-cell recognition. Fusion­blocking antibodies could alter the binding and entry of WIV into DC through binding to Fe-receptors. The latter may lead to enhanced uptake and TLR7 signalling (unpublished results), as has been shown previously for antibody­opsonized Coxsackie B virus [49]. Using FA treatment to inhibit the fusion activity of wrv, we found a lower IFNa production by fusion-inactive WIV, but only at the highest particle concentration. In addition to its effects on fusion activity, FA treatment may also stabilize virus particles against enzymatic degradation in celluar endosomes, or cross-link the viral RNA to nucleocapsid proteins, which could hamper the release of ssRNA for TLR7 recognition [43,44]. Such effect could explain the diminished IFNa production after FA treatment. Regarding the link between endosomal acidification and TLR7 activation demonstrated by others, our results suggest that other processes that depend on a mildly acidic endosomal pH, like viral uncoating and/ or endosomal maturation [ 45], may prove of greater significance for TLR7 signalling than viral membrane fusion. Endosomal acidification and maturation have been proven important for TLR7 activation by synthetic TLR7 ligands, showing that target cell entry of the virus may not be the only pH-dependent process involved in the control of TLR7 activation [48]. In the absence of fusion activity, WIV maintained its capacity to induce normal IgG levels with a predominance of IgG2a/ c subtype antibodies in vivo. This is in line with the relatively preserved capacity of WIV to activate TLR7 and 
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Viral Membrane Fusion and Th l Antibodies to induce IFNa production in vitro. Both TLR7 activation and IFNa act as signals that drive class-switch recombination towards IgG2a/ c production in B cells, as was recently demonstrated in a study investigating in vitro and in vivo B-cell activation by influenza [24]. Furthermore, we did not find evidence that fusion inactivation compromises the induction of HSNl-specific IFNy-producing cells (data not shown), suggesting that also T-cell help to B-cells remains intact. TLR stimulation has been shown to be important for antibody affinity maturation in induction of protective antibodies to respiratory syncytial virus (RSV) [46]. Whether a similar dependency on TLR plays a role in affinity maturation of the antibody response to influenza virus remains to be clarified. Immunization of mice with nanoparticles containing HA, combined with nanoparticles containing a TLR7 ligand, yielded antibodies of higher avidity than with nanoparticles containing HA alone [25]. This clearly suggests that TLR7 could play a role in the affinity maturation of WIV-induced antibodies. We observed no negative effect of fusion inactivation on antibody affinity, which is in line with the notion that the capacity to induce TLR7 signaling was not critically affected by fusion inactivation. Taken together, these results suggest that the critical determinants that shape the antibody response to WIV are relatively unaffected by inhibition of viral membrane fusion. WIV can induce cytotoxic T-cells (CTL), and it has recently been shown that, compared to untreated WIV, WIV treated with 0.5% FA is less efficient in priming naiVe NP366-374-specific cytotoxic T-cells (CTL) in vivo, but not in reactivation of memory CTL in vitro [SO]. Fusion activity therefore might play a role in priming of CTL responses. CTLs induced by cross-priming are known to contribute to protection against heterosubtypic virus infection [51]. This could be favorable especially in a pandemic situation, when there is a chance that stockpiled vaccines do not completely match the pandemic virus. In conclusion, viral membrane fusion is not a prerequisite for TLR7 signalling, and does not have a major effect on IFNa induction and the Thl-type skewing of antibody responses. Although, care should be taken when using FA as an agent to inactivate viral particles for WIV production as it might affect the induction of HI antibodies, it is unlikely that loss of fusion activity is a cause of impairment of vaccine efficacy. 
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Chapter 5 Abstract Clinical trials with pandemic influenza vaccine candidates have focused on aluminium hydroxide as an adjuvant to boost humoral immune responses. In this study we investigated the effect of aluminium hydroxide on the the magnitude and type of immune response induced by whole inactivated virus (WIV) vaccine. Balb / c mice were immunized once with a range of antigen doses (0.04-5 µg) of WIV produced from A/PR/8 virus, either alone or in combination with aluminium hydroxide. The hemagglutination inhibition (HI) titers of mice receiving WIV + aluminium hydroxide were 4-16 fold higher than HI titers in mice receiving the same dose of WIV alone, indicating the boosting effect of aluminium hydroxide. WIV induced a THI skewed humoral and cellular immune response, characterized by strong influenza-specific IgG2a responses and a high number of IFNy-secreting T cells. In contrast, immunization with WIV adsorbed to aluminium hydroxide resulted in skewing of this response to a TH2 phenotype (high IgGl levels and a low number of IFNy-producing T cells). To assess the effect of the observed immune response skewing on viral clearance from the lungs mice immunized once with 1 µg WIV without or with aluminium hydroxide were challenged with A/PR/8 virus 4 weeks later. The immunized mice showed a significant decrease in viral lung titers compared to control mice receiving buffer. However, despite higher antibody titers, mice immunized with WIV adsorbed to aluminium hydroxide suffered from more severe weight loss and had significantly higher virus loads in their lung tissue than mice receiving WIV alone. Major difference between these groups of mice was the type of immune response induced, TH2 instead of THI, indicating that a THI response plays a major role in viral clearance. 
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Alum Boosts TH2 -type Antibody Responses to lnfuenza WIV Introduction 
Influenza virus continues to be a major health burden. According to the World 
Health Organisation (WHO) the estimated number of worldwide excess deaths 
due to influenza is 0.25-0.5 million each year [l]. In addition to the seasonal 
epidemic influenza burden there is the risk of a pandemic caused by an influenza 
virus to which the majority of the world population is immunologically naive. 
Morbidity and mortality of a pandemic influenza strain will likely be much higher 
than that of epidemic influenza [2]. Currently, H5Nl, H7N2, H7N3, H7N7 and 
H9N2 have crossed the species barrier from birds to man to cause human 
infections on multiple occasions [3, 4, reviewed in 5]. H5Nl is considered a likely 
candidate for the next pandemic, having been confirmed to infect 357 people 
resulting in 225 deaths (WHO, Cumulative Number of Confirmed Human Cases 
of Avian Influenza A/ (H5Nl) February 1, 2008). 
The best protection against influenza virus infection remains effective 
vaccination [6]. Inactivated vaccines against influenza virus include whole­
inactivated virus (WIV) vaccines, split virus vaccines, and subunit vaccines [7]. 
WIV vaccine is prepared by inactivation of influenza virus with ls-propiolactone or 
formaldehyde, resulting in presence of all viral proteins in their native 
organization without viral replication. Split influenza virus vaccine consists of 
chemically disrupted inactivated influenza virus. Subunit vaccines are prepared 
by purification of the HA and NA from inactivated and detergent-solubilized 
influenza virus. All of these vaccine formulations have been reported to be in 
clinical trials as pandemic vaccine candidates [8]. 
A major objective in the context of the development of pandemic vaccines is to 
ensure sufficient supply of vaccines despite limited production capacities for 
vaccine virus. Dose sparing strategies are being developed to solve this problem. 
One of these dose sparing strategies is the use of WIV instead of split virus or 
subunit since WIV induces higher antibody responses, especially at low antigen 
doses and in an immunologically na1ve population [9, 10]. Another dose sparing 
strategy to increase the efficacy of pandemic influenza vaccines is addition of 
adjuvants to the vaccines to boost immune responses. 
Adjuvants used most frequently for human vaccination are aluminium 
compounds, including aluminium hydroxide and aluminium phosphate [11, 12, 
reviewed in 13]. Prior to injection the antigen is adsorbed onto a preformed 
aluminium gel (Alhydrogel® or Adju-phos®). Aluminium adjuvants generally 
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Chapter 5 induce a TH2 type of immune response and result in a stronger and more rapid induction of antibody titers. This makes them potentially suitable for the pandemic situation where likely only one vaccination can be achieved before the first wave of the pandemic [14]. Accordingly, in the majority of clinical trials performed to date with pandemic influenza vaccine candidates aluminium hydroxide or aluminium phosphate were used as the adjuvant [15-19, for an overview of all clinical pandemic influenza vaccine trials see 8]. Outcomes of these clinical trials are reported predominantly as hemagglutination inhibition titers and seroconversion rates. So far, six clinical studies have been reported which compare the response to non-adjuvanted and alum-adjuvanted pandemic influenza vaccines, respectively [8]. Three of these studies did not find a benefit or even a negative effect of alum adjuvants [8: Baxter study A/Vietnam/1194/2004 wrv, Sanofi Pasteur study A/Vietnam/1203/2004 split vaccine in adults (= ref 17), Novartis study A/Vietnam/1203/2004 subunit vaccine). Two studies found inconsistent results [8: GSK study H9N2 WIV, Sanofi Pasteur study A/Vietnam/ 1203/2004 split vaccine in the elderly]. One study reported improvement of seroprotection, seroconversion and rise of GMT by alum [8: GSK study A/ Vietnam/ 1194 / 2004 WIV] The mode of action of aluminium compounds is not completely clear yet, they may form a depot for the antigen, either at the site of injection or in the draining lymph nodes. The depot enables slow release from the site of injection and/ or longer contact with cells of the immune system [13, 20]. Another mode of action could be the conversion of soluble antigen to particulate antigen facilitating phagocytosis by antigen-presenting cells [21]. Furthermore, aluminium compounds induce priming of B cells and accumulation of IL-4 producing Grl + myeloid cells facilitating B cell responses [22]. In this study we aim to determine if aluminium hydroxide is indeed a suitable adjuvant for influenza vaccines, using two vaccine formulations, WIV vaccine and subunit vaccine, in a mouse model system. H5Nl vaccines are known to be poorly immunogenic, inducing low antibody titers in both experimental animals and man [23-25]. To mimic this, HlNl A/Puerto Rico/8/34 (PR8) virus was used as a model influenza virus. PR8 has a low immunogenicity compared to the commonly used H3N2 strains (L. Bungener, unpublished observation). Moreover, PR8 causes symptomatic infection in mice and can therefore be used in a challenge model to test the protective efficacy of the vaccines. We determined the effect of addition of aluminium hydroxide to PR8 influenza vaccines on antibody titers, phenotype of 110 
Alum Boosts TH2 -type Anti body Responses to lnfuenza WIV immune response and protective capacity of the vaccines upon challenge. Aluminium hydroxide boosted the antibody response but altered the phenotype of the immune response. Moreover, despite 4-16 times higher hemagglutination inhibition titers in mice receiving aluminium hydroxide-adjuvanted WIV clearance of influenza virus from the lungs was decreased. Materials and methods VIRUS, SUBUNIT AND VIROSOMES PR8 influenza virus (HlNl subtype) grown on Madin-Darby canine kidney cells (MOCK) was kindly provided by Solvay Pharmaceuticals (Weesp, The Netherlands). The virus was purified, inactivated by treatment with formaldehyde and used as whole inactivated virus (WIV). For inactivation, virus was incubated twice with a freshly prepared 4% formaldehyde/ 10% sucrose solution in buffer containing 5 mM Hepes, 150 mM NaCl and 0.1 mM EDTA (HNE buffer) at a final concentration of 0.02% formaldehyde. Inactivation was carried out for 24 hr at 4°C under continuous stirring, maintaining a neutral pH during the entire incubation. After inactivation, the virus was dialysed against HNE buffer. Virus inactivation was confirmed by standard titration of the virus preparation on MOCK cells. Subunit material was prepared by solubilizing inactivated virus for 3 hours under continous rotation in 0.3 mg/ ml Tween-80, 1.5 mg/ ml hexadecyltrimethylammonium bromide (CTAB) in phosphate-buffered saline (PBS). The viral nucleocapsid was removed from the preparation by ultracentrifugation. Detergents were removed by overnight absorption onto Biobeads SM2 (Bio-Rad, Hercules, CA). Finally, the subunit material was filtered through a 0.45 µm filter. Virosomes for stimulation during the ELISPOT assay were prepared essentially as described previously [26-29]. In short, formaldehyde-inactivated virus (1.5 µmol of viral membrane phospholipids) was solubilized in 100 mM octa(ethyleneglycol)-n-dodecyl monoether (C12Es), (Calbiochem, San Diego, CA) in HNE buffer. The nucleocapsid was removed from the preparation by ultracentrifugation. Subsequently, the detergent C12Es was extracted from the supernatant with BioBeads SM2 resulting in the formation of virosomes. Virosomes were purified on a discontinuous sucrose density gradient. Finally, the virosomes were dialyzed against HNE buffer and filtered through a 0.45 µm filter. Viral, virosomal and subunit protein content was determined according to Lowry 111 
Chapter 5 [30]. HA content was assumed to be one third of total viral protein for WIV (based on the constitution of influenza virus particles) and to be equal to total protein for virosomes and subunit (based on silver-stained SDS polyacrylamide gels run under reducing and non-reducing conditions). Equal HA amounts in the vaccine preparations was verified by SDS PAGE. IMMUNIZATION OF MICE Specified-pathogen-free female Balb / c mice were purchased from Harlan CPB (Zeist, The Netherlands) and used at 8 to 10 weeks of age. The protocol for the animal experiments described in this paper was approved by the Animal Experimentation Ethical Committee of the University of Groningen. The amount of HA protein in the vaccines was 5 µg, 1 µg, 0.2 µg or 0.04 µg. Alhydrogel (Gerbu Biotechnik, Gaiberg, Germany; 2% suspension) was added to the vaccines at a final concentration of 40% v / v and the mixture was gently rotated for 6 hours at 4°C just before vaccination of the mice. Vaccines without Alhydrogel adjuvant were incubated in the rotator simultaneously. All adjuvanted vaccine formulations contained 200 µg of aluminium per vaccination dose. Mice (6-8 animals per group) were immunized once intramuscularly (i.m.) with whole inactivated virus (WIV) or subunit vaccine with or without aluminium hydroxide in 50 µl per mouse divided over two hind legs. Four weeks after immunization, mice were bled under anaesthesia, sacrificed and spleens were harvested. Spleen cells were isolated and used in ELISPOT assays. Serum was collected for antibody assays. ELISPOT ASSAY ELISPOT analyses were performed according to a protocol adapted from the method described by Miyahira [31]. ELISA plates (Greiner, Alphen a/ d Rijn, The Netherlands) were coated with purified anti-mouse IFNy or IL-4 (rat IgGl, Pharmingen, San Diego, CA) overnight at 37°C. Plates were washed three times with sterile PBS Tween (PBS + 0.02% Tween 20) and incubated with blocking buffer (PBS containing 4% RIA Grade BSA) for 1 hr. Spleen cells were plated in different quantities in medium containing 5% FCS and incubated overnight with or without 1 µg per well of virosomal protein. Virosomes were chosen for restimulation since they stimulate only HA- and NA-specific T cells (which were to be studied here). In previous studies virosomes were found to be superior to subunit material in T cell stimulation and the optimal stimulation dose was 
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Alum Boosts TH2-type Antibody Responses to l nfuenza WIV determined to be 1 µg (A. Huckriede, unpublished observations). Subsequently, cells were lysed by 10-min incubation in water and plates were washed five times with PBS Tween. IFNy was detected using biotinylated anti-mouse IFNy antibody and streptavidin-alkaline phosphatase (Pharmingen). The substrate for the alkaline phosphatase was 1 mg/ ml 5-bromo-4-chloro-3-indolylphosphate in water containing 6 mg/ml agarose (Sigma), 9.2 mg/ml 2-amino-2-methyl-1-propanol (Sigma) and 0.08 µI/ml Triton X-405. Spots were developed for 3 h at 37°C and counted using an automated ELISA-spot assay video analysis system (A EL VIS, Hannover, Germany). Background (spleen cells incubated without virosomal protein) was usually less than 5 spots per 106 cells plated. This background was subtracted from the number of spots observed in wells containing spleen cells incubated with antigen to obtain the number of IFNy-secreting cells. HEMAGGLUTINATION INHIBITION (HI) ASSAY For determination of HI titers in serum, 75 µI of serum was first inactivated by incubation for 30 min at 56°C. In order to reduce non-specific hemagglutination, 225 µI of a 25% kaolin suspension was added. The mixture was vortexed and incubated for 20 min at room temperature. After centrifugation for 2 min at 6500x 
g, 50 µI of the supernatant was transferred in duplicate to 96-well round-bottom plates (Greiner) and serially diluted twofold in PBS. Next, 4 hemagglutination units (HAU) of influenza PR8 virus were added to each well in a volume of 50 µI. The content of each well was gently mixed with a multichannel pipette and plates were incubated for 40 min at room temperature. Finally, 50 µI of a 1 % guinea pig erythrocyte suspension in PBS was added to each well and hemagglutination was allowed to proceed for 3 h at room temperature. The highest serum dilution capable of preventing hemagglutination was scored as the HI titer. Detection limit of this assay was 4 and non-responding sera were assigned an arbitrary titer of half the detection limit (HI titer of 2). IGG, IcGl AND IGG2A ELISAs Influenza HA-specific antibody responses were determined using ELISA, as previously described [32]. ELISA plates (Greiner, Alphen a/ d Rijn, Netherlands) were coated with 0.2 µg of influenza PR8 subunit antigen per well. Appropriate dilutions of sera of individual mice were applied to the plates, serially diluted twofold in PBS /Tween (PBS containing 0.05% Tween20), and then incubated for 1.5 h at 37°C. Subsequently, plates were washed and incubated with horseradish 
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Chapter 5 peroxidase-conjugated goat antibodies directed against mouse IgG, IgGl or IgG2a (all 1:5000, Southern Biotechnologies). After incubation of the plates with mouse lg isotype- and subtype-specific conjugates for 1 h at 37°C, plates were washed twice with PBS/Tween, and once with PBS. Antibodies were detected using substrate buffer (50 mM phosphate buffer pH 5.5 containing 0.02% o-phenylenediamine and 0.006% H2O2). Plates were developed in the dark for 30 min at room temperature after which the reaction was stopped by addition of 50 µ1 2 M H2SO4 per well, and absorbances were read at 492 run (A492) using a SPECTRA I ELISA reader (SLT, Salzburg, Austria). Titers are given as the loglO or geometric mean titer of the reciprocal of the sample dilution calculated to correspond to an A49z of 0.2. For IgGl and IgG2a, a calibration curve was obtained by coating ELISA plates overnight with 0.1 µg/ well of goat anti mouse IgG (Southern Biotechnologies) instead of subunit antigen and incubating with increasing concentrations of purified mouse IgGl or IgG2a (Southern Biotechnologies) instead of serum dilutions. Results for IgGl and IgG2a are expressed as concentrations of influenza HA-specific IgGl and IgG2a. CHALLENGE EXPERIMENTS For challenge experiments mice were vaccinated i.m. with 1 µg of HA in WN or subunit vaccine, adsorbed or not adsorbed to aluminium hydroxide. Control mice were injected with buffer only. Four weeks after vaccination mice were challenged intranasally under anaesthesia with lxl04 TCIDso PR8 influenza virus in 40 µI of PBS [33]. The dose of challenge virus was chosen to allow the detection of possible differences in the protective capacities of the tested vaccine formulations. Mice were monitored twice a day for signs of clinical illness by weighing the animals and observing their appearance and activity. After three days mice were bled and sacrificed. The left lung lobes were collected and stored in 1 ml of PBS before homogenisation. One of the right lung lobes was isolated and frozen in liquid nitrogen for histopathology. Another right lobe was inflated with formalin for fixation and embedded in paraffin. DETERMINATION OF VIRUS TITERS IN LUNGS OF CHALLENGED MICE Virus titers in the lung tissue were determined by homogenising lung tissue, pelleting debris by centrifugation and collecting the supernatant containing the virus. This lung homogenate was stored at -80°C until virus titration. Virus titration was performed on MDCK cells seeded in 96 well plates. Two-fold 
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Alum Boosts TH2 -type Antibody Responses to lnfuenza WIV dilutions (in duplicate) of virus-containing lung homogenate supernatant were prepared in a flat-bottom 96 well plate. Medium was removed from the monolayer of MDCK cells and 50 µI dilutions of lung homogenates were transferred to the cells. After 1 hour 50 µI medium containing 7.5 µg TPCK trypsin (Sigma) was added per well followed by a 72 hour incubation at 37°C, 5% CO2. Supematants were collected and put in a roundbottom 96 well plate. Addition of 50 µI of a 1 % solution of guinea pig erythrocytes and incubation for 2 hours enabled readout of the dilution at which virus was still present (indicated with hemagglutination), which represents the virus titer in the lungs. Next, the 101og virus titer was calculated per gram of lung tissue. STATISTICAL ANALYSIS The unpaired Student's t-test was used to determine if the difference in immune responses observed between groups of mice was significant. HI and IgG titers were log-transformed prior to statistical analysis. P values are given and in general a p value of p < 0.05 was considered significant. 
Results EFFECT OF ALUMINIUM HYDROXIDE ON THE MAGNITUDE OF THE ANTIBODY RESPONSE TO WIV 
In order to elucidate potential dose-sparing effects of aluminium hydroxide on antibody responses to WIV antigen, mice were immunized once with decreasing doses of WIV PR8. The highest immunization dose was 5 µg and the other experimental groups were injected with five-fold lower doses (1 µg, 0.2 µg and 0.04 ttg). The decision to immunize once was based on the assumption that in case of a pandemic it will most probably not be possible to immunize and boost before the first wave of the pandemic strikes [34]. Only the highest amount of non­adjuvanted WIV (5 µg of HA) was sufficient to induce hemagglutination inhibition (HI) titers > 40 in 5 out of 8 mice with a geometric mean ( GM) HI titer of 37 (Figure lA). In humans, an HI titer of 40 is considered to be protective in at least 50% of the population [35, 36]. Lowering the antigen dose five-fold to 1 µg resulted in a three-fold decrease of the GM HI titer to 13 with only one animal exhibiting a HI titer >40. Immunization with 0.2 µg and 0.04 µg HA without aluminium hydroxide resulted in GM titers of 5 and 4, in these groups half of the mice had no detectable 
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Chapter 5 HI titer and none of the animals showed a titer > 40. These comparatively low HI titers indicate that the PR8 influenza virus is indeed poorly immunogenic in a single dose regimen without adjuvant. Addition of Alhydrogel to the WIV vaccine strongly and significantly enhanced HI titers to the extent that even immunization with 0.2 µg HA resulted in HI titers > 40 in 7 out of 8 mice (Figure lA). GM HI titers were 175 for 5 µg HA, 147 (1 µg), 83 (0.2 µg) and 16 (0.04 µg), respectively. P values for differences between vaccination with and without alum were 0.003, 0.0006, 0.00003, and 0.02 for the indicated antigen doses, respectively. Thus, upon addition of aluminium hydroxide to WIY, HI titers in mice were boosted by 4-16 fold depending on antigen dose. 
In contrast to this clear boost of HI titers, total influenza-specific IgG levels were only marginally higher at all antigen concentrations upon addition of aluminium hydroxide to WIV (Figure lB). This rise in specific total IgG was only significant for the lower antigen dose of 0.2 µg indicating that there was no clear correlation between HI titer and total specific IgG in this experiment. EFFECT OF ALUMINIUM HYDROXIDE ON THE PHENOTYPE OF THE IMMUNE RESPONSE TO WIV 
In order to clarify the incongruence observed between HI titers and total IgG and to obtain insight into the phenotype of the antibody response we determined HA­specific IgGl and IgG2a levels in sera of immunized mice. IgGl was used as a measure for a TH2-biased antibody response and IgG2a as a measure of a THI­biased antibody response. WIV immunization induced low HA-specific IgGl levels and high specific IgG2a responses (Figure 2). Addition of Alhydrogel to WIV strongly altered the phenotype of the immune response. For all vaccine doses tested, influenza-specific IgGl responses increased significantly while IgG2a responses decreased significantly compared to responses in animals that received WIV vaccine alone (p � 0.005 in all cases). All of the animals immunized with WIV alone had higher influenza-specific IgG2a responses than IgGl responses, resulting in IgG2a/IgG1 ratios > 1 (Table 1). In contrast, IgG2a/IgG1 ratios in animals immunized with WIV adsorbed to aluminium hydroxide decreased to 0.06-0.4 indicating a TH2-biased antibody response. When IgGl and IgG2a amounts are added the sum shows the same vaccine dose dependent decrease as observed for total IgG titers (Figure lB). Upon addition of aluminium hydroxide the increase in IgGl is almost 
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Alum Boosts TH2-type Anti body Responses to lnfuenza WIV compensated by a decrease in IgG2a for all vaccine doses. This explains why the titers of total IgG do not increase much upon addition of alum. Moreover, it implies that HI titers are more strongly correlated with IgGl than with IgG2a. 
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5 µg 1 µg 0.2 µg 0.04 µg Figure 1. Hemagglutination inhibition titers (A) and total IgG responses (B) four weeks after a single i.m. immunization with decreasing doses (5 µg, 1 µg, 0.2 µg and 0.04 µg) of WIV vaccine without (open symbols/white bars) and with (closed symbols/black bars) aluminium hydroxide. Results for HI are depicted as responses of individual mice and geometric mean HI titers are given (black lines). For IgG responses the average 10log IgG titers ± standard deviation are given (n=B mice per group). Titers of influenza HA-specific IgG were determined in sera btj ELISA using subunit antigen as the coating substance. Levels of significance are depicted as follows: * p<0.05, ** p<0.01 and *** p<0.001. 
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Chapter 5 Table 1. IgG2a/IgG1 ratio after one immunization with WIV vaccine with or without aluminium hydroxide 
Vaccine 5 µg HA 1 µg HA 0.2 µg HA 0.04 µg HA 
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5 µg 1 µg 0.2 µg 0.04 µg Figure 2. IgG1 (A) and IgG2a (B) antibody responses in mice immunized i.m. with 5 µg, 1 µg, 0.2 µg and 0.04 µg of WIV vaccine without (white bars) and with (black bars) aluminium hydroxide. Quantities of influenza HA-specific IgG1 and IgG2a four weeks after immunization were determined in sera by ELISA using subunit antigen as the coating substance and a calibration curoe of murine IgG1 or IgG2a 011 plates coated with goat anti mouse IgG. Average quantities of influenza-specific IgG1 and IgG2a ± standard deviation are depicted (11=8 mice per group). 
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Alum Boosts TH2 -type Antibody Responses to lnfuenza WIV 
To determine if the strong bias towards a TH2 immune response observed 
upon addition of the aluminium hydroxide to WN extends to the T helper cell 
response, spleen cells of immunized mice were harvested and tested in an 
ELISPOT assay. Influenza antigen-specific IFNy responses were significantly (p = 
0.0008) higher in mice immunized with WN alone compared to mice immunized 
with WN + alum (Figure 3). The IL-4 response in spleen cells on the other hand 
was significantly higher when mice were immunized with WIV combined with 
Alhydrogel (p = 0.02). Mice immunized with WN alone had a THl /TH2 ratio > 1 
with an average of 3.3 whereas animals immunized with WN adsorbed to 
aluminium hydroxide had an average ratio of 0.8. Thus, immunization with WN 
alone results in a dominant IFNy response whereas IL-4 production is dominant in 
spleens from animals immunized with WN adsorbed to aluminium hydroxide. 
*** 










I FNy IL-4 Figure 3. Cytokine-producing T cells after immunization with 5 µg WIV vaccine without (white bars) and with (black bars) aluminium hydroxide. Spleen cells were isolated 4 weeks after immunization and stimulated overnight with virosomes (1 µg of protein per well). IFNy- and IL-4-producing T cells were detected by ELI SPOT. EFFECT OF THE PHENOTYPE OF THE IMMUNE RESPONSE ON VIRAL CLEARANCE FROM THE LUNGS 
To assess the effect of aluminium hydroxide addition to influenza vaccines on 
virus clearance, immunized mice were challenged with a high dose of PR8. For 
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Chapter 5 this purpose, mice were immunized with 1 µg HA formulated as WIV or subunit vaccine, with or without previous absorption to aluminium hydroxide. Four weeks after immunization of the mice, serum samples were taken and animals were infected with lxl04 TCIDso of PR8 virus. Subunit antigen was added as a vaccine candidate in the challenge studies to further clarify the role of the type of immune response (THI versus TH2) on the ability to respond effectively to a virus challenge. Protein antigens alone typically induce a TH2 type of immune response characterized by high IgGl and low IgG2a. Since aluminium hydroxide also stimulates a TH2 response, this vaccine­adjuvant combination might work synergistically. All mice showed strong antibody responses four weeks after immunization, at the time of virus challenge (Table 2). As expected, the results for subunit­immunized mice corroborate the TH2 bias of this protein antigen. Antibody profiles of subunit-immunized mice prior to challenge were TH2 dominated with moderate IgGl induction and almost no IgG2a. Addition of aluminium hydroxide to subunit vaccine significantly boosted IgG and IgGl antibody responses (p = 0.003 and p = 0.002). Pre-challenge antibody titers for WIV with and without aluminium hydroxide were similar to titers observed in previous immunization experiments while the amount of IgGl in the WIV / alum group was higher for reasons unknown. As expected, significant increases in IgGl (p = 0.001) and decreases in IgG2a (p = 0.01) were measured upon addition of aluminium hydroxide to WIV. 
Table 2. Prechallenge influenza HA-specific antibody responses to 1 µ.g WIV or subunit 
vaccine with or without aluminium hydroxide 
Vaccine Total influenza HA- l g G  1 ( µ g / m ll g G 2 a  ( µ g / m llgG2a/IgG1 
specific IgG (10Iog ± 
stdev) ±stdev) ±stdev) 
WN 4.02±0.23 3 . 1±1 .4 3 1 .4±23. 1  1 1 .9 
WN + Alhydrogel 4. 16±0.21 130.5±68.5 2.9±2.5 0.04 
Subunit 2.61±0.42 3.3±3 . 1  0. 1±0. 1 ND 
Subunit + Alhydrogel 3.79±0.28 41 .7±22.6 2.4±3.3 0.06 ND = not detectable because 3/6 mice had no specific IgG2a 
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Alum Boosts TH2 -type Antibody Responses to lnfuenza WIV After virus challenge, control mice showed signs of illness (increased breathing rate, ruffled fur and reduced activity) and substantial weight loss indicating that the challenge was severe (Figure 4A). Control animals injected with buffer lost 11.4% of their weight in the three days following challenge and all of the animals in this group were still losing weight at the moment of sacrifice. Mice immunized with subunit and subunit + Alhydrogel lost 12.6% and 7.5% of their original weights respectively. These weightlosses were not significantly different from those in the control group (p = 0.6 and p = 0.1, respectively). Like the animals in the control group, these mice were still losing weight and showing signs of illness at the time of sacrifice. Mice immunized with WIV or WIV + aluminium hydroxide showed a weight gain during the first one and a half days after challenge, followed by weight loss in the next day and a stabilisation in the last hours before termination. Animals immunized with WIV + Alhydrogel had an average weight loss of 5.3% three days after challenge, this weight loss was lower than that in the control group (p = 0.05). In contrast to all other experimental groups, WIV-immunized animals had an average weight gain on day 3 of 1.5% and this group was statistically different from the control group (p = 0.0004). Moreover, WIV-immunized mice did not show signs of illness and remained active. On day three, animals were sacrificed and virus titers in the lungs were determined (Figure 4B). Buffer-injected mice had an geomean titer of 108·8• With GM titers of 108·4 (subunit alone) and 108·1 (subunit + aluminium hydroxide), virus titers in lungs of subunit-immunized mice were not statistically different from those in the control group (p = 0.14 and p= 0.4, respectively). In contrast, the GM virus titer in mice immunized with WIV (105·5) was about 3 logs lower than that in the control group and this difference was statistically highly significant (p = 0.005). WIV + aluminium hydroxide immunized mice also showed significantly lower virus titers than the control group with a GM lung titer of 107·7 (p = 0.0006). Yet, the virus titer in these mice was significantly higher (p = 0.04) than the titer in mice immunized with WIV alone.despite of high amounts of influenza-specific IgGl and thus presumably a much higher HI titer (in the experiment depicted in Fig. I the difference in HI titer after vaccination with 1 µg WIV with or without alum was factor 12) (Figure lA). 
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vaccine Figure 4. Body weight (A) and virus titers in lungs (B) of mice immunized with WIV or subunit with and without aluminium hydroxide and challenged intranasally 4 weeks later with PRB virus. Animals were vaccinated i.m. with WIV (diamonds) or subunit (squares) containing 1 µg of HA. As a control mice were injected with HNE buffer (triangles). Vaccines were given without aluminium hydroxide (open symbols) or adjuvanted with aluminium hydroxide (closed symbols). Mice were challenged with lx104 TCIDso of live PRB virus given under isofiurane anesthesia to ensure inhalation of the virus into the lungs. Three days after the virus challenge the animals were sacrificed and lungs were harvested. Average body weight per group (11=6 per group) is depicted in (A), virus titers are expressed as the 10log virus titer per gram of lung tissue of individual mice (B ). 
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Alum Boosts TH2-type Antibody Responses to l nfuenza WIV Discussion In this study, the influence of aluminium hydroxide on the magnitude, the phenotype and the protective capacity of the immune response induced by WIV influenza vaccine was determined. WIV was chosen because it is one of the promising pandemic influenza vaccine candidates currently investigated in clinical trials [9, 10]. Aluminium hydroxide was chosen because it is used as an adjuvant in most of the clinical trials currently performed in the context of the development of a pandemic influenza vaccine and because it is one of the few adjuvants licensed in humans [8]. Aluminium hydroxide, a TH2 type adjuvant, boosts antibody responses and protection against influenza virus infection is mediated primarily by influenza-specific antibodies [11, 13, 37]. Data presented in this paper show that absorption of WIV to aluminium hydroxide strongly stimulates HI titers and IgGl titers upon vaccination of mice but suppresses IgG2a titers and impairs the induction of IFNy-producing THl cells. Therefore, addition of aluminium hydroxide to WIV increases the magnitude of the antibody response (HI and IgGl) but changes the phenotype dramatically from a THI-dominated to a TH2-dominated response. Most importantly, despite the higher HI titers induced by WIV + aluminium hydroxide, addition of the adjuvant to the vaccine had no beneficial effect on virus clearance from the lungs upon virus challenge. Total virus titers in lungs of mice immunized with WIV in combination with aluminium hydroxide were even significantly higher than virus titers in lungs of animals immunized with WIV alone. The limited protective capacity of a TH2 response was confirmed in mice immunized with subunit vaccine. This influenza vaccine, consisting only of influenza protein, is a TH2 type vaccine inducing primarily IgGl and IL-4 responses [38]. Addition of the TH2 adjuvant aluminium hydroxide did not change the phenotype of the immune reaction evoked by the vaccine but simply boosted the antibody response (total IgG, IgGl in particular) significantly. However, this TH2 type of immune response did not confer any protection against virus replication in the lungs of immunized mice. Thus, even though total specific IgG levels are similar in mice immunized with WIV alone and animals immunized with subunit + aluminium hydroxide, protection against virus replication in lungs is only observed in WIV immunized mice exhibiting a THl skewed immune response. This strengthens the hypothesis that a TH2 type of immune response is not optimal for protection against virus replication. Again, high HI titers alone do 
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not necessarily correlate with protection against challenge with high virus load, at 
least not in the mouse model. The use of the HI titer as single correlate of 
protection can thus be misleading. 
The effect of aluminium hydroxide adjuvant on the antibody response and 
protective capacity of whole inactivated virus vaccine has recently been studied in 
mice for two vaccines derived from recombinant HSNl strains [39, 40]. In the first 
study, HI titers for the adjuvanted versus the non-adjuvanted groups were 
statistically not different after two immunizations except for the 0.02 µg group 
immunized with A/HK/ 213/ 04-derived vaccine which developed a low HI titer 
of about 11 with adjuvant but no titer without adjuvant [39]. Protection from death 
or weight loss did not correlate with HI titers and occurred even in the absence of 
any hemagglutination inhibiting antibodies. Addition of aluminium hydroxide to 
the vaccine increased survival rates especially upon heterologous challenge. In 
contrast, in the second study survival rates at low antigen doses were found to be 
higher for non-adjuvanted whole inactivated virus vaccine than for alum­
adjuvanted vaccine [40]. This was true for outbred CDI mice whereas in Balb / c 
mice protection after immunization with and without alum did not differ, 
although the latter results are not shown. Unfortunately, the phenotype of the 
immune response in terms of IgGl vs IgG2a and IFNy- vs IL-4-producing T cells 
was not investigated in either of these studies and correlates of protection 
therefore remain unclear. The effect of the site of immunization and the 
immunization scheme on the magnitude and phenotype of the elicited immune 
response to the adjuvanted and non-adjuvanted vaccines certainly deserves 
further investigation. 
Immune responses to a vaccine are determined by both the composition and 
formulation of the vaccine and the presence and nature of added adjuvants. We 
and others have previously shown that WIV induces a stronger and more THI­
skewed antibody response than split, subunit or virosomal vaccine formulations at 
least after a single immunization [38, 41, 42]. Together with the data presented 
here and unpublished results of our group on HSNl vaccines these studies clearly 
demonstrate that the relative magnitude of the immune response and the TH 
profile induced are independent of vaccine strain and vaccine dose but rather 
depend on vaccine formulation and possibly on the number of immunizations 
given [42]. 
In general, induction of influenza-specific antibodies by vaccination clearly 
correlates with protection against infection [43, 44], but the subtype of antibody 
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Alum Boosts TH2 -type Anti body Responses to lnfuenza WIV mediating protection is less clear. In the mouse, the antibody profile induced by influenza virus infection is predominantly of the THl type, characterized by high IgG2a levels and low IgGl levels and earlier reports imply that virus-specific IgG2a is important for protection [45-48]. Superiority of a THl skewed immune response or a mixed THl /TH2 response over a TH2 type response for protection from influenza virus infection as shown here has also been demonstrated by Hovden et al and recently by Huber et al [42, 49]. In the Hovden study, mice were immunized once with A/Panama/2007 /99 (H3N2) WIV or split vaccine resulting in strongly IgG2a-dominated and IgGl-dominated responses, respectively [41]. Upon challenge of the immunized mice with a non-lethal dose of virus, a self­limiting upper respiratory tract infection occurred. After one dose of vaccine, WIV­immunized mice had in general lower virus titers in nose wash samples than control animals or animals immunized with split virus vaccine which would confirm that the WIV-induced THl response is superior [42]. Yet, after 2 immunizations virus shedding was lowest in mice immunized with split vaccine. This might indicate that a mixed THl /TH2 response can be effective in controlling virus growth provided that sufficient amounts of IgG2a are present or that cellular immune mechanisms coming up after a second vaccination also play a role in protection. However, virus titers in the Hovden study were low and variation within experimental groups was extensive. Strong conclusions can therefore not be drawn. In the Huber study, mice were vaccinated with an HA DNA vaccine, with a viral replicon system encoding HA or with a combination of both to induce IgGl-dominated, IgG2a-dominated and mixed IgG1/IgG2a responses, respectively [49]. IgG2a alone protected mice as efficiently from lethal challenge as a mixture of IgGl and IgG2a. In contrast, IgGl alone only protected from mild virus challenge but provided insufficient protection upon high dose challenge. As possible reasons for the superiority of IgG2a the affinity of this subtype for complement factors and Fe receptors is discussed which would both contribute to efficient clearance of virus by phagocytosis and antibody-mediated cellular cytotoxicity [49]. In contrast, IgGl does not lead to complement activation and has only weak affinity for Fe receptors. In humans, HI titers are so far the only correlate of protection measured for the evaluation of seasonal influenza vaccines as well as pre-pandemic vaccine candidates. There are a number of studies, primarily in healthy young adults, indicating that the median HI titer protecting 50% of vaccinated individuals against influenza virus is 28 [reviewed in 36]. Antibody subtypes, in particular the 125 
Chapter 5 levels of IgGl, the human equivalent of murine IgG2a, are not measured in clinical trials. Consequently, the roles of different antibody subtypes for protection against influenza virus infection in humans are so far unclear. Early studies indicate, however, that also in the human situation infection induces predominantly the THl antibody subtype IgGl and provides the best protection against re-infection by homotypic and heterotypic virus strains [50, 51]. Moreover, a decline in the THl response in elderly is correlated with reduced influenza vaccine efficacy, adding further evidence to the importance of the THl response for protection against infection [52]. It is thus likely that similar to the situation in mice antibody subclass distribution is important for the protective effect of influenza vaccination also in humans and more information on this issue is urgently needed. In summary, we show in this study that addition of aluminium hydroxide to WIV vaccines is not beneficial for prevention of virus replication in the lungs and suggest that this is caused by the switch in immune response from THl to TH2 caused by this adjuvant. The fact that mice immunized with WIV alone perform better upon challenge with live virus than mice immunized with WIV adjuvanted with aluminium hydroxide, despite the boost of the HI and IgGl titers, is a clear indication that the phenotype of the immune response is of crucial importance for protection. Further research into pandemic influenza vaccine should therefore take into account that the use of HI titers or total IgG titers alone as readout for vaccine efficacy may not allow reliable prediction of the protective capacity of an influenza vaccine. We therefore strongly recommend to monitor also qualitative parameters of the immune response during pandemic vaccine trials to obtain more insight into the best correlates of protection for influenza vaccines. 
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Chapter 6 
Abstract Stockpiling of pre-pandemic influenza vaccines guarantees immediate vaccine availability to counteract an emerging pandemic. Generally, influenza vaccines need to be stored and handled refrigerated to prevent thermal degradation of the antigenic component. Requirement of a cold-chain, however, complicates stockpiling and the logistics of vaccine distribution. We, therefore, investigated the effect of elevated storage temperatures on the immunogenicity of a pre-pandemic influenza A HSNl whole inactivated virus vaccine. Either suspended in liquid or kept as a freeze-dried powder, vaccines could be stored for 1 year at ambient temperature (20°C) with minimal loss of immunogenicity in mice. Elevation of the storage temperature to 40°C, however, resulted in a significant loss of immunogenic potency within 3 months if vaccines were stored in liquid suspension. In sharp contrast, freeze-dried powder formulations were stable at 40°C for at least 3 months. The presence of inulin or trehalose sugar excipients during freeze-drying of the vaccine proved to be critical to maintain its immunogenic potency during storage, and to preserve the characteristic Thl-type response to whole inactivated virus vaccine. These results indicate that whole inactivated virus vaccines may be stored and handled at room temperature in moderate climate zones for over a year with minimal decline and, if converted to dry-powder, even in hot climate zones for at least 3 months. The increased stability of dry-powder vaccine at 40°C may also point to an extended shelf-life when stored at 4°C. Use of the more stable dry-powder formulation could simplify stockpiling and thereby facilitating successful pandemic intervention. 
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Stable Dry-powder H S N l  Vaccine Introduction Animal influenza A viruses that cross the species barrier to humans pose a potential pandemic threat [1]. Generally, these virus subtypes are antigenically different from the circulating human viruses and thus may spread rapidly in the immunologically naive population, if human-to-human transmission is sustained. Recently, a novel HlNl influenza virus of combined swine, avian, and human origin became pandemic within two months after its emergence in humans in April 2009 [2, 3]. In terms of virulence this virus is comparable to the H2N2 virus that caused the relatively mild pandemic of 1957 [4-7]. However, a similar pandemic scenario with a more virulent virus subtype like the highly pathogenic avian influenza (HPAI) H5Nl virus would be potentially catastrophic [8, 9]. With a lethality rate of approximately 60% in reported laboratory-confirmed human H5Nl cases [10], maximum preparedness is warranted in case sustained human­to-human transmission were to evolve. Vaccines and antivirals are critical assets in intervention strategies against pandemic influenza [11, 12]. They represent the only countermeasures that are clearly efficacious in preventing infection and treating illness [13] and their availability plays a central role in pandemic preparedness planning. Prophylactic use of antivirals could provide short-term protection and may be helpful for early containment of an emerging pandemic [14, 15]. However, the control of infection in a pandemic will ultimately depend on protection provided by vaccination. For the H5Nl virus, effective pre-pandemic vaccines have recently been developed, including whole inactivated virus (WIV) vaccine and split-virus vaccine combined with the oil-in-water emulsion adjuvants AS-03 or MF59 [16-19]. Because the eventual pandemic virus may be an antigenic drift variant of the strain used to produce such pre-pandemic vaccines, a complete match with the pandemic strain cannot be guaranteed. However, the above vaccines have been shown to induce substantial cross-reactive immune responses to viruses of different H5Nl clades [16-18, 20-23]. Moreover, even at suboptimal efficacy pre­pandemic vaccines may reduce attack rates if deployed in an early stage of the pandemic [24, 25] or may serve as priming dose for the true pandemic vaccine, thus saving time and resources [26]. Stockpiling of pre-pandemic H5Nl vaccines is therefore considered an effective tool for containment and mitigation of an emerging pandemic [15], and stockpiles have already been established by multiple countries [27]. 
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Current inactivated influenza vaccine formulations need to be stored 
refrigerated because the major antigenic component, the viral haemagglutinin 
(HA), is prone to degradation at higher temperatures [28]. However, cold-chain 
requirements may seriously complicate the logistics of storage and deployment of 
pre-pandemic and pandemic vaccines, with a risk of vaccines escaping 
refrigeration. In general, cold-chain failure and thermal instability is a major cause 
of vaccine loss in developing countries [29], and has been linked to serious disease 
outbreaks [30]. Development of temperature-stable vaccines for pandemic use 
would promote worldwide usability by diminishing the complexity of refrigerated 
storage and distribution logistics. 
A well known strategy to improve stability is conversion of the liquid 
vaccine into dry powder [31]. Biopharmaceuticals like influenza vaccines are 
preferably desiccated using freeze-drying techniques [32]. The vaccine is rapidly 
frozen and water is, subsequently, extracted by sublimation under reduced 
pressure. Detrimental stresses acting on the HA antigenic components as a result 
of the freeze-dry process, as well as degradation of the HA during subsequent 
storage, can be counteracted by the use of cryoprotectants such as specific sugars 
[33, 34]. Sugar is mixed with the liquid vaccine, and during rapid freezing a glassy 
sugar matrix is formed in which water and vaccine constituents are captured. The 
physical barrier separating the vaccine constituents and molecular immobility 
provided by the matrix prevent the vaccine from degradation. Also, the matrix 
prevents further crystallization of water molecules upon extended cooling. After 
drying the vaccine components are incorporated in a dry sugar glass, in which the 
water has been spatially replaced by sugar and the structural integrity of the 
vaccine constituents is preserved. 
Here, we investigated the effect of ambient and high storage temperatures 
over time on the immunogenicity of influenza A /Vietnam/1203/ 2004 (H5Nl) 
whole inactivated virus (WIV) vaccine. Vaccines were either stored conventionally 
in buffer solution or as sugar-stabilized dry-powder formulations and 
immunogenicity was assessed in a mouse model. Inulin and trehalose sugars, 
which have the intrinsic capacity to maintain a glassy state at high temperatures 
[35, 36], were used as stabilizing agents. 
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Stable Dry-powder H S N !  Vacci ne Methods VACCINE PREPARATION AND STORAGE CONDITIONS H5Nl virus (NIBRG-14) was provided by the National Institute for Biological Standards and Controls (NIBSC, Potters Bar, UK), and is a 2:6 reassortant between A/Vietnam/1194/2004 (H5Nl) and A/PR/8/34 (HlNl) virus produced by reverse genetics technology. WIV was obtained by virus propagation on embryonated chicken eggs, and inactivation of the virus preparation with 0.1 % f3-propiolactone. The haemagglutinin protein concentration in the vaccines was determined by single radial immunodiffusion (SRID) [37]. Freeze-drying of WIV was performed as described previously [38]. Briefly, glass vials containing a mixture of 200 µI of a 16% w / v sugar (either trehalose or inulin) solution in HBS (2 mM Hepes, 0.15 M NaCl, pH 7.4), or HBS without sugar, and 200 µI WIV (66 µg HA) in HBS (approximated sugar:HA ratio of 500:1 (w /w) were frozen in liquid nitrogen for 10 minutes and subsequently lyophilized in a Christ Alpha 1-4 freeze-dryer (Salm en Kipp, Breukelen, The Netherlands). The setting of the freeze-dryer was -35°C for the shelf temperature, -55°C for the condenser temperature, and 0.220 mbar pressure. After 24 h the pressure was reduced to 0.060 mbar and the shelf temperature was gradually raised to 20°C. This status was maintained for another 24 h. The dried samples were either directly rehydrated for experiments or stored in a silica gel containing desiccator at 20°C or 40°C. The humidity in the dessicator was maintained at the level of 10± 2 % RH. As shown by Hinrichs et al. at 10% RH, trehalose and inulin glasses are equally hygroscopic [39]. After storage vaccines were rehydrated shortly before immunization. HEMAGGLUTINATION OF ERYTHROCYTES To determine the particle titer of the vaccines a standard hemagglutination assay was used. Vaccines were serially diluted two fold in PBS in duplicate, starting with a 10 times dilution in the first well of a microtiter plate, so that the end volume per well was 50 µI. An equal volume of a 1 % suspension of fresh guinea pig erythrocytes in PBS was added and the plates were incubated at room temperature for 2 h. The titer was determined as the reciprocal of the highest dilution that yielded complete hemagglutination. 
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Chapter 6 HEMOLYSIS OF ERYTHROCYTES The hemolysis assay was performed as described previously [40]. In short, WIV vaccine (1 µg HA) in 50 µl HNE buffer (5 mM Hepes, 0.15 M NaCl, 0.1 mM EDTA, pH 7.4) was added to 4x107 human erythrocytes in 800 µl HNE. 50 µl fusion buffer (pH 5.5) was added to initiate viral membrane fusion. The total mixture was incubated 0.5 h at 37°C, and subsequently centrifuged at 350 g for 10 minutes. Absorbance of the supernatant was red at 540 nm, representing the haemoglobin liberated from the lysed erythrocytes. The absorbance was corrected for autohemolysis in absence of WIV vaccine. The amount of hemolysis was then given as a percentage of the maximal hemolysis, which was determined by lysing erythrocytes in water. IMMUNIZATION For immunization experiments, 8-10-week-old female Balb / c mice were purchased from Harlan Netherlands B.V. (Zeist, The Netherlands). All experiments were conducted with approval of the local Institutional Animal Care and Use Committee. Mice were intramuscularly injected in both their calf muscles with a total of 50 µl WIV vaccine (5 µg HA) in HBS, equally divided over both injection sites. Mouse numbers per immunization group were as follows: liquid WIV; n=5-6, freeze-dried WIV with or without sugar; n=6-8, liquid WIV after 1 year at 20°C; n=3. Twenty eight days after immunization, sera were collected for evaluation. ELISA ELISA assays were performed as described previously [41]. Briefly, microtiter plates (Greiner, Alphen a/ d Rijn, The Netherlands) coated with 0.2 µg influenza H5Nl (NIBRG-14) subunit vaccine per well were blocked with a 2% milk solution. Two-fold serial dilutions of serum samples in 0.05%Tween 20/PBS (PBS/T) were added to the wells in duplicate and incubated for 1.5 h. Bound H5Nl specific IgG, IgGl or IgG2a antibodies were detected with a horseradish peroxidase-conjugated goat anti-mouse IgG-isotype antibody (Southern Biotech, Birmingham, Alabama). All incubations were performed at 37°C. The staining was performed with o­phenylene-diamine (OPD) (Eastman Kodak Company) and absorbance at 492 nm was measured by an ELISA reader (Bio-tek Instruments, inc.). The antibody titer was calculated by extrapolating the serum dilution corresponding to an OD of 0.2, using linear regression. 
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The HI assay was performed as described previously [42] . In short, 50 µl kaolin 
absorbed, heat-inactivated mouse serum in PBS (1:4) was serially diluted two-fold 
in a microtiter plate in duplicate. Next, 50 µl of 4 hemagglutination units (HAU) of 
H5Nl (NIBRG-14) virus in PBS was added and incubated for 40 min at RT. Finally, 
50 µl of 1 % guinea pig erythrocytes (Harlan) in PBS was added to each well and 
HI titers were determined after 2 h incubation at RT. HI titers are given as the 
reciprocal of the highest serum dilution producing complete inhibition of 
hemagglutination. STATISTICAL ANALYSIS 
Statistical analysis on antibody titers was performed using the unpaired Student's 
t test. P values of p<0.05 and p<0.01 were considered statistically significant and 
highly significant, respectively. 
Results EFFECT OF FREEZE-DRYING AND RECONSTITUTION ON VACCINE IMMUNOGENICITY 
WIV vaccines were freeze-dried with or without sugar and samples were stored, 
with WIV vaccine kept in suspension (liquid WIV ). Immediately after drying, 
samples of each vaccine were reconstituted in water and tested alongside liquid 
WIY, to assess the effect of the actual freeze-drying process on the vaccines, and to 
obtain reference values for the storage experiments. Evaluation involved 
assessment of the hemagglutination or hemolytic activities of the vaccines as a 
measure for the structure and function of the viral particles. Any effect of inulin or 
trehalose on the hemagglutination and hemolysis assay was excluded, by testing a 
similar concentration of the freeze-dried sugar without viral particles. The results 
shown in Table 1 demonstrate that freeze-drying of WIV with or without trehalose 
or inulin did not have adverse effects on its hemagglutination or hemolytic 
activities. Preservation of these activities indicates that the sialic-acid-binding 
capacity and the membrane fusion activity of the HA proteins were retained. 
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Chapter 6 Table I. Effect of High Storage Temperature on Hemagglutination and Hemolysis Activity of the Vaccines 
Vaccine Hemagglutination titer ( 1Qx2log) Hemolysis (% of max) 
Temperature 40°c 40°c 
Duration O Day 3 Months O Day 3 Months 
Liquid 1 1  5 67.9 0 
FD 2'.:12 7 90.6 4.3 
FDT 1 1  8 8 1 .5 35.3 FDI 1 1  8 83.3 1 5 . 1  Immunization groups: liquid liquid WIV, FD freeze-dried WIV without sugar, FDT freeze-dried WIV with trehalose, FDI freeze-dried WIV with inulin To determine whether the preservation of in vitro vaccine activity after freeze­drying was accompanied by preservation of in vivo vaccine potency, mice were intramuscularly injected with vaccine doses of 5 µg HA. Four weeks after immunization, the antibody responses induced by the freeze-dried vaccines were compared to those induced by liquid WIV. WIV freeze-dried without sugar (FD) induced slightly lower IgG titers (p=0.001) than liquid WI\!, while hemagglutination-inhibition (HI) titers were not significantly diminished (p=0.08) (Fig. la, b; 0 Day). WIV freeze-dried with trehalose (FDT) was equally immunogenic as liquid WI\!, while WIV freeze-dried with inulin (FOi) induced slightly lower IgG titers (p=0.02) but similar HI titers. In conclusion, freeze-drying with or without sugar did not affect the immunogenic potency of HSNl WIV vaccine substantially. EFFECT OF STORAGE AT AMBIENT TEMPERATURE ON VACCINE IMMUNOGENICITY The freeze-dried vaccines and liquid WIV were subsequently stored at 20°C. Three months and one year later samples were tested for their capacity to induce antibody responses in mice. After 3 months of storage, no significant differences in serum IgG and HI titers induced by liquid WIV, FDT or FDI vaccines were observed compared to liquid WIV conventionally stored at 4°C (Fig la, b; 3 Months). In contrast, FD vaccine induced substantially lower mean IgG and HI titers compared to liquid WIV at 4°C (22.4-fold (p=0.03) and 3.5-fold (p=0.04), respectively (Fig la, b; 3 Months). Consequently, FD vaccine was excluded from further evaluation. 
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Liquid Liquid FD FDT FOi 
4'C 20'C 20'C 201C 20'C Figure 1. Antibody responses illduced by liquid and freeze-dried WIV vaccines before and after storage at ambient temperature. Serum HSN1-specific IgG titers were determined by ELISA and are given as geometric mean titers + standard error of the means (SEM), before storage, and after 3 months and one year storage (a) . The serum capacihJ to inhibit agglutination of guinea pig en1throe1 tes btj HSN1 vaccine virus is given in geometric mean HI titers + SEM, before storage, and after 3 months and one year of storage (b). Immunization groups are plotted on the x­axis with the vaccines' actual storage temperature in degrees Celsius: liquid: liquid WHI, FD: freeze-dried WIV without sugar, FDT: freeze-dried WIV with trehalose, FDI: freeze-dried WIV with inulin. HI titers below the detection limit were assigned half the value of the lowest detectable serum dilution, which was 8. * p<0.05, ** p<0.01 . Nd; not determined. 
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Liquid Liquid FD FDT FDI 
4°c 20°c 20°c 2o•c 2o•c Figure 2. Effect of storage duration on the vaccines capacity to induce antibody responses. Pooled sera of each group of mice immunized at different time points with liquid or freeze-dried WIV vaccine were tested simultaneously on HSNl-specific IgG or hemagglutination inhibiting capacity. Bars represent the average values of duplicate determinations (deviations were less than 0.2). Immunization groups are plotted and labelled as in Fig. 1. Storage duration: 0 day (white bars), 3 months (grey bars), 1 year (black bars). Nd; not determined. 
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Stable Dry-powder H S N !  Vaccine EFFECT OF HIGH STORAGE TEMPERATURE ON VACCINE IMMUNOGENICITY 
To simulate more challenging conditions vaccines may encounter during storage 
and transportation, the vaccines were put on shelf at 40°C for 3 months. These 
conditions negatively affected the hemagglutination and hemolysis activity of all 
vaccines, but strongest for liquid WIV and FD vaccine (Table 1). Subsequent 
immunization of mice revealed a strong decrease in IgG and HI titers induced by 
liquid WIV stored at 40°C, compared to WIV freshly prepared from a frozen virus 
stock (Fig 3a, b ). The immunogenic potency of vaccines freeze-dried with sugars 
was much better preserved under these challenging conditions. For FDT vaccine a 
slight decrease in mean IgG titer (1.4 fold, p=0.08) together with a more substantial 
decrease in HI titer (2.3 fold, p=0.01) was found. Responses to FDI vaccine were 
not significantly different from those to freshly prepared vaccine (Fig 3a, b ). In 
contrast, freeze-drying without additional measures to stabilize the vaccine 
resulted in strongly reduced IgG and HI titers after storage at 40°C. Compared to 
liquid WIV stored at 40°C ,  both FDT and FDI stored at 40°C induced significantly 
higher IgG titres (p=0.002 and p=0.00001, respectively), and HI titres (p=0.002 and 
p= 0.02, respectively), which was not the case for FD vaccine (Fig 3a, b ). 
The effect of high storage temperature relative to ambient storage 
temperature on vaccine immunogenicity is summarized in Figure 4. Serum pools 
of the different immunization groups were run in a single assay, and the IgG and 
HI titers were plotted including those induced by liquid WIV stored at 4°C as a 
reference. The deteriorating effect of increasing temperature was most explicit for 
liquid WIV and FD vaccine. In case of FD formulation, maximum deterioration 
was already observed at moderate temperatures. If stored as FDT or FDI 
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Liquid Liquid FD FDT FDI 
40°c 40°c 40°c 4o0c Figure 3. Effect of high storage temperature on the immunogenic potency of the vaccines. Vaccines were stored for 3 months at 40°C and subsequently injected in mice. Serum H5N1-specific IgG titers (a) and HI titers (b) were determined, and are shown as geometric mean titers + SEM. Immunization groups are labelled as in Fig. 1. The group immunized with liquid WTV, which had not been subjected to the storage experiment, serves as a standard. * p<0.05, when compared with the standard. # p<0.05, # # p<0.01, when compared with liquid WIV stored at 
40°C. 
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Liquid FD FDT FDI Figure 4. Effect of storage temperature on the vaccines' capacity to induce antibody responses. Pooled sera of each group of mice immunized with liquid or freeze-dried WIV vaccine, which had been stored for 3 months at different temperatures, were tested simultaneously on HSNl-specific IgG or HI capacihJ. Bars represent the average values of duplicate determinations (deviations were less than 0.2). Immunization groups as in Fig 1. Storage temperatures: 4°C (white bars), 20°C (grey bars), 40°C (black bars). PRESERVATION OF THE QUALITY OF THE IMMUNE RESPONSE TO WIV 
The ratio of IgG2a and IgGl subtype antibodies induced by the vaccine is 
important for protective efficacy. Relatively high IgG2a titers are representative of 
the Thl type response characteristically induced by whole virus particles [42, 43] 
and are associated with better protection against a challenge with homologous 
virus in mice [44]. We, therefore, evaluated the effect of freeze-drying and storage 
of the vaccine on the phenotype of the induced antibody response. When WIV was 
stored in buffer solution, the IgG2a-dominated antibody response was preserved 
at all storage temperatures and storage durations tested (Table 2.). Freeze-drying 
in absence of a stabilizing sugar excipient reduced the IgG2a/IgG1 ratio to the 
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Chapter 6 level of a mixed IgG2a/lgG1 phenotype. Subsequent storage of the FD vaccine further lowered the IgG2a/IgG1 ratio resulting in a shift to a IgGl-dominated antibody response within 3 months, independent of the storage temperature. In contrast, FDT and FDI vaccine induced an IgG2a-dominated antibody response after storage independent of storage duration and temperature. 
Table II. Dominance of IgG Subtypes in the Antibody Response to Vaccination. 
Immunization Groups are Labeled as in Table I 
Vaccine 0 months 3 months 12 months Liquid 4°c lgG2aa lgG2a lgG2a 20°c nd lgG2a lgG2a 40°c nd lgG2a nd FD 20°c lgG 1/lgG2ah lgGl nd 40°c nd lgGl nd FDT 20°c lgG2a lgG2a lgG2a 40°c nd lgG2a nd FDI 20°c lgG2a lgG2a lgG2a 40°c nd lgG2a nd nd not done a IgG2a or IgGl were defined dominant if the IgG2a/IgG1 ratio was 2:.1 .5 or �0.5, respectively b For ratios between 0.5 and 1 .5, the response was defined as mixed 
Discussion The immunogenicity of WIV vaccine depends on the presence and integrity of the HA proteins and an intact viral particle structure [42, 45]. The HA antigens provide the B-cell epitopes and define the specificity of the antibody response, while the viral particle acts as a vehicle for the vaccines primary immunopotentiating agent, the viral single-stranded RNA (ssRNA). Its immunopotentiating activity is exerted through binding to Toll-like receptor 7 (TLR7) in the endosomes of recipient host cells, and triggering of the innate immune system [41, 46, 47]. To a large extent, this mechanism accounts for the superior immunogenicity of WIV compared to split-virus formulations or subunit vaccines, which do not contain intact viral RNA [41]. TLR7 signaling also determines the response type, being characteristically of a Thl type for wrv, with a high amount of IgG2a / c antibodies in mice. 144 
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In liquid WIV vaccine, the antigenic properties of HA and the immunopotentiating activity provided by the ssRNA appear to be remarkably stable. Our results show that the immunogenicity of WIV vaccine stored in buffer solution at 20°C remained well preserved with minimal loss of activity over a period of at least 12 months. In contrast, seasonal subunit vaccine (H3N2) stored in buffer solution at ambient (25°C) temperature was reported to lose potency already over a period of 12 to 20 weeks [28]. Compared to subunit vaccine, WIV, therefore, appears to be more stable. Yet, it should be noted that the comparability of the two studies is limited since they differ in the virus strains used for vaccine production and the method by which vaccine stability was assessed (in vivo immunogenicity versus single radial immunodiffusion assay (SRID) [31]). At high storage temperature (40°C), the immunogenic potency of liquid WIV rapidly deteriorated. Progressive degradation of HA antigens and/ or loss of intact viral particles, as reflected in the strongly reduced hemagglutination and hemolytic activity of the vaccine, may likely be the cause. Yet, the antibody response remained Thl skewed, which may indicate that a small amount of viral particles escaped degradation, as it was shown previously that even a very low dose of viral particles is sufficient for Thl skewing of the response to WIV vaccine [44]. At high storage temperature dry-powder formulations were superior to liquid wrv, as reported by others [29, 48]. With the use of sugar stabilization no substantial loss of immunogenicity was observed after storage of freeze-dried WIV for 3 months at 40°C. Furthermore, sugar stabilization played a critical role in preserving the Thl-skewing capacity of the vaccine during freeze-drying and subsequent storage. Freeze-drying in absence of sugar led to a mixed Thl /Th2 antibody response, which further shifted during storage at elevated temperature to an overt Th2 type response, while the characteristic Thl phenotype of the WIV response was retained when sugars were used during freeze-drying. Sugar molecules obviously play a role in preserving effective TLR7 signaling by the ssRNA, probably by stabilizing the viral particle structure and protecting the viral ssRNA from degradation. Sugars are known to stabilize enveloped viruses during freeze-drying [ 49, 50] and trehalose and inulin have the capacity to stabilize lipid bilayers [35, 36, 51]. In freeze-drying experiments with 'empty' viral envelopes (virosomes), use of inulin was found to preserve the vesicular structure, while absence of sugar stabilization resulted in complete disintegration after rehydration [38]. The mode of action of trehalose and inulin is presumably by replacement of the water molecules situated in between the hydrophilic heads of the lipids. 
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Chapter 6 Hereby, a detrimental phase transition of the viral membrane upon rehydration is prevented and the vaccine particles are preserved [35]. By assessing immunogenicity in vivo we discovered an important role for sugar compounds in preserving not only the quantity but also the quality of the immune response to WIV after freeze-drying and storage. Previous storage studies that showed improved stability of freeze-dried WIV used the hemagglutination assay to determine vaccine stability, which provides a quantitative measure only [29, 33]. The shift from a Thl response to WIV before freeze-drying to a Th2 response to WIV after freeze-drying in absence of sugar-stabilization could not have been predicted from hemagglutination results, nor by other in vitro tests that assess the integrity of the HA component, like the SRID. In vitro HA stability tests alone are therefore insufficient to obtain a complete representation of WIV vaccine stability. The efficacy of influenza vaccines is determined by the induction of an effective antibody response. The serum HI titre, which is a measure for the magnitude of the antibody response, is the principle correlate of protection used to evaluate the efficacy of current human seasonal and pre-pandemic influenza vaccines. For seasonal vaccines an HI titre of >40 is considered to be protective [52-55] . For the mouse model no protective titre has been defined. Due to the intrinsic low immunogenicity of H5Nl virus and the single-dose immunization scheme the maximal titre reached in our experiments was 32. It has to be noted that immunogenicity in terms of HI and IgG titers does not necessarily correlate with protective efficacy. In the mouse model, the relative amounts of IgGl and IgG2a (or IgG2c), expressed in the IgG2a/IgG1 ratio, appear to be decisive for protection [ 40, 56, 57] IgG2a-dominated responses are clearly more effective than IgGl-dominated responses. Yet, in the absence of significant differences in HI and IgG titres and similar IgG subtype dominance, as observed for example for liquid WIV, FDI and FDT during storage at ambient temperatures, protective efficacy is likely to be comparable. The preservability of WIV vaccine is strongly increased by sugar stabilization and freeze-drying. Similarly, other formulations like subunit, split­virus and virosome [31] vaccines have been successfully freeze-dried and stabilized with sugars (summarized in [31]). Yet, a combination of increased stability together with specific features of WIV which promote vaccine availability, like strong immunogenicity, dose sparing quality and manufacturing simplicity [ 46], make dry-powder WIV an apt candidate formulation for pre-pandemic 
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Stable Dry-powder H S N l  Vaccine stockpiling. Based on the results of storage at 40°C it may also be predicted that dry-powder WIV will have a shelf-life exceeding that of liquid WIY, when kept under optimal refrigerated conditions [52, 58]. An extended vaccine shelf-life could delay costly replacement of stocks when vaccines reach their expiry date. In case of a pandemic emergency, deployment of dry-powder vaccine stocks may be exerted without refrigeration unless the temperatures are extremely high. This could speed up pandemic intervention and reduce losses due to cold-chain failures. Conclusion The lack of suitable vaccines during the initial emergence of the New Influenza A (HlNl)swl pandemic virus in 2009, and its rapidly global spread underscores the importance of effective pre-pandemic vaccine stockpiles. Although this virus was of an unforeseen subtype, it remains important that stockpiles of vaccines against identified potentially dangerous virus strains like the H5Nl virus are prepared and kept in place. Our results suggest that for stockpiling liquid H5Nl WIV vaccine refrigeration may not be an absolute requirement to preserve the vaccines immunogenicity, as long as the temperature remains below 20°C. Furthermore, conversion from liquid to dry-powder formulation increases the versatility of WIV vaccine by allowing storage outside the fridge at higher temperatures, up to 40°C for at least 3 months. Because of its improved stability, use of sugar-stabilized freeze-dried H5Nl WIV vaccine could increase the efficacy of pre-pandemic stockpiling and subsequent vaccine deployment. Acknowledgements We thank the NIBSC for providing NIBRG-14 influenza virus. We thank Tjalke Westra and Tjarko Meijerhof for technical assistance. This study was conducted under the auspices of the Netherlands Influenza Vaccine Research Centre (NIVAREC), with financial support from the Netherlands Organization for Health Research and Development (ZonMw ). 
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Chapter 7 
Abstract Influenza vaccines have been in use since more than 60 years and have proven to be efficacious in protecting from influenza infections during epidemics and the recent HlNl pandemic. Yet, the development of influenza vaccines has so far been largely based on empirical grounds, which leaves room for vaccine improvement by implementation of recent insights in innate and adaptive immunity. Also, evaluation and approval of new vaccines relies on rather broad correlates of protection like the hemagglutination inhibition titer thereby neglecting qualitative aspects of the immune response. Here we discuss how current inactivated influenza vaccine formulations differ in the type of immune response they elicit and in their protective capacity and what causes these differences. Finally, we will discuss how this knowledge can guide the development of new adjuvants which optimize the protective efficacy of influenza vaccines. 
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General Discussion Part I Introduction Influenza A virus is a highly transmissible infectious agent responsible for 500.000 deaths in annual epidemics and excess deaths during sporadically occurring pandemics [l] .  The most dramatic example is the Spanish flu in 1918, with an estimated death toll of over 50 million worldwide [2] . Infection with influenza virus can be asymptomatic but usually produces symptoms, classically fever, cough and other respiratory symptoms. Especially during pandemics more atypical and severe symptoms may be seen, like diarrhea and life threatening viral pneumonia [3,4]. Influenza infections induce vigorous immune responses comprising antibodies of the IgA and IgG subclass, T helper 1 (Thl) cells and cytotoxic T lymphocytes [5-7]. Nevertheless, re-infections are common due to rapid mutational changes of antigenic epitopes on the major influenza virus surface antigen, hemagglutinin (HA). Such mutations, caused by the poor fidelity of the viral RNA polymerase, lead to 'antigenic drift' and are considered the reason for the occurrence of yearly influenza epidemics. The genome of influenza A virus is built up of 8 segments and antigenic variation may take a leap when whole segments of the viral genome change. Such a change of the HA-encoding segment is associated with 'antigenic shift' and may lead to new virus strains which can spread easily in an immunologically nruve human population thus causing a pandemic. Segment changes may be the result of reassortment of genomic segments between circulating viruses and other subtype viruses from different species, like avian influenza. Such reassorted viruses caused the 1957 Asian Flu and the 1968 Hong Kong Flu [8] . Alternatively, a virus subtype circulating in animal species and carrying an HA subtype that differs strongly from those of human virus strains may cross the species barrier and start a pandemic if sustained human-to-human transmission evolves. Such zoonoses were the causes of the Spanish Flu and the 2009 HlNl pandemic [9,10]. Also the avian H5Nl virus is a zoonotic virus which regularly crosses the species barrier. Due to its very high mortality (about 60% of laboratory-confirmed cases) H5Nl poses a serious threat 
[11], yet human-to-human transmission so far occurs only very sporadically if at all [12] . Vaccination has proven to be highly efficacious in preventing influenza during epidemic periods and is considered as the most promising mitigation strategy in case of a pandemic [13] . Yet, current epidemic vaccines still suffer from 
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reconstitution Figure 1. Current inactivated influenza vaccines. Egg- or cell-grown virus is chemically inactivated to obtain WIV vaccine. Solubilization of the viral membrane by detergent treatment results in SV vaccine. By further purification steps SU vaccine is obtained which contains only the viral membrane proteins. These can be reconstituted with natural or synthetic lipids to emphj virus envelopes, so-called virosomes. 
In primed individuals, unadjuvanted wrv, SV, and SU vaccines in general 
induce similar immune responses in terms of hemagglutination inhibition (HI) 
titers (for a meta-analysis over 24 studies see [21]). However, in individuals that 
have not been exposed to the vaccine antigens before, WIV vaccines are more 
immunogenic than SV and SU vaccines [21-23]. Among inactivated, unadjuvanted 
H5Nl candidate vaccines only WIV (derived from wild-type virus) evoked 
antibody titers which met the EMEA and FDA criteria [24]. A cell culture-derived 
WIV mock-up vaccine, Celvapan®, was licensed in Europe in 2009 and an HlNl 
Celvapan® vaccine has been used during the 2009 HlNl pandemic. 
No data are available on the relative protective efficacy of wrv, SV and SU 
influenza vaccines in humans. Yet, in animal models a head-to-head comparison of 
different vaccines in terms of their protective capacity can be performed. 
Challenge studies in mice show that a single immunization with WIV protects 
more efficiently from weight loss (Fig. 2 ) and leads to a stronger decrease in nose 
or lung virus titer than immunization with other vaccines (ref. [25], and Chapter 
5). Moreover, WIV prevents weight loss and reduces viral loads in the lung 
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days post challenge Figure 2. Protection from influenza challenge by different vaccines. Mice were immunized intramuscularly on day O with 5 µg HA formulated as WIV vaccine (filled squares) or SU vaccine (open squares), or were injected with buffer (filled triangles). On day 28 the mice were challenged with 100 TCIDSO of A/PRB virus and weight was measured for 16 days. Mice were euthanized when weight loss exceeded 20% . Detailed comparison of the immune response in vaccinated mice revealed that WIV induces higher serum HI titers than SV and SU vaccine especially after a first immunization (refs. [26,27] and Chapters 2, and 3). These data are in line with the superior immunogenicity of WIV in unprimed individuals mentioned above. Interestingly, the different vaccine formulations also induce different types of responses. WIV vaccine elicits an overt Thl type immune response characterized by high IgG2a/ c titers and high numbers of IFNy-producing T cells. In contrast, subunit and split vaccines induce primarily a Th2 response with large amounts of IgGl and high numbers of IL4-producing T cells (refs. [26,27], and Chapters 2, and 3). The relative contribution of IgG subtypes to protection from influenza challenge has been investigated in detail by Huber et al [28]. Mice were vaccinated with an HA DNA vaccine, with a viral replicon system encoding HA or with a combination of both to induce IgGl-dominated, IgG2a-dominated or mixed IgGl / IgG2a responses, respectively. IgG2a alone protected mice as efficiently from lethal 
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challenge as a mixture of IgG 1 and IgG2a and could contain both mild and severe 
virus challenge. In contrast, IgGl alone only protected from mild virus challenge 
but provided insufficient protection upon a high-dose challenge. Thus, antibody 
subclasses differ in their capacity to neutralize virus. As possible reasons for the 
superiority of IgG2a the affinity of this subtype for complement factors and Fe 
receptors has been proposed as both mechanisms contribute to efficient clearance 
of virus by phagocytosis and antibody-mediated cellular cytotoxicity [28]. In 
contrast, IgGl does not lead to complement activation and has only weak affinity 
for Fe receptors. 
Thus, current unadjuvanted vaccine formulations differ substantially in the 
magnitude but also in the phenotype of the immune reaction they evoke and this 
may have profound effects on their protective capacity at least in animal models. 
Data on the phenotype of the immune response to influenza vaccination and the 
relevance of the immune phenotype for protection in humans are urgently needed. 
Moreover, for a rational design of improved vaccines we need to understand 
which vaccine properties determine the differential immune reactions. Mechanisms involved in vaccine-induced immunity 
In order to reveal which mechanisms are responsible for the superior immunity of 
wrv, we and others have evaluated the effects of influenza vaccines on dendritic 
cells (DC) in vitro. Similar to live virus, WIV induced the production of IL12 and a 
variety of pro-inflammatory cytokines in conventional DC ( cDC) generated from 
bone marrow by culture in the presence of GM-CSF (Chapter 2, and ref. [29]). In 
contrast, SV and SU vaccine had little effect. Plasmacytoid DC (pDC) were either 
generated from bone marrow by culture in the presence of Flt3-ligand or were 
directly purified from spleen. When incubated with live virus or wrv, these cells 
responded with production of type I interferons (IFN-a and IFN-�), while neither 
SV nor SU vaccine had any effect (Chapters 2, and 3, and ref. [30]). 
Type I interferons are antiviral cytokines produced immediately upon viral 
infection. They have been shown to augment antibody responses in vivo and to 
steer the phenotype of the response to a Thl type by direct interaction with B-cells, 
(but also T-cells) [31-34]. The role of type I interferons in the immune response to 
WIV was recently studied by Koyama and co-workers using IFNa / �  receptor 
knock-out mice [30]. In contrast to wild type mice, IFNa/ �  receptor knock-out 
mice immunized with WIV showed little induction of antibodies and no induction 
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Chapter 7 of influenza-specific IFNy-producing Th cells and died quickly upon lethal virus challenge. Since pDC had been identified as an important source of type I IFN in vitro, the role of this cell type for the immune responses in vivo was investigated. Depletion of pDC by antibody treatment prior to intranasal immunization with WIV largely abolished IgG induction and significantly reduced induction of Thl cells. Interestingly, pDCs were essential only during primary immunization while depletion prior to a booster immunization had no effect [30]. These results show that type I IFNs have an important role in the strong antibody and T cell response to immunization with WIV and that pDC as the major producers of type I IFNs are important, at least in the context of intranasal immunization. The role of pDC in the response to parenterally administered vaccines remains to be elucidated. In the in vitro experiments described above only WIV but not SV or SU vaccine induced IFNa production by pDC (Chapters 2, and 3). WIV differs from the other vaccine formulations by retaining the structure of the virus envelope and by containing the viral RNA (which is degraded in SV and removed in SU vaccines). Although an intact envelope structure may enhance antigen uptake, it does not by itself trigger production of IFNa since pDC incubated with reconstituted viral envelopes (virosomes) do not secrete this cytokine (Chapter 2). Single-stranded RNA (ssRNA) is known as the ligand of Toll-like receptor (TLR) 7 which is expressed in pDC [35]. Indeed, bone-marrow derived Flt3-ligand pDC from TLR7 knock-out mice do not produce IFNa when incubated with WIV (Chapter 3, and ref. [30]). On the other hand, transfection of pDC with viral RNA purified from WIV leads to similar IFNa production as incubation with WIV itself (Chapter 3). Thus, binding of the viral ssRNA in WIV to TLR7 is the trigger for activation and IFNa production in pDC. TLR7 is also essential for immune responses to WIV in vivo. In TLR7 k.o. mice antibody induction to intramuscularly or intranasally administered WIV is significantly reduced or completely abolished, respectively, and Thl induction is largely lost (Chapter 3, and ref. [30]). Not only pDC but also B cells express TLR7 [36]. In fact, B cell-intrinsic TLR signaling was found recently to be essential for class switching to IgG2a / c in immunization and infection [37]. Moreover, B cells also possess IFNa/ � receptors. Accordingly, B cells can react to viruses and vaccines carrying TLR7 ligands in a direct way by intrinsic TLR7 signalling as well as in an indirect way imposed by pDC-derived IFN-a [38]. Additionally, pDC-derived IFN-a can up-regulate the expression of TLR7 in B-cells, thereby increasing TLR7 sensitivity [39]. A third 
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General Discuss ion Part I signalling route can be provided by interactions between B cells and T cells via CD40-CD40L binding. Thus, B cells receive a variety of signals either via direct contact with the antigen, via cell-cell contact with T cells and via cytokines derived from pDC and cDC. Heer and co-workers suggested a model illustrating how the different signaling mechanisms might be integrated and affect antibody production by B cells [38]. In this model, triggering of either TLR7 or CD40 on B cells alone induces cell proliferation and production of IgGl, whereas stimulation of both receptors together induces production of IgGl and IgG2a/ c antibodies. Additional signaling through the IFNa/f3 receptor further polarizes the subtype ratio in favor of IgG2a. Fig. 3 illustrates how WIV and SU vaccine would activate B cells in mice according to this model. WIV can activate B cells directly via cross-linking of B cell receptors and engagement of B cell-intrinsic TLR7. Via triggering of TLR7 in pDC it induces secretion of IFNa which in tum can further activate B cells. WIV also strongly stimulates cDC which produce cytokines like IL-12 and activate Th cells. By direct cell-cell contact between B and T cells involving CD40-CD40L binding and by cytokines derived from cDC and Th cells B cells are further activated. Integration of all these signals leads to B cell proliferation, class switching to IgG2a / c and strong production of antibodies. In contrast, SU vaccine does not activate B cells directly and does not involve pDC. Instead SU-activated cDC stimulate Th2-skewed Th responses via direct contact and via cytokines. Cell-cell contact between B cells and T cells and cytokines derived from cDC and Th cells induce B cell proliferation and production of antibodies of the IgGl subclass. To what extent this model applies to the working mechanisms of WIV and SU vaccines in humans remains to be elucidated. 161 
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19G1 , lgG2a/c lgG 1 ,  lgG2a/c Figure 3. Model of B cell activation by WIV (a) or SU (b) vaccine. See text for explanation. 
Adjuvants for influenza vaccines The results obtained with WIV carrying TLR ligands versus SV or SU vaccines which are devoid of TLR ligands indicate that synthetic TLR ligands might be promising adjuvants for influenza vaccines. Indeed, the Koyama study shows that the lack of IFNa induction and immunogenicity of intranasally administered SV vaccine can be completely restored by addition of a CpG-based adjuvant [30]. Other TLR ligands investigated in the context of influenza vaccines include MPLA, flagellins, Poly I:C, and peptide-modified CpG (IC31) [30, 40-43]. Of these adjuvants, IC31 consisting of CpG oligomers bound to an immunostimulatory peptide has already successfully passed Phase I clinical testing [44]. Yet, no influenza vaccine adjuvanted with TLR ligands has obtained registration so far. Adjuvants currently licensed for use with influenza vaccines comprise aluminium salts and the oil-in-water emulsions MF59 and AS03. Neither of these falls in the category of TLR ligands, rather these adjuvants work via other, so far only partly elucidated mechanisms. Aluminium salts (phosphate or hydroxide) were introduced as adjuvants for human vaccines in 1932. Being components of diphtheria, tetanus, pertussis, and some Haemophilus influenzae, hepatitis A and hepatitis B vaccines, aluminium 162 
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salts are currently the principle adjuvants in clinical use [45]. Originally, 
aluminium adjuvants were thought to stimulate immune responses by providing a 
depot from which antigen is released slowly during an extended time period. 
Currently, activation of inflammasomes is considered as the primary mechanism 
of action [46]. Aluminium salts are known to stimulate predominantly Th2-type 
responses characterized by IL-4 and IL-5 production and the generation of 
antibodies of the IgGl subtype in mice [46]. 
Clinical trials with aluminium-adjuvanted influenza vaccines in the past 
showed low to modest enhancing effects of the adjuvant on HI titers. More 
recently, aluminium adjuvants have been tested in the context of HSNl 
prepandemic vaccines. These studies, which were performed with WIV as well as 
subvirion vaccines, rendered inconsistent results varying from modest 
enhancement to a decrease in antibody titers when unadjuvanted and adjuvanted 
vaccines were compared side-by-side [47,48]. Nevertheless, WIV influenza 
vaccines adjuvanted with aluminium salts were registered for use during the 2009 
HlNl pandemic in Hungary and in China [49]. No data are available on the effect 
of aluminium adjuvants on the protective efficacy of influenza vaccines in 
humans. 
Influenza immunization studies in mice confirmed the known Th2-skewing 
properties of aluminium-based adjuvants. When combined with subunit vaccine, 
which by itself raised an IgGl-dominated antibody response, aluminium 
hydroxide increased HI and IgGl titres. When combined with wrv, the IgG2a/c  
response usually evoked by this formulation was completely blocked. Instead, a 
strong IgGl response was elicited which was correlated with enhanced HI titres. 
Yet, the efficacy of the vaccines to protect from severe virus challenge was not 
improved and was even decreased for aluminium-adjuvanted WIV (Chapter 5). 
The situation might be different for mild virus challenge as others reported 
improved protection after immunization with aluminium-adjuvanted WIV [SO]. 
The differing results might thus be related to the fact that IgGl alone can protect 
from mild virus challenge but that IgG2a is essential to contain the virus upon 
severe challenge as discussed above [28]. In any case, these results underline that 
the HI titer alone is insufficient as correlate of protection. Rather, qualitative 
parameters such as the phenotype of the elicited response also need to be 
evaluated and adjuvants used in combination with influenza should preferably 
support a mixed Thl /Th2 response or a Thl-dominated response. 
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Other adjuvants used clinically in combination with influenza vaccines are 
the water-in-oil emusions MF59 and AS03. A seasonal MF59-adjuvanted SV 
vaccine (Fluad®) is licensed in Europe for use in elderly and has been administered 
to more than 27 million subjects without causing significant side effects [51]. In 
clinical trials of H5Nl prepandemic vaccines, MF59 proved to enhance antibody 
titers, allow antigen dose reduction and, importantly, induce cross-reactive 
antibodies against drift strains [52-54]. The latter is explained by the fact that MF59 
broadens the antibody response such that a larger number of HA epitopes is 
recognized [55] . An MF59-adjuvanted vaccine, Focetria®, was used during the 2009 
HlNl pandemic. 
The working mechanism of MF59 is not entirely clear yet. Obviously, it 
involves enhanced recruitment of mononuclear cells to the injection site, 
promotion of differentiation of monocytes to dendritic cells with concomitant 
upregulation of costimulatory molecules, and enhanced antigen uptake [56]. In 
mice, MF59 induces a Th2 type immune response dominated by IgGl and IL5-
producing Th cells. Combination of MF59 with Thl-skewing adjuvants like CpG 
or synthetic TLR4 ligands might allow skewing of the response into the desired 
Thl direction [57]. In ferrets, MF59 modestly improved the cross-protective 
potential of a WIV H5Nl vaccine. Yet, no further analysis of immune parameters 
was done [58] . In a clinical study, MF59 had little effect on the phenotype of the Th 
response to a subunit H5Nl vaccine, the response consisting mainly of IL2+IFNy­
cells [59]. 
AS03, another oil-in-water adjuvant, was explored extensively in the 
context of H5Nl prepandemic vaccines (for recent review see [19]). AS03 has been 
used on a large scale as adjuvant in the 2009 HlNl pandemic vaccine Pandemrix®, 
with a very high estimated efficacy of 98.6 and 83.3 in 14-59 year olds and > 60 
year olds, respectively [60] . Similar to MF59, it enhances antibody titers, allows 
antigen dose sparing and elicits protection against homotypic and heterotypic 
influenza strains [61]. So far, the mechanism of action of AS03 and the immune 
phenotype elicited by AS03-adjuvanted influenza vaccines remain elusive. 
Thus, currently used adjuvants were included in influenza vaccines with 
the aim of enhancing HI titers, the only correlate of protection generally accepted 
so far. Other parameters like the phenotype of the response induced and the 
effects of adjuvants in naYve versus primed individuals have only been 
investigated sporadically if at all. Taking these parameters into consideration 
might greatly enhance the benefits of future adjuvants. 
1 64 
General Discuss ion Part I Concluding remarks So far, vaccine development, including the development of influenza vaccines, has taken place largely by a 'trial-and-error' approach. Undoubtedly, this approach has been successful in the sense that influenza vaccines with high efficacy are available at least for adolescents and young to middle-aged adults. Yet, implementation of recent insights in innate and adaptive immune response has the potential to significantly improve current vaccines in their protective efficacy with possibly lower amounts of antigen needed than used today. Such a more rational approach to vaccine design has found its way into vaccine development only recently. Clues for vaccine improvement come from the detailed study of the immune responses to and the immune mechanisms involved by current vaccines. Animal experiments indicate that the value of HI titers as correlate of protection may be limited and, rather, knowledge of the immune phenotype is needed to judge the potential of influenza vaccines. In this context, immunological experience may be relevant. The majority of adolescents and adults will have developed a Thl memory response to influenza virus caused by natural infection. In these subjects vaccination against seasonal influenza will probably boost this response without changing its phenotype. Things are different when young children need to be vaccinated or when vaccination against a new virus strain is necessary as in case of a pandemic. Results from mouse experiments imply that the phenotype imposed by priming might govern the response during later infection. Thus, a vaccine-induced Th2 response leads to an unnatural and suboptimal Th2 reaction during later influenza infection (A. Huckriede, unpublished observations). If this would hold true for the human situation, special care should be taken to induce the appropriate immune response in individuals who are immunologically nai"ve for the antigen in question. These observations indicate that it is highly important to learn more about the relevance of the immune phenotype in humans. Clinical evaluation of influenza vaccines should therefore include determination of immunoglobulin subclasses and/ or Th cell profiles. Regarding current knowledge, influenza vaccines should activate DC to secrete Thl-skewing cytokines like type I IFNs and IL-12. In this light, vaccines based on intact virus particles are interesting as they contain ssRNA as an intrinsic natural adjuvant with Thl-skweing properties. Live-attenuated vaccines as in use 
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Chapter 7 in the US and the former Soviet Union fall in this category. Yet, in Europe these vaccines have so far not received approval due to safety concerns related to the possibility of reassortment between vaccine strain and circulating strains. WIV vaccines can be an alternative provided that reactogenicity, associated with early WIV vaccines, can be controlled. Post-marketing surveillance is now possible for the 2009 HlNl WIV vaccine Celvapan® and should shed light on this issue. Our knowledge about innate immunity and the interaction between innate and adapative immune responses has made enormous progress during the last 10 years. Moreover, much has been learned about influenza vaccines since the threat of an H5Nl pandemic boosted research activities. Implementation of this knowledge will be decisive for the development of safe and highly efficacious influenza vaccines needed to control seasonal influenza in an aging population and future influenza pandemics. Acknowledgements We thank Jan Wilschut, University Medical Center Groningen, for helpful comments on the manuscript. F.G. worked under the auspices of the Netherlands Influenza Vaccine Research Centre (NIV AREC), financially supported by the Netherlands Organisation for Health Research and Development (ZonMw) 166 
General Discussion Part I 
References 1. Stohr K, Kieny MP, Wood D. Influenza pandemic vaccines: how to ensure a low-cost, low­dose option. Nat Rev Microbiol 2006; 4:565-566. 2. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76:105-115. 3. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. Clinical aspects of pandemic 2009 influenza A (HlNl) virus infection. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (HlNl) 2009 Influenza. N Engl J Med 2010; 362:1708-1719. 4. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol 2008; 3:499-522. 5. Rothbarth PH, Groen J, Bohnen AM, de Groot R, Osterhaus AD. Influenza virus serology--a comparative study. J Virol Methods 1999; 78:163-169. 6. Roman E, Miller E, Harmsen A, Wiley J, Von Andrian UH, Huston G, Swain SL. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 2002; 196:957-968. 7. Boon AC, Fringuelli E, Graus YM, Fouchier RA, Sintnicolaas K, Iorio AM, Rimmelzwaan GF, Osterhaus AD. Influenza A virus specific T cell immunity in humans during aging. Virology 2002; 299:100-108. 8. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin HlNl influenza virus. Nature 2009; 459:931-939. 9. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893. 10. Novel Swine-Origin Influenza A (HlNl) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. Emergence of a novel swine-origin influenza A (HlNl) virus in humans. N Engl J Med 2009; 360:2605-2615. 11. htt_p://www.who.int/csr/disease/avian influenza/country/cases table 2010 06 08/en/ index.html 12. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5Nl). Emerg Infect Dis 2007; 13:1348-1353. 13. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006; 194 Suppl 2:Slll-118. 14. Wood JM, Williams MS History of inactivated influenza vaccines. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science. (1998) pp 317-323. 15. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pollabauer EM, Kistner 0, Barrett PN; Baxter H5Nl Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5Nl vaccine derived from cell culture. N Engl J Med 2008; 358:2573-2584. 
167 
Chapter 7 16. Kistner 0, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Briihl P, Kreil TR, Ehrlich HJ, Barrett PN. A whole virus pandemic influenza HlNl vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010; 5 :e9349. 17. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A HlNl vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49-55. 18. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion HlNl influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649. doi: 10.1136/bmj.c2649. 19. Leroux-Roels G. Prepandemic H5Nl influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-1071. 20. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73. 21. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta­analysis of the literature. Clin Drug Investig 1998; 15:1-12. 22. Nicholson KG, Tyrrell DA, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (HlNl) vaccine: serological responses and clinical reactions. J Biol Stand 1979; 7:123-136. 23. Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, Verlander NQ Warburton F, Wood JM, Zambon MC. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959-1966. 24. http: //www.who.int/ vaccine research/ diseases/influenza/ flu trials tables/ en/ 25. Hovden AO, Cox RJ, Madhun A, Haaheim LR. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 2005; 62: 342-352. 26. Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 2008; 26: 6555-6563. 27. Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB / c mice. Scand J Immunol 2005; 62:36-44. 28. Huber VC, McKean RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced 
1 68 
General Discussion Part I imrnunoglobulin Gl (lgGl) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006; 13:981-990. 29. Saurwein-Teissl M, Zisterer K, Schmitt TL, Gluck R, Cryz S, Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin Exp Immunol 1998; 114:271-276. 30. Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, Sakurai K, Coban C, Horii T, Akira S, Ishii KJ. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010; 2:25ra24. 31. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, Belardelli F. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002; 169:375-383. 32. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14:461-470. 33. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006; 176:4343-4351. 34. Chang WL, Coro ES, Rau FC, Xiao Y, Erle DJ, Baumgarth N. Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol 2007; 178:1457-1467. 35. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-1531. 36. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-4537. 37. Barr TA, Brown S, Mastroeni P, Gray D. B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c. J Immunol 2009; 183:1005-1012. 38. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 2007; 178:2182-2191. 39. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005; 174:4043-4050. 40. Miyaki C, Quintilio W, Miyaji EN, Botosso VF, Kubrusly FS, Santos FL, Iourtov D, Higashi HG, Raw I. Production of H5Nl (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 2010; 28:2505-2509. 41. Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010; 28:4103-4112. 42. Asahi-Ozaki Y, ltamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sata T, Kurata T, Hasegawa H. Intranasal administration of adjuvant-
1 69 
Chapter 7 combined recombinant influenza virus HA vaccine protects mice from the lethal H5Nl virus infection. Microbes Infect 2006; 8:2706-2714. 43. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 2008; 26:3461-3468. 44. http://www.intercell. com/main / forvaccperts /products I ic31R-seasonal-influenza­vaccine/. 45. Eickhoff TC, Myers M. Workshop summary. Aluminum in vaccines. Vaccine 2002; 20 Suppl 3:51-4. 46. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-293. 47. Keitel WA, Atrnar RL. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbial Immunol 2009;333:431-51. 48. http://www.who.int/ vaccine research/ diseases/ influenza/ flu trials tables/ en/ index.html 49. h t t p : / / e c d c . e u r o p a . e u I e n / h e a I t h t o p i c s / d o c u m e n t s / 0911 pandemic influenza (hlnl) qa on vaccines and vaccination experts.pdf 50. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5Nl whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5Nl avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-3560. 51. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-3222. 52. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5Nl influenza. Lancet 2001; 357:1937-1943. 53. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. Cross­reactivity to highly pathogenic avian influenza H5Nl viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza /Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-1215. 54. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5Nl vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384. 55. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5Nl influenza virus. Sci Transl Med 2010; 2:15ra5. 56. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27:3331-3334. 
1 70 
General Discuss ion Part I 57. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 2009; 26:1477-1485. 58. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. Single­and multiple-clade influenza A H5Nl vaccines induce cross protection in ferrets. Vaccine. 2009; 27:4187-4195. 59. Galli G, Merlini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhaf£ A, Rappuoli R, Del Giudice G, Castellino F. Adjuvanted H5Nl vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S  A 2009; 106:3877-3882. 60. Wichmann 0, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T. Pandemic influenza A(HlNl) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 2010; 15:pii: 19561. 61. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanan E, Osterhaus AD. Cross-protection against lethal H5Nl challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008; 3:e1401. 
171 
172 
General Discussion Part II Revival of whole inactivated virus vaccine for influenza pandemics 
Chapter 8 WIV vaccine has found renewed interest as (candidate) formulation in the context of an imminent HSNl pandemic and the recent 2009 HlNl pandemic [1-4]. Its response induction in nai:Ve recipients is superior to other unadjuvanted formulations [5-8], which means that protective immunity may be established with a lower vaccine dose. Use of WIV can therefore be dose-sparing. Indeed, converting vaccine production to WIV is a strategy to increase vaccine availability, as was suggested by the WHO in response to the HSNl pandemic threat [12]. In the past, WIV lost in popularity to less reactogenic split-virus and subunit vaccine. In a pandemic, however, reactogenicity is likely to be a minor problem [9]. Moreover, modem production technology may diminish WIV reactogenicity [10], and when compared to ASO3A-adjuvanted split-virus vaccine used in the 2009 pandemic, WIV formulation was even better tolerated [11]. Recently, the number of companies having HSNl and other subtype WIV vaccines under investigation has been increasing (up to 10) [13]. Yet, not everyone zeroed in on the revival of an archaic vaccine for pandemic use. At the height of HSNl pandemic alertness in 2006, many companies would have gone with the vaccine type they were already producing [9]. Meanwhile, new powerful oil-in-water adjuvanted split-virus vaccines have been introduced, which seems to make the whole-versus-split virus issue less pressing than before. However, a recent head-to-head comparison between an HlNl 2009 pandemic ASO3A-adjuvanted split-virus vaccine and an unadjuvanted whole-virus vaccine shows that the discussion is still alive [9,11,14]. The ASO3A­adjuvanted split-virus vaccine showed better dose-sparing properties, but the outcome of the study was contested by others. Still, WIV may have special qualities that would favor it over split-virus and subunit vaccine as a basic formulation for a pandemic vaccine, especially if a proper adjuvant could be added. Unique features of viral particles Compared to split-virus and subunit vaccines, WIV has unique structural and functional features that may steer and augment the antibody response, as has been shown in mice (Chapter 2). Most importantly, WIV contains viral RNA that may act as an internal Thl-steering adjuvant, through interaction with TLR7 and induction of IFNa, as demonstrated in Chapter 3 and discussed in detail in Chapter 7. Furthermore, the viral particle structure may serve to target the viral RNA to TLR7 
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General Discuss ion Part I I  in the endosomes, by facilitating receptor mediated uptake and protecting the RNA against degrading enzymes [15]. In absence of a particle structure, 'naked' influenza RNA has been shown to be a very inefficient stimulator of TLR7 in vitro [16]. Therefore, even if there would remain some viral RNA in split-virus vaccine after destruction of the particles ( which is unlikely see Chapter 3 ), it may not be able to activate TLR7 efficiently. Considering the above, the HA in WIV not only serves as the primary antigen like in split-virus and subunit vaccine, but may also function in the immune response by its binding capacity to the host immune cell, which facilitates receptor-mediated uptake. In addition, the HA in the viral particle facilitates viral membrane fusion, a function which remains intact in (3-propiolactone-inactivated virus (Chapter 3) but might be abolished by (harsh) treatment with formalin ( Chapter 4 and reference 52 ). Theoretically, fusion activity of WIV could play a role in the antibody response following two lines of thought. First, it was proposed by others that influenza viral membrane fusion could be important for efficient TLR7 signaling, through mechanisms unknown [17]. If TLR7 activation depends on membrane fusion, membrane fusion activity of WIV could be an important factor that co-determines the antibody response. Yet, we found that fusion activity of WIV had no effect on the serum quantities of influenza-specific IgG and Thl type antibodies, as determined by ELISA. Loss of fusion activity led to moderately raised levels of Th2-type antibodies [Chapter 4]. Serum HI titers, assumed to be indicative of virus-neutralizing antibodies, seemed to be lower in mice immunized with fusion-inactive WN. However, a change in the antigenic determinants resulting from formaldehyde treatment, as a method to inactivate fusion activity, may also play a role in this. Second, membrane fusion may lead to efficient deposition of viral ssRNA in the cytoplasm of the recipient's immune cells, where it could stimulate RIG I-like receptors (RLR) of the innate immune system. RIG-I senses replicating influenza virus by its double stranded RNA intermediates, leading to production of IFNa [18]. However, RIG-I may also sense viral genomic ssRNA in absence of replication, through the formation of loops in the RNA molecules creating a double stranded 'panhandle' structure [19]. Stimulation of RIG-I, with concomitant IFNa production, by fusion active (but replication inactive) WIV could assist in Thl steering of the immune response. In knock-out mice lacking both TLR7 and RIG-I signaling-function no Thl-type antibodies were found upon immunization with WIV [20], whereas low levels of Thl-type antibodies were 
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found in WN-immunized TLR7 knock-out mice [20, and Chapter 3]. Yet, the role of 
RLR as compared to TLR7 in protective immunity seems to be small. After 
immunization with wrv, mice which lack RIG-I signalling are equally well 
protected as wild-type mice against a lethal viral challenge, whereas mice which 
lack TLR7 are not protected [21]. In conclusion, any contribution of fusion activity 
of WN to the Thl-type antibody response, whether or not by facilitating RLR 
activation or by supposedly affecting TLR7 signalling, seems to be small [ Chapter 3 and 4]. 
The process of viral uncoating, initiated by the low pH in the endosomes, 
has been linked to efficient TLR7 recognition of influenza virus [17,22]. Whether 
this process may play a role in the immune response to WN is something which 
still needs to be studied. Low pH treatment of WN prior to incubation with 
plasmacytoid dendritic cells (pDCs) leads to a strong reduction in IFNa 
production, while the binding capacity of WN to MDCK cells does not seem to be 
affected (unpublished results). This might hint to a role for the proper timing of 
pH related effects on wrv, like viral uncoating, in the TLR7-mediated response. It 
may also suggest that potentially acidifying conditions should be avoided in the 
production process of WIV to assure maximal responses. A role for WIV particles in priming 
The advantage of having a machinery for effective TLR7 stimulation in case of 
WIV, seems highest when there is no pre-existing immunity, as would be in a 
pandemic caused by a virus which is unrelated to the circulating human virus 
strains, like avian HSNl. It has been shown that the activation of pDC' s with 
subsequent IFN-alpha production plays a critical role in the primary response to 
an i.n. influenza WN vaccine, while it does not seem to be involved in secondary 
responses [20]. In the primary response to vaccination, antibody-secreting cells 
and memory B-cells are formed in a process which usually includes antigen 
recognition, presentation and T cell help, and which may be augmented by co­
stimulatory signals as provided by adjuvants or microbial vaccine components 
[38]. The response to WN differs from that to split-virus and subunit vaccine by a 
strong activation of cDC and pDC in vitro, leading to production of 
proinflammatory cytokines and IFNa, as well as a strong induction of Thl cells in vivo [Chapter 2 and 3]. These features will not be distinctive in a secondary 
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General Discussion Part I I  response, which merely requires the interaction between antigen and high affinity memory B-cells, the presence of which is accumulating after priming [38]. WIV and cross-protection Cross-reactive anti-HA antibodies Protective efficacy against drift variants of the vaccine virus is highly desirable for pandemic and epidemic vaccines, and a strong argument to maintain stockpiles of pre-pandemic HSNl vaccines. Cross-reactive anti-HA antibodies recognizing drift variants of the HSNl strain used for vaccination have been encountered with different pre-pandemic HSNl vaccines in animals and humans [30-36]. In humans an HSNl (clade 1) WIV vaccine induced substantial virus-neutralizing antibodies against clade 2 and 3 viruses (up to 45% and 78% seroconversion respectively). In contrast, HSNl (clade 1) split-virus vaccine in two other studies induced neutralizing sero-conversion rates to a clade 2 virus that did not exceed 9% [30-32]. Cross-reactive neutralizing responses to heterologous virus induced by split­vaccine can be increased by the addition of oil-in-water adjuvants [31,32]. It is however unknown if the cross-neutralizing titers found in these studies would protect humans from a heterosubtypic HSNl infection. In a mouse model WIV vaccine prepared from different HSNl clades (1, 2.1, 2.2, 2.3.4) induced full or partial cross-protection against lethal infection with heterologous HSNl viruses of different clades [36]. This was in part explained by the induction of cross-reactive antibodies, and it has been suggested that there is a common protective epitope shared by many different HSNl viruses [36]. In ferrets similar cross-clade protection by HSNl WIV vaccines, with or without the oil-in-water adjuvant MF59, against lethal infection has been observed [69]. Pre-pandemic vaccines may become even more effective in pandemic mitigation if the vaccines could also provide protection against shift variants. It has been shown in mice that an H3N2 WIV formulation fully protects against a lethal infection with HSNl, after 3 doses given in the presence of an adjuvants [37]. In the demonstrated cross-subtype protection B-cells seem to play a more important role than cytotoxic T-cells, likely by production of antibodies that recognize a common cross-reactive epitope on the HA shared by H3 and HS [37]. The mechanism behind the induction of cross-reactive antibodies remains unclear. Cross-reactive antibodies may be directed to (neutralizing) epitopes located in the highly conserved stem domains of the HA (HA2) of different 
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Chapter 8 subtypes [71], or possibly against some epitopes on the head domain of the HA (HAl) that are conserved between drift variants [66]. It has been shown that MF59-adjuvantation increases the production of antibodies recognizing HAl rather than HA2. Adjuvantation also increased the avidity of these antibodies, as well as the diversity of epitopes that are recognized [70]. The increase in binding to HAl epitopes correlated with broadening of cross-clade neutralization. MF59-adjuvantation strongly increases CD4+ T helper cell induction, and it has been suggested that this may be responsible for the broadening of the antibody response [66]. Obviously, adjuvantation plays a critical role in eliciting cross­reactive antibodies when using split-virus vaccine. It would be interesting to see whether the internal (RNA) adjuvant in WIV and TLR7 triggering, are important for cross-reactive antibody induction, but this seems rather likely. Antibodies against M1, M2, and NP The protein content in WIV and split-virus vaccine differs from subunit vaccine in that WIV and split-virus contain all of the viral proteins (except for NSl), whereas subunit only contains HA and NA. Ml, M2 and NP are relatively conserved and induction of antibodies against these proteins is of special interest because it may contribute to heterosubtypic immunity [24,27-29]. Antibodies against Ml and M2 are produced upon infection but their contribution to virus neutralization is small compared to that of anti-HA [23]. Yet, induced by vaccination, anti-M2 has been shown to protect against lethal viral challenge [24], whereas immune-serum to Ml did not confer protection [25] . The mechanism of protection provided by antibodies against M2 is largely unclear. Possibly, expression of M2 on the cell surface and antibody-mediated cell cytotoxicity plays a role [68]. An anti-M2 monoclonal antibody has been shown to diminish viral spread in a plaque assay, but does not prevent infection [67]. Anti-NP antibodies were shown to be induced by WIV vaccination of mice [26]. Immunization of mice with large amounts of NP resulted in an antibody dependent reduction in morbidity and virus titers after viral challenge [27,28]. Anti-NP antibodies may protect in several ways. Anti-NP monoclonal antibodies can stimulate dendritic cell function and CTL induction through formation of immune complexes, and anti-NP IgG can induce complement mediated cytolysis, due to expression of NP on the cell surface [Summarized in 27]. 
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Stimulating CTL responses by vaccination may be another target in a pandemic 
situation. Compared to robust anti-viral antibody responses induction of cytotoxic 
T lymphocytes (CTL) seems negligible for protective immunity against influenza 
infection [50]. It is however believed that cross-protective CTLs may contribute to 
a reduction in morbidity and mortality when protective antibodies are absent. 
Such will be the case in an outbreak with a virus new to humans, like H5Nl [50]. 
In nafve mice formalin- as well as BPL-inactivated WIV induce CTLs, which may 
protect against challenge with homologous virus [51-53]. However, despite of the 
presence of conserved proteins in WIV and the capacity to induce CTL, 
intramuscular vaccination of mice with a formalin-inactivated seasonal influenza 
H3N2 strain did not deliver cross-protection against avian H5Nl [53]. The 
administration route as well as the method of WIV inactivation may play 
important roles in cross-protective CTL mediated immunity [52,54]. A recent study 
shows that intranasally delivered HlNl WIY, inactivated by y-irradiation, 
protected mice against a lethal infection with H5Nl with only a single dose [55]. 
The authors argue that CTLs are likely the cause of this heterosubtypic immunity. 
This demonstrates that induction of heterosubtypic immunity may be feasible 
using a WIV formulation, where this could not be shown for a commercial 
unadjuvanted split-virus vaccine [54]. 
Dose-sparing property of WIV 
The limited vaccine production capacity makes strategies that minimize the dose 
of antigen needed for protection of utmost importance [12]. The rate-limiting step 
in vaccine production is the amount of virus that can be produced. Therefore, 
comparative evaluation of dose-sparing quality should at least take into account the number of protective doses that can be produced from a given virus stock within a certain time. It is for instance unknown how much HA is lost in the consecutive 
production steps to yield WIY, split-virus and subunit vaccine. Based on older 
research reports, loss of HA antigen by detergent and/ or ether-treatment of whole 
virus may be estimated to be 10-30% [39-42]. More recently it was estimated that 
production of an H5Nl split-virus vaccine would lead to an HA loss of 20-30% 
[10] Even if this wastage could be strongly decreased by better production efficacy, 
a loss of only 1 % would mean that of the few billion pandemic doses envisaged, 
millions will be lost. 
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Chapter 8 Also, as we have shown in Chapter 5 (and discussed in Chapter 7), the quality of the immune response, in terms of Thl- or Th2-type response induction may be important to consider when evaluating a dose-sparing strategy. Until now a WIV formulation adjuvanted with aluminum-phosphate-gel has been the only H5Nl vaccine capable of meeting the European and U.S. licensing criteria using a single dose (of 6 µg HA) [43]. This may be very encouraging. We have, however, shown that aluminum-hydroxide skews the response to HlNl WIV from a Thl to a less effective Th2 type in mice [Chapter 5]. Whether this also applies to aluminum­phosphate-gel in the human situation remains to be seen. In contrast to our findings, another study in mice revealed a mixed Thl /Th2 response to an aluminum-hydroxide adjuvanted H5Nl WIV and better protective quality. The authors suggested that the vaccine dose, virus strain or the virulence of the virus might play a role in this discrepancy [46]. Addition of ASO3 to an H5Nl split-virus vaccine reduces the minimal antigen dose needed to meet European and FDA licensing criteria with more than 20 fold to 3.75 µg (in two doses), as compared to unadjuvanted split-virus [31, 32, 44]. The adjuvanted vaccine induced seroconversion in 82% of the recipients, compared to 4% without adjuvants. ASO3 seems to enhance both Thl and Th2 responses [45]. To compare, 7.5 µg of an H5Nl WIV (in two doses) yielded a seroconversion rate of 69%, which was in the absence of an added adjuvants [30]. It would be very interesting to see if ASO3 could add to WIV' s dose-sparing property, while preserving the Thl response phenotype. In Sweden and Finland, an ASO3-adjuvanted HlNl split-virus vaccine used during the 2009 pandemic has been associated with an increased risk of narcolepsy-cataplexy in children [72]. The causative mechanism remains to be resolved, but the presence of the ASO3 adjuvant may play a role [73]. It may turn out that strategies that minimize the dose of ASO3, for instance by combining ASO3 with WI\1, could be favorable to reduce the risk of this rare side-effect. MF59, another oil-in-water adjuvant [see also Chapter 7] with dose-sparing potential [47], is a Th2-steering adjuvant in mice [48], while in humans it may induce a Thl-type reponse [49]. Added to H5Nl WI\1, MF59 enhances and skews the response in mice to a mixed Thl /Th2 type, which is superior in protection to unadjuvanted WIV or Al(OH)3 adjuvanted WI\1, at least in type I diabetic mice [46]. 
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General  Discuss ion Part I I  WIV and vaccine stability When it comes to timely production and distribution of billions of vaccine doses associated with a pandemic, logistics may become very complicated. A strong dependence on cold-chain requirements could hamper transportation and storage, and lead to vaccine losses due to cold-chain failures. H5Nl WIV vaccine was shown to be very stable and could be kept outside the fridge for at least a year without considerable losses in immunogenicity [Chapter 6]. WIV appeared to be more stable than subunit vaccine which lost potency under similar conditions after 3-5 months [56]. However, differences in vaccine virus and stability readout systems between these studies make a thorough comparison difficult. The stability of WIV can be increased by freeze-drying and the use of sugar-glass technology, which allows storage at higher temperatures (40 degrees Celsius) for months [Chapter 6]. Considering the geographic distribution of human infections there is a fair chance that putative H5Nl outbreak containment actions may have to be performed in countries close to the equator, possibly in a rural area with poor infrastructure [57-59]. Moreover, use of dry-powder formulations may benefit the stockpiling of pre-pandemic vaccines performed by several countries and the WHO (for containment action and resource-poor countries) [60]. The improved stability of these vaccines creates longer shelf lives and might speed up vaccine deployment with minimal vaccine losses due to cold-chain failures. Concluding remarks During the last four decades evidence is accumulating that WIV vaccine induces stronger, better, broader and faster immune responses in unprimed individuals than other unadjuvanted inactivated vaccines [Chapter 2 and 3, references 5-8,61,62]. Its characteristic Thl-type response seems to be associated with better protection than Th2 type responses induced by the other vaccines [Chapter 5]. Production of WIV requires fewer production steps as compared to split-virus and subunit vaccines which would translate in a faster and cheaper production process, with minimal loss of HA, and requiring minimal technology and know­how. Additionally, WIV proved to be very stable in storage [ Chapter 6]. An academic view on a solution for a worldwide problem posed by an imminent influenza pandemic may therefore favor inactivated whole influenza virus as the 
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Chapter 8 antigen constituent of pandemic vaccines. On the other hand, it has been shown that addition of oil-in-water adjuvants, like MF59 and AS03, to subunit and split vaccine increases and broadens the immune response to WIV-like proportions and maybe beyond [11,13,14]. Yet, the immunogenic capacity of WIV in combination with an adjuvant, other than aluminum, is only recently being investigated. These studies, all performed in animals, include MF59-adjuvanted wrv, WIV and CpG encapsulated into nanoparticles, cationic lipid/DNA complex-adjuvanted WIV, and CoVaccine HT-adjuvanted wrv, where the presence of the adjuvant increased the immune response in each study [ 46,63,64,65]. Yet, the ultimate comparative laboratory and clinical trials using the same (new) adjuvants combined with different basic formulations of HA, including WIV, needs to be awaited. WIV vaccine in combination with a proper adjuvant could in potential provide the best pragmatic solution for pandemics in the near future. 
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Chapter 9 The continuous threat of a new influenza pandemic urges the development of optimally effective vaccines for better pandemic preparedness. Many challenges accompany vaccine development for pandemics. These relate to factors such as the uncertainty of the timing and causative virus subtype of a next pandemic, the speed of global spreading of the virus, and limitations in the vaccine production capacity. One important challenge is the accomplishment of a dose-reduction to diminish the anticipated vaccine shortage. This may be achieved by use of a vaccine formulation that induces stronger and better immune responses than those generally induced by seasonal flu vaccines. Developing a completely new and better formulation is a risky and time-consuming process, while the threat of an HSNl pandemic required immediate pandemic preparedness. We therefore set out to identify -among the non-adjuvanted vaccine formulations available for clinical use- the best formulation in terms of the quantity and quality of the induced antibody response and to clarify its working mechanism. We tried to further increase vaccine immunogenicity by adding an adjuvant, and to improve vaccine stability by freeze-drying, for storage in anticipation of a pandemic. In a first set of experiments, we compared classic influenza vaccine formulations, in use for vaccination against seasonal influenza, in a head-to-head immunization trial in mice. Inactivated whole virus vaccine (WIV) was superior in inducing virus-specific antibodies, as compared to split-virus (SV), subunit (SU) or virosomal (VS) vaccine. The antibody response to WIV correlated with better neutralization of the virus in vitro (Chapter 2 and 3). Also, WIV induced a Thl­type immune response, characterized by high levels of IgG2a / c subtype antibodies in mice, in contrast to SV, SU or VS vaccine. The latter vaccines all induced a Th2-type response, in which IgGl antibodies dominate. The presence of IgG2a/ c correlates with better protection against a viral challenge than the presence of IgGl antibodies, according to literature and also to our own experience (see Chapter 5). Inbred mice used in our experiments are genetically almost identical. We showed that WIV consistently induced a Thl-type response in two different inbred mouse strains with genetic predisposition for an antibody­dominated immuno-phenotype (Balb / c) and a cell-dominated immuno­phenotype (C57Bl/ 6), respectively. This holds promise that WIV might induce a similar response type in an outbred population, where more genetic variation exists (Chapter 2). Taken together, in naYve mice WIV proved superior in terms of magnitude and phenotype of the induced immune response. Based on these results, and results from animal and human studies by others that report of a 
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similar superiority of WIV above other classic influenza vaccines in nai've 
individuals, WIV may be favoured as candidate pandemic vaccine formulation. 
Intrigued by the better potential of this oldest vaccine formulation (1945) 
amongst the current influenza vaccines, we set out to unravel the immunogenic 
mechanisms of wrv, hoping that insights into its superior response induction 
might aid future vaccine improvement. First of all, we found that the Thl 
immuno-phenotype induced by immunization with WIV was associated with the 
induction of cytokines important for the adaptive immune response, including 
type I interferon (IFN), by dendritic cells (DCs) in vitro (Chapter 2). Because type I 
IFN is strongly induced by viral ssRNA upon recognition by TLR7 receptors of the 
innate immune system, we hypothesized a link between TLR7 and the superiority 
of the WIV-induced immune response. To test this, we immunized TLR7 knock­
out mice with wrv, SV, and SU. In TLR7 k.o. mice the levels of virus-specific 
antibodies induced by WIV were significantly reduced as compared to wild-type 
mice, and the response type was reversed to a Th2 type ( Chapter 3 ). This result 
showed that TLR7 plays a crucial role in the superiority of the WIV response, 
likely due to the presence of viral ssRNA in the core of the intact viral particles in 
WIV. In contrast, SV and SU vaccines contain only low amounts of viral ssRN A. A 
long-standing enigma as to why splitting of virus and purification of proteins for 
vaccine production lead to a loss of immunogenicity seems to be resolved. 
Aside from the structural aspects of the viral particles, also functional 
aspects seem to be important for the response induction by WIV. To reach the 
endosomes of the target cell, where TLR7 is located, viral particles likely follow 
the route of natural infection that includes the receptor-mediated uptake by the 
host cell. Another function of intact viral particles is viral membrane fusion, which 
was linked by others to TLR7 activation. We tested the role of fusion activity of 
WIV on vaccine immunogenicity (Chapter 4). Inactivation of the fusion capacity of 
WIV was accomplished using formaldehyde. In vitro, fusion-inactive WIV showed 
a reduced but not abrogated capacity to activate TLR7. In vivo, fusion-inactive 
WIV did not differ much from fusion-active WIV in its capacity to induce a Thl­
type antibody response in mice, as measured by ELISA. However, in the 
hemagglutination-inhibition assay (HI), which is the generally used read-out 
system for vaccine efficacy, sera from mice that had received fusion-inactive WIV 
showed somewhat lower antibody titers against native virus than sera from mice 
immunized with fusion-active WIV. This discrepancy was, in part, explained by a 
possible effect of the formaldehyde treatment on epitopes on the hemagglutinin 
Chapter 9 protein. Therefore, although fusion activity of WIV particles does not seem to play a major role in its immunogenicity, care should be taken when using formaldehyde to produce inactivated vaccines. We considered increasing the immunogenicity of WIV by addition of an adjuvant, to further enhance its dose-sparing qualities. We tested aluminium hydroxide (Alum), which at that time was one of the few adjuvants licensed for use in influenza vaccines (Chapter 5). Although the addition of Alum increased the levels of hemagglutination-inhibiting antibodies induced by WIY, it also induced a shift from a Thl- to a Th2-type antibody profile, which proved to be of inferior protective quality in a virus challenge model. Alum therefore does not seem to have an additive value when combined with WIV for use in a pandemic. Moreover, this study showed that the quality of the immune response may be important to consider when evaluating a vaccine, instead of relying on HI titers alone. Vaccine stability is an important issue when it comes to stockpiling vaccines for imminent pandemics, and when cold-chain requirements could hamper rapid vaccine distribution. We tested whether and for how long the immunogenicity of WIV remained intact at elevated temperatures (Chapter 6). When stored for a period of one year at room temperature WIV hardly lost immunogenicity as tested in mice. However, at 40°C the immunogenicity of WIV quickly deteriorated. Yet, by freeze-drying WIV after addition of a sugar excipient (trehalose or inulin), the imunogenicity of WIY, including the Thl-response type, could be maintained for at least 3 months of storage at 40°C. Taken together, these studies support the potential of WIV as a pandemic vaccine candidate formulation. In Chapter 7 we discuss how the insights gained in the context of the here described studies combined with insights provided by others may facilitate rational vaccine design. In Chapter 8 we discuss the further merits of WIV for its use in pandemics. Future research should reveal whether the immunogenicity of WIV can be enhanced, for instance by finding a proper adjuvant, or by exploiting the knowledge of its working mechanism, to improve pandemic vaccines and increase their worldwide availability. Based on the results described in this thesis we can give the following recommendations for pandemic influenza vaccines: Of the current vaccine formulations WIV should be preferred as formulation in non-adjuvanted vaccines. Alum should not be used as an adjuvant in combination with WIV. Instead, new 192 
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adjuvants should be tested, preferably with different basic vaccine formulations 
including WIY, to decide which adjuvanted formulation is optimal for use in a 
pandemic. The quality of the immune response should be included when 
measuring vaccine efficacy. WIV may be preferred for stockpiling vaccines because 
of its good stability. To further increase vaccine stability, and allow storage at high 
temperatures, WIV may be freeze-dried with a sugar excipient. Interactions with 
the innate immune system, which critically determine the superiority of wrv, as 
well as structural and functional properties of viral particles and their 
components, may be further exploited for vaccine improvement. 
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Chapter 10 
lntroductie 
Het influenza virus is de verwekker van de griep en veroorzaakt in de 
wintermaanden epidemieen op het noordelijk halfrond. Sporadisch veroorzaakt 
het influenza virus een pandemie, waarbij het virus zich binnen korte tijd 
wereldwijd verspreidt met extra ziekte- en sterftegevallen tot gevolg. Tijdens de 
'Spaanse griep' pandemie van 1918 zijn naar schatting tussen 50 en 100 miljoen 
mensen omgekomen. Het ontstaan van een pandemie hangt samen met de 
introductie van een nieuw subtype influenza virus vanuit het dierenrijk in de 
menselijke populatie. Er bestaat dan nog geen immuniteit tegen dit nieuwe virus, 
waardoor het zich snel kan verspreiden. Het is onvoorspelbaar wanneer zo' n 
introductie plaats gaat vinden, en welk subtype influenza virus dit zal betreffen, 
maar dat het in de toekomst weer een keer gaat gebeuren is zeer waarschijnlijk. 
De uitbraken van het dodelijke H5Nl vogelgriep virus onder pluimvee in 
Zuidoost- Azie, waarbij ook mensen gemfecteerd raakten, vormden een directe 
pandemische dreiging. De eerste uitbraak vond plaats in 1997. Sinds 2003 is het 
virus echter niet meer weggeweest en heeft zich in die tijd verspreid over 
meerdere continenten. De wereld gezondheidsorganisatie (WHO) hanteert nog 
steeds een verhoogde alarmfase, een stap onder het niveau waarbij 
overdraagbaarheid van mens naar mens gesignaleerd wordt. Tot nu overleed 60% 
van de mensen met een bewezen H5Nl infectie. Als er een air-borne H5Nl virus 
ontstaat dat van mens naar mens overdraagbaar is -dit kan door mutaties van het 
virus of door vermenging (reassortment) met een menselijk influenza virus- kan 
dit tot een levensgevaarlijke pandemie leiden. 
Vaccinatie biedt de beste bescherming tegen infectie met het influenza 
virus. Echter, het ontwikk.elen van een vaccin voor een eerstvolgende pandemie 
wordt bemoeilijkt door tal van zaken. Hieronder vallen de onzekerheid over de 
exacte identiteit (subtype) van het nieuwe pandemische virus, de onbekendheid 
van het tijdstip waarop de pandemie ontstaat, en de snelle wereldwijde 
verspreiding van het virus. Daamaast is de totale vaccin productiecapaciteit 
gelimiteerd en zijn de productiefaciliteiten gesitueerd in met name 
geindustrialiseerde landen. Tijdens een pandemie kan daarom niet iedereen ter 
wereld tijdig over vaccins beschikk.en. Het vergroten van de beschikbaarheid van 
vaccins is dan ook een van de grote uitdagingen voor vaccinonderzoekers. In 
principe zouden door een verkleining van de benodigde dosis per vaccin, meer 
vaccindoses in dezelfde tijd geproduceerd kunnen warden. Met dit idee is er in 
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Samenvatting het laatste decennium een sterke focus geweest op het verbeteren van de immunogeniciteit van het vaccin; een sterkere immuunrespons geeft betere bescherming bij een lagere vaccindosis. De oplossing kan worden gezocht in de formulering van het vaccin zelf en in de toevoeging van een adjuvans, een stof die het immuunsysteem extra stimuleert. Het vinden van de beste dosis-sparende vaccins is een race die nog steeds gelopen wordt. Dit proefschrift DOELSTELLING Het doel van het onderzoek dat wordt beschreven in dit proefschrift was in eerste instantie het identificeren van de beste formulering voor een pandemisch vaccin in het scala van formuleringen die al in productie zijn voor de seizoensgriep. Het ontwikkelen van een compleet nieuwe formulering kost namelijk tijd, terwijl de dreiging van een HSNl pandemie juist een onmiddellijke paraatheid vereist. Hiervoor hebben wij in een muismodel de immuunrespons tegen de verschillende vaccinformuleringen vergeleken, waarbij we gelet hebben op niet alleen hoogte (kwantiteit) van de antistof respons maar ook naar het type (kwaliteit) van de respons. Het volgende doel was het vinden van de verklaring voor de waargenomen verschillen in de immuunrespons tegen de verschillende formuleringen aan de hand van structurele en functionele aspecten van die formuleringen. Het laatste doel was de pandemische toepasbaarheid van de beste formulering te verbeteren door de immunogeniciteit verder te vergroten met behulp van een adjuvans, en door het vaccin te stabiliseren zodat het beter opgeslagen kan worden. VERSCHILLENDE FORMULERINGEN, VERSCHILLENDE ANTISTOFRESPONSEN Voor de productie van vaccins voor de seizoensgriep zijn verschillende formuleringen in gebruik. Wat deze formuleringen met elkaar gemeen hebben is dat ze de belangrijkste virale antigenen bevatten. Antigenen zijn eiwitten waartegen de beschermende antistoffen opgewekt worden. Voor het influenza virus zijn dit het haemagglutinine (HA) en het neuraminidase (NA) eiwit. Deze bevinden zich aan de buitenkant van het virus partikel, en zijn dus goed 197 
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'zichtbaar'voor het immuunsysteem. Om aan die eiwitten te komen wordt eerst, 
ongeacht welke van de gangbare formuleringen gebruikt gaat warden, een bulk 
aan virus geweekt. Dit virus wordt vervolgens chemisch geinactiveerd. De oudste 
formulering dateert uit 1945 en betreft een vaccin dat hele geinactiveerde virussen 
bevat ( whole inactivated virus, WIV). Toevoeging van een detergens aan WIV 
vernietigt de structuur van het virus partikel en geeft een zogenaamd split-virus 
vaccin (SV). Verdere zuivering van het HA en NA geeft een subunit vaccin (SU). In 
een virosomen vaccin (VS) is eerst de virale kern met het genetisch materiaal van 
het virus, het virale RNA, verwijderd en vervolgens de structuur van het virus 
hersteld. Deze verder 'lege' virus partikels bevatten wel het HA en het NA. 
Om te achterhalen wat de beste formulering is hebben wij groepen muizen 
ge1mmuniseerd met de verschillende vaccinformuleringen (Hoofdstuk 2). WIV 
induceerde hogere antistof (IgG) titers dan SV, SU en VS in muizen, wat 
correleerde met een betere neutralisatie van het virus in vitro (Hoofdstuk 2 en 3). 
Hierbij werden hoge titers van het IgG2a / c subtype aangetroffen en relatief lage 
titers IgGl . Dit komt overeen met een Thl-type respons. Ook het verhoogde aantal 
gamma-interferon producerende cellen in de milten van de muizen duidt hierop. 
Dit is het type respons dat in het algemeen door virusinfecties gei'nduceerd wordt. 
IgG2a / c antistoffen lijken geassocieerd te zijn met betere bescherming tegen 
infectie vergeleken met IgGl, zoals blijkt uit de literatuur en onze eigen ervaring 
(zie Hoofdstuk 5). SV, SU en VS induceerden Th2-type responsen waarin het IgGl 
subtype antistof domineert. Dus behalve dat WIV vaccins minder bewerkelijk in 
de productie zijn geven ze, tenminste in muizen, een kwantitatief en kwalitatief 
betere respons en zouden ze daarom in principe lager gedoseerd kunnen warden, 
dan de andere vaccins. Dit is in lijn met bevindingen van andere 
onderzoeksgroepen, niet alleen in diermodellen maar ook in de mens. Op basis 
van deze gegevens zou WIV de beste optie zijn voor een pandemisch vaccin. 
Sinds 1960-70 zijn de SV en SU vaccins meer in trek voor de seizoensgriep, 
vanwege een wat lager bijwerkingenprofiel ten opzichte van WIV. Echter, bij 
productie van SV en SU gaat een deel van de immunogeniciteit verloren, wat 
vooralsnog onbegrepen was. SV en SU vaccins induceren een lagere 
immuunrespons dan WIV in individuen die niet eerder in contact zijn geweest 
met het subtype virus waarvoor ge1mmuniseerd wordt (en dus immunologisch 
nruef zijn, net zoals de muizen in bovengenoemde experimenten). Dit is niet het 
geval tijdens een seizoensgriep epidemie, maar wel tijdens een pandemie. In een 
rapport van de WHO wordt een switch naar de productie van WIV in de 
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Samenvatti ng vaccinindustrie als een reele mogelijkheid gezien om de wereldwijde beschikbaarheid van vaccins te vergroten. 0NTRAFELEN VAN HET WERKINGSMECHANISME VAN WIV We begonnen met het ontrafelen van het werkingsmechanisme achter de superieure immunogeniciteit van wrv, met het idee dat de kennis daaromtrent bij zou kunnen dragen aan het verbeteren van vaccins. Allereerst vonden wij in vitro dat de inductie van een Thl-type respons door immunisatie van muizen met WIV samen ging met de productie van bepaalde cytokinen, stoffen, die belangrijk zijn voor de adaptieve antistofrespons. Met name interferon-alpha (IFNa), een cytokine met anti-virale werking, werd sterk geinduceerd (Hoofdstuk 2). Het was eerder aangetoond dat viraal RNA de productie van IFNa stimuleert door Toll-like receptor 7 (TLR7) te activeren. TLR7 is een van de zogenaamde 'pattern recognition' receptoren van het aangeboren immuunsysteem, die verschillende grove structuren van infecterende micro-organismen herkennen, zoals bijvoorbeeld het RNA of DNA (TLR9). We stelden de hypothese dat de superieure immunogeniciteit van WIV afhangt van de activatie van TLR7. In de kemen van de geinactiveerde virus partikels in WIV bevindt zich namelijk nog steeds het virale RNA genoom. Om de hypothese te toetsen hebben we wrv, SV en SU naast elkaar getest in muizen die deficient zijn gemaakt voor TLR7 en in wildtype muizen. We zagen dat de antistofrespons tegen WIV in TLR k.o. muizen ten opzichte van wildtype muizen niet alleen significant gereduceerd was, maar ook dat de respons-type veranderd was van een Thl-type in een Th2-type (Hoofdstuk 3). TLR7-activatie blijkt dus in grate mate verantwoordelijk voor de superieure immunogeniciteit van WIV ten opzichte van de andere formuleringen. Experimenten van anderen ondersteunen deze bevinding. Het blijkt dat de hoeveelheid RNA in SV en SU vaccin erg laag is ten opzichte van WIV. Hiermee lijkt het oude raadsel van het verlies aan immunogeniciteit door van WIV een SV of SU vaccin te maken opgelost. Tevens tonen onze resultaten aan dat het aangeboren immuunsysteem belangrijk is voor de activatie en sturing van de adaptieve immuunrespons tegen vaccins. 199 
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Naast de aanwezigheid van RNA in de viruspartikels lijken ook functionele 
aspecten van de partikels belangrijk voor de irnmuunrespons op WIV. Om bij 
TLR7 in de endosomen te komen moeten de viruspartikels eerst op natuurlijke 
wijze via receptoren aan de gastheercel binden en actief opgenomen warden. In 
dezelfde endosomen waar TLR7-activatie plaats vindt versmelt (fuseert) een deel 
van de viruspartikels met de gastheercel. Fusie-activiteit is een functie van het 
viruspartikel, en TLR7-activatie is door andere onderzoekers in verband gebracht 
met deze fusie-activiteit. Stappen in het productieproces van WIV die de fusie­
activiteit zouden kunnen beinvloeden, zoals het gebruik van formaldehyde om 
virus te inactiveren, zouden dus de irnmunogniciteit van WIV kunnen 
compromitteren. Of dit zo is hebben we getest door muizen te irnmuniseren met 
WIV nadat we het eerst fusie-inactief hadden gemaakt door middel van 
formaldehyde behandeling (Hoofdstuk 4). De fusie-activiteit lijkt evenwel geen 
invloed te hebben op de aantallen en de typen antistoffen die geproduceerd 
warden, gemeten met de ELISA test. Daarentegen vallen de aantallen antistoffen 
gemeten met de haemagglutinatie inhibitie (HI) test beduidend lager uit in geval 
van fusie-inactief WIV. Het laatste kon grotendeels verklaard warden door een 
effect van formaldehyde op de HI epitopen, en heeft waarschijnlijk niets met fusie­
activiteit te maken. In vitro was de TLR7-activatie wel verminderd is (alleen bij de 
hoogste concentratie WIV) maar zeker niet nul. Dus fusie-activiteit lijkt geen 
belangrijke rol te spelen, maar voorzichtigheid lijkt geboden bij gebruik van 
formaldehyde om vaccines te inactiveren. KAN WIV VERBETERD WORDEN MET EEN ADJUVANS ?  
Het toevoegen van een adjuvans is een belangrijk manier om de irnmunogeniciteit 
van laag-immunogene vaccins te vergroten. Inmiddels zijn er krachtige olie-in­
water adjuvantia voor influenza vaccins op de markt die dat ook daadwerkelijk 
kunnen doen. Wij hebben WIV in combinatie met aluminium-hydroxide (Alum) -
een van de weinige adjuvantia met een gebruikslicentie voor influenza vaccins op 
dat moment- getest in een muismodel (Hoofdstuk 5). Echter, toevoeging van Alum 
ging gepaard met een shift van een Thl naar een Th2-type antistofrespons. 
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Ondanks dat de muizen hogere HI antistof titers genereerden tegen WIV in 
combinatie met Alum, dan tegen WIV alleen, bleken ze minder goed beschermd 
tegen een challenge met actief virus in de neus. Dit onderzoek toonde aan dat 
gebruik van Alum in combinatie met WIV niet zinvol is, zoals ook is gebleken uit 
klinische studies. Tijdens de pandemie van 2009 ('Mexicaanse griep') zijn 
geadjuvanteerde SV of SU vaccins en WIV naast elkaar gebruikt. Volgens een 
recente studie zou de dosis-sparende capaciteit van een olie-in-water 
geadjuvanteerd SV vaccin beter zijn dan die van WIV vaccin. De vraag is hoe deze 
verhouding wordt als aan WIV ook een goed werkend adjuvans zou warden 
toegevoegd (zie Hoofdstuk 8). VERBETEREN VAN DE STABILITEIT VAN WIV 
Het opslaan van vaccins, in anticipatie op een mogelijke pandemie, kreeg veel 
aandacht toen bleek dat zogenaamde pre-pandemische HSNl vaccins toch 
aanzienlijke bescherming geven tegen drift-varianten van het HSNl virus. Dit zijn 
HSNl virus stammen die ontstaan zijn als gevolg van kleine mutaties in de 
antigenen. Deze treden vaker op naarmate er meer tijd verstrijkt tussen de 
productie van het pre-pandemisch vaccin en het daadwerkelijk optreden van de 
pandemie. Voor menig vaccin geldt dat de houdbaarheidsdatum van een jaar is 
gesteld voor opslag bij 4° C. Wij hebben de stabiliteit van WIV onderzocht na 
opslag bij hogere temperaturen (Hoofdstuk 6). WIV liet na een jaar opslag bij 
kamertemperatuur nauwelijks verval in de immunogeniciteit zien. De stabiliteit 
van WIV na opslag bij 40° C bleek beduidend minder; na 3 maanden trad een 
aanzienlijke verval in de antilichaam respons op. Door WIV te vriesdrogen in een 
matrix van suikers, ook wel suikerglas techniek genaamd, bleef de 
immunogeniciteit van het vaccin bij deze extreme temperatuur wel behouden, 
inclusief de inductie van een Thl-type respons, voor een opslagduur van ten 
minste 3 maanden bij 40° C. De stabiliteit van WIV kan dus effectief vergroot 
warden door vriesdrogen in suikerglas. Gevriesdroogd WIV is dus minder 
afhankelijk van de koude-keten (cold-chain) en beter inzetbaarheid voor opslag en 
snelle verspreiding van vaccins ten tijde van een pandemie, met name in landen 
met een warmer klimaat. 
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Op basis van de in dit proefschrift beschreven resultaten kunnen wij de volgende 
aanbevelingen geven ten aanzien van pandemische influenza vaccins: Van de 
huidige vaccinformuleringen zou WIV geprefereerd moeten worden als 
formulering in niet-geadjuvanteerde vaccins. Aluminium hydroxide zou niet 
gebruikt moeten worden als adjuvans in combinatie met WIV. Nieuwe adjuvantia 
zouden getest moeten worden met verschillende van de huidige formuleringen, 
inclusief Wiv, om uit te maken welke geadjuvanteerde formulering het best in een 
pandemie gebruikt kan gaan worden. Bij het meten van de effectiviteit van een 
vaccin zou ook gekeken moeten worden naar de kwaliteit van de immuunrespons. 
Een WIV formulering zou gekozen moeten worden voor opslag van vaccins 
vanwege een goede stabiliteit. Om de stabiliteit verder te vergroten en opslag bij 
hoge temperaturen mogelijk te maken kan WIV gevriesdroogd worden met een 
suiker bestanddeel. Interacties met het aangeboren immuunsysteem, waarvan we 
aangetoond hebben dat die van groot belang zijn voor de superieure 
immunogeniciteit van Wiv, als wel de structurele en functionele eigenschappen 
van de virus partikel met zijn componenten, zouden verder benut kunnen worden 
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